US20040033546A1 - Novel microarrays and methods of use thereof - Google Patents
Novel microarrays and methods of use thereof Download PDFInfo
- Publication number
- US20040033546A1 US20040033546A1 US10/367,204 US36720403A US2004033546A1 US 20040033546 A1 US20040033546 A1 US 20040033546A1 US 36720403 A US36720403 A US 36720403A US 2004033546 A1 US2004033546 A1 US 2004033546A1
- Authority
- US
- United States
- Prior art keywords
- microarray
- protein
- antibody
- antibodies
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002493 microarray Methods 0.000 title claims abstract description 366
- 238000000034 method Methods 0.000 title claims abstract description 219
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 143
- 150000001875 compounds Chemical class 0.000 claims abstract description 134
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 89
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 89
- 239000000017 hydrogel Substances 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 354
- 102000004169 proteins and genes Human genes 0.000 claims description 313
- 241000193738 Bacillus anthracis Species 0.000 claims description 142
- 108090001090 Lectins Proteins 0.000 claims description 85
- 102000004856 Lectins Human genes 0.000 claims description 85
- 239000002523 lectin Substances 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 65
- 229940065181 bacillus anthracis Drugs 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 abstract description 45
- 230000027455 binding Effects 0.000 abstract description 42
- 238000009739 binding Methods 0.000 abstract description 38
- 230000001580 bacterial effect Effects 0.000 abstract description 15
- 210000002540 macrophage Anatomy 0.000 abstract description 13
- 238000002405 diagnostic procedure Methods 0.000 abstract description 12
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract description 9
- 108091007433 antigens Proteins 0.000 description 245
- 102000036639 antigens Human genes 0.000 description 245
- 239000000427 antigen Substances 0.000 description 228
- 150000001720 carbohydrates Chemical class 0.000 description 130
- 229920001282 polysaccharide Polymers 0.000 description 125
- 229920002307 Dextran Polymers 0.000 description 122
- 239000005017 polysaccharide Substances 0.000 description 121
- 239000000523 sample Substances 0.000 description 117
- 230000000890 antigenic effect Effects 0.000 description 113
- 235000014633 carbohydrates Nutrition 0.000 description 107
- 238000000018 DNA microarray Methods 0.000 description 105
- 150000004676 glycans Chemical class 0.000 description 95
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 87
- 241000282414 Homo sapiens Species 0.000 description 83
- 238000002360 preparation method Methods 0.000 description 75
- 101710194807 Protective antigen Proteins 0.000 description 63
- 208000015181 infectious disease Diseases 0.000 description 59
- 238000001514 detection method Methods 0.000 description 57
- 230000000813 microbial effect Effects 0.000 description 56
- 210000002966 serum Anatomy 0.000 description 49
- 239000011521 glass Substances 0.000 description 43
- 238000005516 engineering process Methods 0.000 description 42
- 238000004519 manufacturing process Methods 0.000 description 39
- 244000052769 pathogen Species 0.000 description 39
- 238000007639 printing Methods 0.000 description 38
- 102000003886 Glycoproteins Human genes 0.000 description 35
- 108090000288 Glycoproteins Proteins 0.000 description 35
- 238000002474 experimental method Methods 0.000 description 34
- 238000010186 staining Methods 0.000 description 34
- 239000000243 solution Substances 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 230000004044 response Effects 0.000 description 30
- 235000000346 sugar Nutrition 0.000 description 30
- 238000003556 assay Methods 0.000 description 29
- 230000009260 cross reactivity Effects 0.000 description 29
- 238000010790 dilution Methods 0.000 description 29
- 239000012895 dilution Substances 0.000 description 29
- 238000002255 vaccination Methods 0.000 description 29
- 230000000875 corresponding effect Effects 0.000 description 27
- 238000003745 diagnosis Methods 0.000 description 27
- 230000009257 reactivity Effects 0.000 description 27
- 208000035473 Communicable disease Diseases 0.000 description 26
- 238000011835 investigation Methods 0.000 description 26
- 230000001717 pathogenic effect Effects 0.000 description 26
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 25
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 25
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 25
- 208000035475 disorder Diseases 0.000 description 25
- 239000005090 green fluorescent protein Substances 0.000 description 25
- 238000011161 development Methods 0.000 description 24
- 230000018109 developmental process Effects 0.000 description 24
- 239000002953 phosphate buffered saline Substances 0.000 description 24
- 239000000126 substance Substances 0.000 description 24
- 108090000695 Cytokines Proteins 0.000 description 22
- 102000004127 Cytokines Human genes 0.000 description 22
- 238000002965 ELISA Methods 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- 101150026046 iga gene Proteins 0.000 description 22
- 150000002482 oligosaccharides Chemical class 0.000 description 22
- 231100000518 lethal Toxicity 0.000 description 21
- 230000001665 lethal effect Effects 0.000 description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 229920001542 oligosaccharide Polymers 0.000 description 20
- 241000894007 species Species 0.000 description 20
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Chemical group 0.000 description 19
- 238000003018 immunoassay Methods 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 19
- 210000002421 cell wall Anatomy 0.000 description 18
- 229920000642 polymer Polymers 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 230000001413 cellular effect Effects 0.000 description 17
- 238000012512 characterization method Methods 0.000 description 17
- 239000003053 toxin Substances 0.000 description 17
- 231100000765 toxin Toxicity 0.000 description 17
- 108700012359 toxins Proteins 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 17
- 241000588748 Klebsiella Species 0.000 description 16
- 230000008901 benefit Effects 0.000 description 16
- 230000001900 immune effect Effects 0.000 description 16
- 230000035945 sensitivity Effects 0.000 description 16
- 101710090322 Truncated surface protein Proteins 0.000 description 15
- NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 description 15
- 230000005875 antibody response Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229920002521 macromolecule Polymers 0.000 description 15
- 238000003860 storage Methods 0.000 description 15
- 241000193755 Bacillus cereus Species 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000003278 mimic effect Effects 0.000 description 13
- 102000008579 Transposases Human genes 0.000 description 12
- 108010020764 Transposases Proteins 0.000 description 12
- 210000001124 body fluid Anatomy 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 235000001727 glucose Nutrition 0.000 description 12
- 230000005923 long-lasting effect Effects 0.000 description 12
- 238000012775 microarray technology Methods 0.000 description 12
- 241000193830 Bacillus <bacterium> Species 0.000 description 11
- 235000014469 Bacillus subtilis Nutrition 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 102100034349 Integrase Human genes 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 238000013461 design Methods 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 108020004635 Complementary DNA Proteins 0.000 description 10
- 229930186217 Glycolipid Natural products 0.000 description 10
- 229920001213 Polysorbate 20 Polymers 0.000 description 10
- 230000004075 alteration Effects 0.000 description 10
- 238000003491 array Methods 0.000 description 10
- 238000010804 cDNA synthesis Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 10
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 229920001202 Inulin Polymers 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 9
- 230000002924 anti-infective effect Effects 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000010839 body fluid Substances 0.000 description 9
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229940029339 inulin Drugs 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 238000004321 preservation Methods 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 208000032163 Emerging Communicable disease Diseases 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000009870 specific binding Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 244000000010 microbial pathogen Species 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 238000004445 quantitative analysis Methods 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000606768 Haemophilus influenzae Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 238000013090 high-throughput technology Methods 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 238000013207 serial dilution Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- -1 without limitation Chemical class 0.000 description 6
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 241000607479 Yersinia pestis Species 0.000 description 5
- 230000009830 antibody antigen interaction Effects 0.000 description 5
- 239000003618 borate buffered saline Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000003759 clinical diagnosis Methods 0.000 description 5
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004001 molecular interaction Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 230000004763 spore germination Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HRANPRDGABOKNQ-ORGXEYTDSA-N (1r,3r,3as,3br,7ar,8as,8bs,8cs,10as)-1-acetyl-5-chloro-3-hydroxy-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1[C@H](O)C[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 HRANPRDGABOKNQ-ORGXEYTDSA-N 0.000 description 4
- 241000193388 Bacillus thuringiensis Species 0.000 description 4
- 101710205625 Capsid protein p24 Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 208000015943 Coeliac disease Diseases 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 108700010908 HIV-1 proteins Proteins 0.000 description 4
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 4
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 4
- 101710177166 Phosphoprotein Proteins 0.000 description 4
- 101710149279 Small delta antigen Proteins 0.000 description 4
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- 208000022338 anthrax infection Diseases 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000002274 desiccant Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009509 drug development Methods 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000012268 genome sequencing Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000003100 immobilizing effect Effects 0.000 description 4
- 230000000984 immunochemical effect Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000009456 molecular mechanism Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 101000725897 Bacillus anthracis Heme A synthase Proteins 0.000 description 3
- 241001079719 Bacillus cereus ATCC 4342 Species 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- 241000193155 Clostridium botulinum Species 0.000 description 3
- 241000617590 Escherichia coli K1 Species 0.000 description 3
- 241000654838 Exosporium Species 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 101000718497 Homo sapiens Protein AF-10 Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 108010061833 Integrases Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102100026286 Protein AF-10 Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 230000007503 antigenic stimulation Effects 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000009073 conformational modification Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 3
- 230000035784 germination Effects 0.000 description 3
- 150000002339 glycosphingolipids Chemical class 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000000951 immunodiffusion Effects 0.000 description 3
- 238000000760 immunoelectrophoresis Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- FBJQEBRMDXPWNX-FYHZSNTMSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)C(O)O2)O)O1 FBJQEBRMDXPWNX-FYHZSNTMSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000009105 vegetative growth Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 208000003508 Botulism Diseases 0.000 description 2
- 101100311260 Caenorhabditis elegans sti-1 gene Proteins 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- 108010001682 Dextranase Proteins 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000589602 Francisella tularensis Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000237369 Helix pomatia Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000272168 Laridae Species 0.000 description 2
- 241000712902 Lassa mammarenavirus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001115401 Marburgvirus Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 208000031662 Noncommunicable disease Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 101710099182 S-layer protein Proteins 0.000 description 2
- 108091058545 Secretory proteins Proteins 0.000 description 2
- 102000040739 Secretory proteins Human genes 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- 208000001203 Smallpox Diseases 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 208000034784 Tularaemia Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000870995 Variola Species 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960005447 anthrax vaccines Drugs 0.000 description 2
- 230000003092 anti-cytokine Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- DIUIQJFZKRAGBZ-UHFFFAOYSA-N chetoseminudin A Natural products O=C1C(SSS2)(CO)N(C)C(=O)C32CC2(N4C5=CC=CC=C5C(CC56C(N(C)C(CO)(SS5)C(=O)N6C)=O)=C4)C4=CC=CC=C4NC2N31 DIUIQJFZKRAGBZ-UHFFFAOYSA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000002967 competitive immunoassay Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940118764 francisella tularensis Drugs 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 230000007540 host microbe interaction Effects 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000000680 phagosome Anatomy 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 231100000033 toxigenic Toxicity 0.000 description 2
- 230000001551 toxigenic effect Effects 0.000 description 2
- 108091008023 transcriptional regulators Proteins 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LLTDOAPVRPZLCM-UHFFFAOYSA-O 4-(7,8,8,16,16,17-hexamethyl-4,20-disulfo-2-oxa-18-aza-6-azoniapentacyclo[11.7.0.03,11.05,9.015,19]icosa-1(20),3,5,9,11,13,15(19)-heptaen-12-yl)benzoic acid Chemical compound CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)[NH+]=4)(C)C)=CC3=3)S(O)(=O)=O)S(O)(=O)=O)=C1C=C2C=3C1=CC=C(C(O)=O)C=C1 LLTDOAPVRPZLCM-UHFFFAOYSA-O 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 241000220436 Abrus Species 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101100059544 Arabidopsis thaliana CDC5 gene Proteins 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 101100218316 Bacillus anthracis atxA gene Proteins 0.000 description 1
- 101100392330 Bacillus anthracis gerXA gene Proteins 0.000 description 1
- 101100392331 Bacillus anthracis gerXB gene Proteins 0.000 description 1
- 101100392332 Bacillus anthracis gerXC gene Proteins 0.000 description 1
- 101100350745 Bacillus anthracis pagR gene Proteins 0.000 description 1
- 241000034280 Bacillus anthracis str. Sterne Species 0.000 description 1
- 241000193747 Bacillus firmus Species 0.000 description 1
- 241000194106 Bacillus mycoides Species 0.000 description 1
- 101100437361 Bacillus subtilis (strain 168) bcrC gene Proteins 0.000 description 1
- 101100103078 Bacillus subtilis (strain 168) xerD gene Proteins 0.000 description 1
- 101100544712 Bacillus subtilis (strain 168) yocA gene Proteins 0.000 description 1
- 101100160692 Bacillus subtilis (strain 168) yrkO gene Proteins 0.000 description 1
- 101100321172 Bacillus subtilis (strain 168) yrpE gene Proteins 0.000 description 1
- 101100107005 Bacillus subtilis (strain 168) ywqF gene Proteins 0.000 description 1
- 101710147103 Calmodulin-sensitive adenylate cyclase Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241001569772 Celithemis elisa Species 0.000 description 1
- 101710168515 Cell surface glycoprotein Proteins 0.000 description 1
- 241001137881 Cepaea nemoralis Species 0.000 description 1
- 241000191363 Chlorobium limicola Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 210000004128 D cell Anatomy 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710150441 DNA-invertase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101710174610 Disulfide bond formation protein Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 101000843477 Escherichia coli (strain K12) RNA-binding protein Hfq Proteins 0.000 description 1
- 108010074122 Ferredoxins Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101001022682 Glycine max Lectin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 241000219726 Griffonia simplicifolia Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000614095 Homo sapiens Proton-activated chloride channel Proteins 0.000 description 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 1
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241001468155 Lactobacillaceae Species 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101150115300 MAC1 gene Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000003843 Metalloendopeptidases Human genes 0.000 description 1
- 108090000131 Metalloendopeptidases Proteins 0.000 description 1
- 108010013690 Methyl-Accepting Chemotaxis Proteins Proteins 0.000 description 1
- 101001082628 Mus musculus H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 101000902581 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Putative decaprenylphosphoryl-5-phosphoribose phosphatase Rv3807c Proteins 0.000 description 1
- 101000902580 Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh) Putative decaprenylphosphoryl-5-phosphoribose phosphatase MT3914 Proteins 0.000 description 1
- 101000930820 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Putative decaprenylphosphoryl-5-phosphoribose phosphatase MSMEG_6402 Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 101100436307 Plasmodium falciparum (isolate 3D7) ATG11 gene Proteins 0.000 description 1
- 241000223830 Plasmodium yoelii Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710112376 Probable integrase/recombinase Proteins 0.000 description 1
- 102100040631 Proton-activated chloride channel Human genes 0.000 description 1
- 101710167959 Putative UTP-glucose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- 101710091955 Putative integrase Proteins 0.000 description 1
- 241000522615 Pyrococcus horikoshii Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical group CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 1
- 101710189064 Response regulator aspartate phosphatase C Proteins 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 108010082913 S-layer proteins Proteins 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 108010052160 Site-specific recombinase Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710183296 Surface layer protein Proteins 0.000 description 1
- 102000003705 Syndecan-1 Human genes 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 1
- 102100029640 UDP-glucose 6-dehydrogenase Human genes 0.000 description 1
- 108030001662 UDP-glucose 6-dehydrogenases Proteins 0.000 description 1
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 1
- 102100038834 UTP-glucose-1-phosphate uridylyltransferase Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 101710199192 Uncharacterized membrane protein Proteins 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 206010057293 West Nile viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000002299 affinity electrophoresis Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical group C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- GZCGUPFRVQAUEE-UHFFFAOYSA-N alpha-D-galactose Natural products OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 1
- 125000003169 alpha-Gal epitope group Chemical group [C@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)O[C@H]1[C@@H]([C@H](C(O[C@@H]1CO)*)NC(C)=O)O)O 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 108010008975 asialogalactoorosomucoid Proteins 0.000 description 1
- 229940005348 bacillus firmus Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000033383 cell-cell recognition Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229940107200 chondroitin sulfates Drugs 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 108010014459 endo-N-acetylneuraminidase Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 101150111615 ftsZ gene Proteins 0.000 description 1
- FJEKYHHLGZLYAT-FKUIBCNASA-N galp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)[C@@H](C)O)C(C)C)C1=CNC=N1 FJEKYHHLGZLYAT-FKUIBCNASA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 101150051757 glaB gene Proteins 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 229920000550 glycopolymer Polymers 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 108091005446 macrophage receptors Proteins 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 101150021072 rapC gene Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 101150097091 tnpA gene Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 101150000568 ydiL gene Proteins 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/005—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00614—Delimitation of the attachment areas
- B01J2219/00617—Delimitation of the attachment areas by chemical means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00614—Delimitation of the attachment areas
- B01J2219/00621—Delimitation of the attachment areas by physical means, e.g. trenches, raised areas
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00623—Immobilisation or binding
- B01J2219/00626—Covalent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00632—Introduction of reactive groups to the surface
- B01J2219/00637—Introduction of reactive groups to the surface by coating it with another layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00639—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium
- B01J2219/00641—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium the porous medium being continuous, e.g. porous oxide substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00639—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium
- B01J2219/00644—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium the porous medium being present in discrete locations, e.g. gel pads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00725—Peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00727—Glycopeptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/0074—Biological products
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
Definitions
- the Human Genome Project is rapidly approaching its end: the complete mapping and sequencing of the human genome, and the identification of all genes therein. Emerging from this effort is a new generation of biotechnologies, collectively known as “functional genomics”. These technologies, including DNA chips (1) and cDNA microarrays (2, 3), make use of the sequence information and genetic materials provided by the human genome project, combine advanced laser and fluorescence sensor technology, and take advantage of computer-aided large-scale data management systems. Differing from classical molecular biology methods which focus on a specific gene or its product, these new approaches monitor the expression of genes on a genome-wide scale, and identify their characteristic overall patterns. The scope of biological investigation has therefore been expanded from the study of a single gene or protein to the study of numerous genes and/or proteins simultaneously.
- Proteins are the final gene products, acting as fundamental elements of living organisms. However, the amount of mRNA expression does not always indicate the level of its encoded protein in a cell. The protein molecule has its own life span and kinetics of metabolism. There are specialized cellular machineries, such as the ubiquitin-dependent and -independent pathways of protein degradation, allowing rapid turnover of a protein when its function is no longer required. The fate of a newly synthesized protein is also significantly influenced by post-translational modifications, such as phosphorylation, glycosylation, acetylation or myristylation, at specific amino acid residues.
- Carbohydrate-containing macromolecules are the secondary products of genes. Their synthesis requires multiple enzymatic reactions and many steps of intracellular trafficking, transportation and modification. Multiple genes contribute to the synthesis of cellular elements containing complex carbohydrates. “Glycomics”, a new scientific discipline, has emerged to create a comprehensive understanding of the structure, function, synthesis and genetic regulation of cellular carbohydrate molecules.
- Carbohydrates are abundant on cell surfaces, existing as either membrane-bound glycoconjugates or secreted substances. These molecules play fundamental structural and protective roles. They are also abundant intracellularly, and serve as an active and dynamic energy reservoir.
- the carbohydrate molecules of microorganisms are important in establishing the biological relationships of microbes and their hosts (7-9). These relationships especially include the host recognition of microorganisms and the induction of an immune response by a microbial antigen.
- the carbohydrate moieties of microbial antigens frequently serve as the key structures for immune recognition (10). Identifying such determinants is of fundamental importance for understanding the molecular mechanisms of host recognition and immune responses.
- These assays include (a) classical direct immunoassays, such as immunodiffusion, immunoelectrophoresis, agglutination and immunoprecipitation assays, and (b) recently developed methods such as immunofluorescence, radioimmunoassay (RIA), enzyme-immunoassay (EIA) and western blot assays.
- RIA radioimmunoassay
- EIA enzyme-immunoassay
- western blot assays exploit the specificity of antigen-antibody interactions. However, they are designed for analyzing only one agent at a time, and are therefore limited as to the number of molecules that can be analyzed in a single assay.
- the first microarray comprises a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- the second microarray comprises a plurality of nitrocellulose or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, wherein (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- the first article comprises a nitrocellulose or Hydrogel support having dextran affixed to its surface at discrete loci.
- the dextran is ⁇ (1, 6) dextran.
- the third microarray comprises the first article, wherein at least one compound is affixed to the dextran at each discrete locus, the composition of compounds at each discrete locus differing from the composition of compounds at at least one other discrete locus.
- the second article comprises a plurality of nitrocellulose or Hydrogel supports, each support having dextran affixed to its surface at one or more discrete loci.
- the dextran is ⁇ (1, 6) dextran.
- the fourth microarray comprises the second article, wherein at least one compound is affixed to the dextran at each discrete locus, the composition of compounds at each discrete locus differing from the composition of compounds at at least one other discrete locus.
- the fifth microarray comprises a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (a) at at least one discrete locus is affixed a compound associated with Bacillus anthracis and selected from the group consisting of a glycomer and a protein, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- the sixth microarray comprises a plurality of nitrocellulose or Hydrogel or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, wherein (a) at at least one discrete locus is affixed a compound associated with Bacillus anthracis and selected from the group consisting of a glycomer and a protein, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- the first method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known glycomers, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; and (b) determining whether any known glycomer in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the second method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known insoluble proteins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known insoluble protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding insoluble protein in the microarray; and (b) determining whether any known insoluble protein in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the third method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known antibodies or lectins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; and (b) determining whether any known antibody or lectin in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the fourth method is a method of detecting in a sample the presence of one or more agents associated with Bacillus anthracis which specifically bind to one or more glycomers, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; and (b) determining whether any glycomer in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the fifth method is a method of detecting in a sample the presence of one or more agents associated with Bacillus anthracis which specifically bind to one or more proteins, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding protein in the microarray; and (b) determining whether any known protein in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the sixth method is a method of detecting in a sample the presence of one or more glycomers or proteins which specifically bind to one or more antibodies or lectins associated with Bacillus anthracis, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; and (b) determining whether any antibody or lectin in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the first method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known glycomers, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known glycomer is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; (b) for each known glycomer in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- the second method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known insoluble proteins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known insoluble protein is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding insoluble protein in the microarray; (b) for each known insoluble protein in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- the third method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known antibodies or lectins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known antibody or lectin is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; (b) for each known antibody or lectin in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- the first method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known glycomer, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known glycomer in the microarray; and (b) determining whether the known glycomer in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- the second method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known insoluble protein, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known insoluble protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known insoluble protein in the microarray; and (b) determining whether the known insoluble protein in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- the third method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known antibody or lectin, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known antibody or lectin in the microarray; and (b) determining whether the known antibody or lectin in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- This invention further provides a method of determining whether an antibody known to specifically bind to a first glycomer also specifically binds to a second glycomer, which method comprises: (a) contacting the antibody with the first or second microarray, wherein a plurality of glycomers, other than the first glycomer, are affixed at discrete loci in the microarray, and wherein the contacting is performed under conditions which would permit the antibody to specifically bind to the first glycomer if it were present in the microarray; and (b) determining whether any of the glycomers in the microarray, other than the first glycomer, has the antibody specifically bound thereto, thereby determining whether the antibody also specifically binds to a second glycomer.
- This invention further provides a method of determining whether an antibody known to specifically bind to a first insoluble protein also specifically binds to a second insoluble protein, which method comprises: (a) contacting the antibody with the first or second microarray, wherein a plurality of insoluble proteins, other than the first insoluble protein, are affixed at discrete loci in the microarray, and wherein the contacting is performed under conditions which would permit the antibody to specifically bind to the first insoluble protein if it were present in the microarray; and (b) determining whether any of the insoluble proteins in the microarray, other than the first insoluble protein, has the antibody specifically bound thereto, thereby determining whether the antibody also specifically binds to a second insoluble protein.
- This invention further provides a method of making a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, which method comprises contacting the nitrocellulose or Hydrogel support with the compounds under suitable conditions, whereby (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides a method of making a microarray comprising a plurality of nitrocellulose or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, which method comprises contacting the nitrocellulose or Hydrogel supports with the compounds under suitable conditions, whereby (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides a method of making the first article comprising contacting a nitrocellulose or Hydrogel support with dextran at discrete loci under suitable conditions.
- This invention further provides a method of making the second article comprising contacting a plurality of nitrocellulose or Hydrogel supports with dextran, whereby each support has dextran affixed to its surface at one or more discrete loci.
- This invention further provides six kits.
- the first kit comprises one of the instant microarrays and instructions for use.
- the second kit comprises one of the instant microarrays and a desiccant.
- the third kit comprises one of the instant microarrays immersed in an aqueous solution.
- the fourth kit is a kit for practicing the first diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the glycomer to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- the fifth kit is a kit for practicing the second diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the insoluble protein to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- the sixth kit is a kit for practicing the third diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the antibody or lectin to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- This invention further provides a first antibody capable of specifically binding to a glycomer present on the surface of a mammalian macrophage, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell.
- This invention further provides a second antibody capable of specifically binding to a glycomer present on the surface of a mammalian intestinal epithelial cell, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell.
- This invention further provides a method of determining whether a subject is afflicted with a disorder characterized by the presence of a glycomer on the surface of macrophages in an afflicted subject, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell, comprising: (a) contacting a sample of the subject's macrophages with the first antibody; and (b) determining whether the antibody specifically binds to the macrophages in the sample, such binding indicating that the subject is afflicted with the disorder.
- this invention provides a method of determining whether a subject is afflicted with a disorder characterized by the presence of a glycomer on the surface of intestinal epithelial cells in an afflicted subject, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell, comprising: (a) contacting a sample of the subject's intestinal epithelial cells with the second antibody; and (b) determining whether the antibody specifically binds to the intestinal epithelial cells in the sample, such binding indicating that the subject is afflicted with the disorder.
- FIG. 1 [0050]FIG. 1
- This Figure shows a carbohydrate microarray and its application in characterizing the epitope-binding specificity of monoclonal antibodies (“mAb”).
- mAb monoclonal antibodies
- Dextran preparations of defined structural characteristics including N279, LD7, B1299S and B1355S, were immobilized on a nitrocellulose-coated micro-glass slide in serial dilutions and stained with anti- ⁇ (1,6)dextran antibodies. These antibodies were either a groove-type antibody, i.e., 4.3.F1, or a cavity-type antibody, i.e., 16.4.12E, and were conjugated with fluorescence.
- Their distinct epitope-binding specificities were visualized by scanning the carbohydrate microarray using a GMS 418 microarray scanner.
- FIG. 2A anti-DEX 4.3.F1
- FIG. 2B anti-DEX 16.4.12E.
- Intensity values of cross-reacting spots were compared with those of specific binding to ⁇ (1,6)dextran N279.
- N279 was applied as a series of 1:5 dilutions of a 100 ⁇ g/ml solution (a).
- Other antigens were applied as 500 ⁇ g/ml.
- Identical antigens are arrayed in FIG. 2A and FIG. 2B.
- FIGS. 3 A- 3 D mAb 4.3.F1
- FIGS. 3 E- 3 H isotype control.
- FIG. 4A This Figure shows that groove-type and cavity-type anti- ⁇ (1,6)dextran monoclonal antibodies recognize distinct cellular markers: a groove-type mAb 45.21.1 (IgA) identifies a cell population in the lamina intestinal of the small intestine (FIGS. 4C and 4F), and a cavity-type mAb 16.4.12E (IgA) stains the epithelial cells in the crypts of the small intestine (FIGS. 4B and 4E).
- IgA isotype control mAb purchased from BD PharMingen was applied as a background control (FIGS. 4A and 4D).
- This Figure shows the recognition of a cell population in the human small intestinal tissue using anti- ⁇ (1,6)dextran antibodies.
- the intestinal section of a normal (FIGS. 5A and 5B) and of a celiac individual (FIGS. 5C and 5D) were stained with the fluorescence-conjugate of mAb 16.4.12E (FIGS. 5B and 5D) and co-stained with DAPI to reveal the intestinal structures (FIGS. 5A and 5C).
- This Figure shows the immobilization of polysaccharides on a nitrocellulose-coated glass slide.
- Panel A Image of the carbohydrate microarray (microarrays of dextrans and inulin) spots before and after washing.
- Panel B Quantitative illustration of the relation of fluorescence intensity and the concentration of printed carbohydrate microarrays before and after washing. Fluorescent conjugates of dextrans or inulin were dissolved in saline (0.9% NaCl) and spotted at an initial concentration of 10 mg/ml and then diluted in serial dilutions of 1:5. The microarray slides were scanned before and after washing. The data of six repeats of the same experiment is statistically analyzed and presented. Legend: ⁇ : 2000 k; ⁇ : 70 k; ⁇ : 20 k; ⁇ : Inulin.
- Panel A Microarray binding curves of a groove-type anti-Dex 4.3F1 (IgG3/Kappa) and a cavity-type anti-dextran 16.4.12E (IgA/Kappa) to dextran molecules of distinct structure. Dextran molecules were printed with an initial concentration of 0.1 mg/ml and diluted by a 1:5 series titration.
- the printed arrays were washed to remove unbound antigens and then stained with biotinylated anti-dextran, either 4.3F1 or 16.4.12E, at a concentration of 1 ⁇ g/ml, and then stained with Cy3-streptavidin at 1:500 dilutions.
- the readout of the experiment i.e., fluorescent intensity of the microspot
- the cavity-type mAb 16.4.12E bound to N279 and B12995, but not LD7.
- the groove-type mAb 4.3F1 bound to the dextran preparations N279 and LD7, but bound poorly to B1299S.
- Panel B ELISA binding curve of anti-Dex 4.3F1 and 16.4.12E.
- Dextran preparations were coated on an ELISA plate at an initial concentration of 10 ⁇ g/ml and then diluted by a 1:5 series titration in 0.02 M borate-buffered saline, pH 8.0.
- the antigen-coated plates were incubated with biotinylated anti-dextrans at a concentration of 1 ⁇ g/ml.
- the bound antibodies were revealed with an alkaline phosphatase (AP)-streptavidin conjugate and AP substrate.
- AP alkaline phosphatase
- Bacillus anthracis exposes and releases a number of antigens of distinct structural characteristics to trigger and induce a comprehensive picture of a host response.
- Dormant spores present in vitro are highly resistant to adverse environmental conditions.
- spores establish vegetative growth.
- these infective particles are ingested by the phagocytic cells and accumulate in the local lymphoid tissue. Some may survive from the phagocytes and initiate their germination and vegetative growth.
- the vegetative form of the bacteria is square-ended and capsulated.
- Antigens & toxins Vegetative bacillus releases multiple factors, such as toxins, protein factors, and soluble polysaccharides (1-3,4 of the Third Series of Experiments).
- the protein fractions, such as the protective antigen, named PA can provide strong protection to the immunized animals. It is now well understood that PA is an integrated component of the lethal toxin of Bacillus anthracis. It binds to a specific cellular receptor and forms toxic, cell bound complexes with edema factor (EF) and lethal factor (LF) (1-3 of the Third Series of Experiments).
- Neutralization antibodies to PA or a polyvalent factor that inhibits the formation of the complex may protect animals from the lethal attack by the toxin (5 of the Third Series of Experiments).
- a considerable amount of polysaccharides are also present in the culture media of the growing bacteria. Its sugar compositions are similar (if not identical) to the cell wall Gal-NAG polysaccharide.
- the native immunity forms the first line of a host anti-infection response. These include macrophages, natural killer cells (NK), pre-existing “natural antibody” of IgM isotype and perhaps a specific B cell lineage, the B-1 cells, TCR ⁇ T cells, and other cells.
- the acquired immune system includes B cells (the bone marrow derived B cells, or B-2 cells) and T cells (the thymus derived TCR ⁇ T cells).
- B cells mount a specific antibody response to a microbial antigen, either a T-independent antigen, such as an anthrax polysaccharide, or a T-dependent antigen, for example the protective antigen (PA) of B. anthracis; specific T cells can be activated by a TD protein antigen to regulate a B cell responses, either positively (T helper, Th1 and Th2) or negatively.
- a T-independent antigen such as an anthrax polysaccharide
- a T-dependent antigen for example the protective antigen (PA) of B. anthracis
- specific T cells can be activated by a TD protein antigen to regulate a B cell responses, either positively (T helper, Th1 and Th2) or negatively.
- Tc cytotoxic T cells
- Many host cells including immune cells and non-immune cell types, may produce cytokines or other inflammation factors to assist a host anti-infection response.
- This Figure shows a simple and efficient procedure for producing a carbohydrate microarray.
- Microspotting Carbohydrate antigens were printed using Cartesian Technologies' PIXSYS 5500C (Irvine, Calif.) with STEALTH 3 pins.
- Supporting substrate FAST Slides (Industrial partner A, Schleicher & Schuell, Keene, N.H.).
- the printed carbohydrate microarrays were air dried and stored at room temperature without desiccant before application.
- Immuno-staining Immediately before use, the microarrays were rinsed with phosphate-buffered saline (PBS). The staining procedure utilized is essentially identical to regular immunoflourescent staining of tissue sections.
- Microarray-scanning A ScanArray 5000 Standard Biochip Scanning System and its QuantArray software (Packard Biochip Technologies, Inc.) were applied for scanning and data capturing.
- This Figure shows a schematic of the 8-chamber sub-arrays.
- This Figure shows probing of the repertoires of human serum antibodies using Antigen Chip 4000. Left: HIV negative normal serum. Right: Serum of an HIV-1 infected individual. For each microarry analysis, 10 ml of serum were applied on an antigen chip at 1:10 dilutions. Anti-human antibodies with distinct fluorescent tags were applied to recognize and quantify the bound human IgG, IgM and IgA. In this Figure, human IgG was stained in Red/Cy5 and human IgM in Green/Cy3. The two images of contrasting colors were overlaid. IgA human antibodies were detected on the same chip with an anti-human IgA FITC (data was not shown).
- This Figure shows the scanning of human antibodies specific for a large panel of HIV proteins using a protein-based microarray biochip.
- Serum specimens of four normal individuals and six AIDS patients were characterized by a protein biochip that displays a large panel of HIV-1 proteins. Each preparation was printed four times on the same biochip.
- 10 ⁇ l of serum were applied at 1:10 dilutions on a single chip.
- Human IgG that was captured by the immobilized antigens was recognized and quantified by a Cy3-labeled second antibody.
- Data of each group, normal and HIV-infected individuals, were statistically analyzed. Results were presented as the mean value of the ratio of fluorescent intensity over the background of given microspots (Histogram). Their standard division was also shown. Significant variations that were observed in the HIV-1 infected group may reflect the diversity of the HIV-1 specific antibody responses, as well as the level of antigenic cross-reactivities of HIV-1 proteins that were expressed by different clades or strains of HIV-1 virus.
- This Figure shows a schematic of a hypothetical structural and immunological relationships of the type II backbone structure of blood group substances, type XIV pneumococcal polysaccharide and the cell wall Gal-NAG polysaccharide.
- This Figure shows a carbohydrate microarray characterization of human and murine antibodies. Forty-eight distinct antigen preparations were arrayed on slides at antigen concentrations of 0.5 mg/ml and 0.02 mg/ml. They were incubated with combined human serum specimens at a concentration equivalent to 1:100 dilutions of each specimen or with binotinylated mouse monoclonal antibodies at 1 mg/ml. The human IgM captured by microarrays was visualized using an anti-human IgM-AP conjugate and the color developed using Vector Red. The human IgG anti-carbohydrates were detected using a biotinylated anti-human IgG.
- a Cy3-Streptoavidin conjugate was then applied to visualize the human IgG or murine monoclonal antibodies bound on microarray.
- the readout of the experiment i.e., fluorescent intensity of the microspot, reflects the amounts of antigen immobilized and epitopes displayed for antibody recognition.
- Data of four repeats of microarray staining are summarized in Table 2.
- This Figure shows the prediction of protein structure using TMHMM version 2.0 (55 of the Third Series of Experiments): PX01-54 of B. anthracis encodes a S-layer protein, a novel molecular target for anthrax diagnosis and vaccination.
- This Figure shows biochip detection of human antibody reactivities to either anthrax polysaccharide or Pneumococcus type XIV polysaccharide in mixed human serum specimen which confirms that these antigen preparations are applicable for producing diagnostic microarrays.
- This Figure shows a schematic of diagnosis and surveillance of emerging infectious diseases using antigen arrays.
- An emerging infection may attack human as well as animal populations. Detecting specific antibodies in their bodily fluids using antigen microarrays is a powerful means for the diagnosis and surveillance of emerging infectious diseases.
- This Figure shows long-lasting antigenic reactivities of protein microarrays in some but not all preparations.
- This Figure shows that purified GFPuv protein is stably immobilized on the nitrocellulose-coated slide (upper row) but is less stable on a poly-Lys treated DNA ready slide (bottom row).
- a preparation of purified GFPuv was spotted on slide at 0.5 mg/ml (left side) and 0.05 mg/ml (right side). Scanning was performed 1) at the same day after spotting; 2) after overnight air-drying the slide; and 3) after washing the slide extensively in a buffer containing 0.1% Tween 20 1 ⁇ PBS.
- PA is a long, flat molecule of dimensions 100 ⁇ ⁇ 50 ⁇ 30 ⁇ . and is composed of four domains 46 .
- Domain 1 (residues 1-258) comprises a b-sandwich with jelly-roll topology, several small helices, and a pair of adjacent calcium ions coordinated by residues in a variant of the EF-hand motif.
- Domain 2 (residues 259-487) has a b-barrel core with modified Greek-key topology and elaborate excursions, including a large flexible loop between strands 2b2 and 2b3 that is implicated in membrane insertion.
- Domain 3 (residues 488-595) has a four-stranded mixed b-sheet, two smaller sheets and four helices; it adopts the same fold as ferredoxins and resembles domain A of toxic-shock-syndrome toxin-1.
- Domain 4 (residues 596-735) has an initial hairpin and helix, followed by a b-sandwich with an immunoglobulin-like fold. Domains 1, 2 and 3 are intimately associated, but domain 4 has limited contact with the other 3 domains.
- D1 is the N-terminal domain, contains two calcium ions and the cleavage site for activating proteases.
- D2 contains a large flexible loop for membrane insertion.
- D3 is a small domain of unknown function.
- D4 is the C-terminal receptor-binding domain.
- This Figure shows a schematic of a molecular approach to construct GFP fusion proteins of PA and its derivatives.
- Primers for PCR reactions are designed based on sequence information of each domain target. Restriction sites are selected to avoid digesting the PA chains or its domains. Following are primer sequences of PA derived portion: Integral PA (nt bases 143,799-146,073): 5′ ATGGTTCTTTAGCTTTCTG (19 mer, Start: 143,409); 3′ CCTAGAATTACCTTATCCTATC (22 mer, Stop: 146,085).
- P63 (nt bases 144,376-146,070): 5′ GCGAAGTACAAGTGCTGG (18 mer, Start: 144,363); 3′ TTGAATGTGCAATTGTCCTC (20 mer, Stop: 146,321).
- PA Domain 1 (nt bases 143,866-144,639): 5′ TCAGGCAGAAGTTAAACAGG (20 mer, Start: 143,859); 3′ GATAAGCTGCCACAAGGG (18 mer, Stop: 144,643).
- PA Domain 2 (nt bases 144,640-145,326): 5′ TGGCAGCTTATCCGATTG (18 mer, Start: 144,632); 3′ GCAGTTGTTTCTTGAATTTGCG (22 mer, Stop: 145,331).
- PA Domain 3 (nt bases 145,327-145,650): 5′ CAAGAAACAACTGCACGTATC (21 mer, Start: 145,318); 3′ CTTCTCTATGAGCCTCCTTAAC (22 mer, Stop: 145,720).
- PA Domain 4 (nt bases 145,651-146,070): 5′ TATCAAGAATCA GTTAGCG (19 mer, Start: 145,548); 3′ ACCTTATCCTATCTCATAGCC (21 mer, Stop: 146,076).
- This Figure shows lectin staining of ⁇ -Gal specific oligosaccharides displayed by the neoglycocojugates.
- This Figure shows that ⁇ -Gal-sugar chains are displayed by the PAGE-based neoglycocojugates and are detected by the human anti- ⁇ -Gal antibodies.
- This Figure shows a carbohydrate microarray characterization of antibody fingerprints in rabbit serum-specimens.
- Panel A A microarray staining of rabbit anti-anthrax spore anti-serum revealed a broad spectrum of antibody specificities;
- Panel B Clustering analysis of antibody profiles of an un-immunized (subject 1) and two anthrax spore-immunized rabbit antibodies, one obtained from an U.S. company (subject 2) and another from an U.K.-based company (subject 3).
- Panel A Anti-anthrax antiserum-U.S.
- Panel B Anti-anthrax antiserum-U.K.
- Slashed open circles represent the diagnostic index of antigens relevant to B. anthraces, including the anthrax cell-wall polysaccharide, Pn14-polysaccharide which is cross-reactive to anthrax cell-wall polysaccharide, anthrax protective protein (PA) and the Pn23-polysaccharide, which is proposed by this investigation as a cross-reactive antigen to the sugar structure(s) of anthrax spores.
- PA anthrax protective protein
- Black spots represent the diagnostic index of antigens that are not relevant to B. anthracis based on our current understanding and available information.
- the two lines are set to 2 times the standard deviation from the mean value of the corresponding chip. Spots distributed outside the lines are statistically significant.
- the only slashed open circle outside the green lines is Pn23 polysaccharide, which is commonly seen in the two anti-anthrax spore responses from different subjects.
- the dimension reduction analysis algorithm was developed in our laboratory. In principle, we applied the microarray signals detected in non-immunized/uninfected serum specimens as the “filters” to subtract the microarray signals that exist in both the experimental condition and the control condition.
- This Figure shows ELISA confirmation of the cross-reactivities of rabbit anti-anthrax spore antibodies to Pn23-polysaccharide but not Pneumococcus type 14 (Pn14).
- Polysaccharides were coated on an ELISA plate at concentration of 10 ⁇ g/ml in 0.02M BBS. The initial concentration of rabbit sera were 1/250 with serial 1:5 dilution titrated in 2% NBC-PBS/tween20.
- Panel A ELISA binding curves of non-immunized rabbit serum (rabbit-D); and Panel B: anthrax spore immunized rabbit serum (rabbit-G).
- Panel C ELISA value for anti-anthrax spore antibodies of rabbit serum at OD 405 nm at serum dilution of 1/250.
- This Figure shows the structural unit of Pn23 polysaccharide (from van Steijn et al. 41 ).
- Glcp represents the p ring form of glucose
- Galp represents the p ring form of galactose
- Rhap represents the p ring form of 6-deoxy-mannose.
- Linkages between the sugars have two possible anomeric designators: a (alpha) or b (beta), and are indicated in the structure.
- D or L stands for two possible absolute designators.
- the numbers presented between the two linked sugars specify which carbon molecules form the disaccharide bonds. Since the two numbers are presented between the two sugars that are bonded, the number that is closest to the respective sugar represents the carbon number of the sugar that forms the linkage. For example, in the adjacent molecule, carbon 1 from the glucose molecule is linked to carbon 4 of the galactose molecule.
- This Figure shows the antigenic cross-reactivities of anti-anthrax spore antibodies to Pn23 polysaccharide that were substantially reduced by pre-absorption of the rabbit anti-sera with the spores of B. cereus 4342.
- This Figure shows lectin staining of ⁇ -Gal specific oligosaccharides displayed by the neoglycoconjugates.
- This Figure shows non-covalent absorption to immobilize proteins and polysaccharides on a nitrocellulose-coated microchip.
- affixed shall mean attached by any means. In one embodiment, affixed shall mean attached by a covalent bond. In another embodiment, affixed shall mean attached non-covalently.
- Agent shall mean any chemical entity, including, without limitation, a glycomer, a protein, an antibody, a lectin, a nucleic acid, a small molecule, and any combination thereof.
- Antibody shall mean (a) an immunoglobulin molecule comprising two heavy chains and two light chains and which recognizes an antigen; (b) polyclonal and monoclonal immunoglobulin molecules; and (c) monovalent and divalent fragments thereof.
- Immunoglobulin molecules may derive from any of the commonly known classes, including but not limited to IgA, secretory IgA, IgG and IgM.
- IgG subclasses are also well known to those in the art and include, but are not limited to, human IgG1, IgG2, IgG3 and IgG4.
- Antibodies can be both naturally occurring and non-naturally occurring.
- antibodies include chimeric antibodies, wholly synthetic antibodies, single chain antibodies, and fragments thereof.
- Antibodies may be human or nonhuman. Nonhuman antibodies may be humanized by recombinant methods to reduce their immunogenicity in man.
- Aqueous solution shall mean any solution in which water is a solvent.
- aqueous solutions include water and water-based buffer solutions.
- Associated with Bacillus anthracis shall mean physically derived from Bacillus anthracis, present on or within Bacillus anthracis, a derivative or degradation product of Bacillus anthracis or a portion thereof, and/or able to bind to any or all of the forementioned.
- agents associated with Bacillus anthracis include, without limitation, any anti- Bacillus anthracis antibody and an immunogenic oligosaccharide present on the surface of Bacillus anthracis.
- Complex carbohydrate shall mean a carbohydrate polymer comprising more than two types of saccharide monomer units.
- Examples of complex carbohydrates include blood group substances such as Lewis X and Lewis Y.
- composition of compounds at a discrete locus shall mean the identity of the one or more compounds at that locus. For example, if locus 1 has compounds A and B, and locus 2 has compounds A and C, then the composition of compounds at locus 1 differs from that at locus 2.
- Compound shall mean any molecule. Compounds include, but are not limited to, proteins, nucleic acids, glycomers, lipids and small molecules.
- “Dextran” shall mean a branched polymer of glucose consisting mainly of ⁇ (1,6)-glycosidic linkages.
- Discrete locus shall mean a point, region or area for the affixation of a compound which does not overlap with another such point, region or area, and which may further be separated from another such point, region or area by physical space.
- Glycomer shall mean any carbohydrate-containing moiety.
- Glycomers include, without limitation, (a) complex carbohydrates, (b) polysaccharides, (c) oligosaccharides and (d) glycoconjugates.
- glycoconjugates include, without limitation, glycoproteins, glycolipids and glycopolymers. In one embodiment of the glycomer, the carbohydrate moiety thereof is conjugated, either covalently or noncovalently, to polyacrylamide.
- insoluble protein shall mean any protein which does not solubilize in aqueous solution.
- insoluble proteins include trans-membrane proteins.
- Lectin shall mean a protein that is capable of agglutinating erythrocytes, binding sugars, and/or stimulating mitosis.
- lectins include concavalin A.
- “Microarray” shall mean (a) a solid support having one or more compounds affixed to its surface at discrete loci, or (b) a plurality of solid supports, each support having one or a plurality of compounds affixed to its surface at discrete loci.
- the instant microarrays can contain all possible permutations of compounds within the parameters of this invention.
- the instant microarray can be an all-glycomer microarray, an all-insoluble protein microarray, an all-antibody microarray, a disease-specific microarray, a species-specific microarray, or a tissue-specific microarray.
- Nitrocellulose or Hydrogel support shall mean any solid support having nitrocellulose or Hydrogel affixed to its surface.
- Nitrocellulose or Hydrogel supports include, without limitation, nitrocellulose-coated or Hydrogel-coated chips (e.g. silicone chips), slides (e.g. glass slides), filters, plates and beads.
- Polysaccharide shall mean a carbohydrate polymer comprising either one or two types of saccharide monomer units.
- Examples of polysaccharides include bacterial cell surface carbohydrates.
- sample when used in connection with the instant methods, includes, but is not limited to, any body tissue, skin lesion, blood, serum, plasma, cerebrospinal fluid, lymphocyte, urine, exudate, or supernatant from a cell culture.
- Specifically bind shall mean the binding of a first entity to a second entity based on complementarity between the three-dimensional structures of each. In one embodiment, specific binding occurs with a K D of less than 10 ⁇ 5 . In another embodiment, specific binding occurs with a K D of less than 10 ⁇ 8 . In a further embodiment, specific binding occurs with a K D of less than 10 ⁇ 11 .
- Subject shall mean any organism including, without limitation, a mouse, a rat, a dog, a guinea pig, a ferret, a rabbit and a primate. In the preferred embodiment, the subject is a human being.
- the first microarray comprises a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- the second microarray comprises a plurality of nitrocellulose or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, wherein (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- the first article comprises a nitrocellulose or Hydrogel support having dextran affixed to its surface at discrete loci.
- the dextran is ⁇ (1,6) dextran.
- the third microarray comprises the first article, wherein at least one compound is affixed to the dextran at each discrete locus, the composition of compounds at each discrete locus differing from the composition of compounds at at least one other discrete locus.
- the second article comprises a plurality of nitrocellulose or Hydrogel supports, each support having dextran affixed to its surface at one or more discrete loci.
- the dextran is ⁇ (1,6) dextran.
- the fourth microarray comprises the second article, wherein at least one compound is affixed to the dextran at each discrete locus, the composition of compounds at each discrete locus differing from the composition of compounds at at least one other discrete locus.
- the nitrocellulose or Hydrogel support is selected from the group consisting of a chip, a slide, a filter, and a plate.
- the nitrocellulose or Hydrogel support is selected from the group consisting of a chip, a slide, a filter, a plate, and a bead.
- the number of discrete loci is at least 100. In another embodiment, the number of discrete loci is at least 1000. In a further embodiment, the number of discrete loci is at least 10,000. In a further embodiment, the number of discrete loci is at least 50,000.
- a glycomer is affixed at at least one locus.
- an insoluble protein is affixed at at least one locus.
- a lectin is affixed at at least one locus.
- an antibody is affixed at at least one locus.
- the microarray has affixed to its surface two or more compounds selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody.
- the microarray has further affixed to its surface a compound selected from the group consisting of a soluble protein, a nucleic acid and a small molecule.
- a glycomer is affixed to the dextran at at least one locus.
- an insoluble protein is affixed to the dextran at at least one locus.
- a lectin is affixed to the dextran at at least one locus.
- an antibody is affixed to the dextran at at least one locus.
- the microarray has affixed to the dextran two or more compounds selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody.
- the microarray has affixed to its surface a compound selected from the group consisting of a soluble protein, a nucleic acid and a small molecule.
- each locus is affixed only one compound. In another embodiment, at at least one locus is affixed a plurality of compounds.
- the first method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known glycomers, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; and (b) determining whether any known glycomer in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the second method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known insoluble proteins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known insoluble protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding insoluble protein in the microarray; and (b) determining whether any known insoluble protein in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the third method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known antibodies or lectins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; and (b) determining whether any known antibody or lectin in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the agent is an antibody which correlates with a disease.
- the agent is an antibody which correlates with an inflammatory disease.
- the agent is an antibody which correlates with an infection or the presence of a tumor.
- the method comprises detecting the presence of a plurality of agents in the sample, each of which binds to either a plurality of glycomers, a plurality of insoluble proteins, or a plurality of lectins or antibodies, as applicable.
- the method comprises determining the amount of a plurality of agents in the sample, each of which binds to either one glycomer, one insoluble protein or one lectin or antibody, as applicable.
- Determining whether an agent is bound to a compound in a microarray can be performed according to methods well known in the art. Such methods include, but are not limited to, fluorescence, radioimmunoassay, and immunolabeling detection.
- the first method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known glycomers, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known glycomer is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; (b) for each known glycomer in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- the second method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known insoluble proteins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known insoluble protein is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding insoluble protein in the microarray; (b) for each known insoluble protein in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- the third method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known antibodies or lectins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known antibody or lectin is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; (b) for each known antibody or lectin in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- the agent is an antibody which correlates with a disease.
- the agent is an antibody which correlates with an inflammatory disease.
- the agent is an antibody which correlates with an infection or the presence of a tumor.
- the method comprises determining the amount of a plurality of agents in the sample, each of which binds to either a plurality of glycomers, a plurality of insoluble proteins, or a plurality of lectins or antibodies, as applicable. In another embodiment of the instant quantitative methods, the method comprises determining the amount of a plurality of agents in the sample, each of which binds to either one glycomer, one insoluble protein or one lectin or antibody, as applicable.
- “Determining” the amount of an agent which is bound to a compound in a microarray can be performed according to well known methods in the art.
- the “known standards” useful for the instant quantitative methods include, for example, correlations between known concentrations of agents in a control sample and their corresponding values as determined using the instant microarray.
- the first method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known glycomer, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known glycomer in the microarray; and (b) determining whether the known glycomer in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- the second method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known insoluble protein, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known insoluble protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known insoluble protein in the microarray; and (b) determining whether the known insoluble protein in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- the third method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known antibody or lectin, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known antibody or lectin in the microarray; and (b) determining whether the known antibody or lectin in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- the subject is human.
- the disorder is an inflammatory disorder.
- the inflammatory disorder is celiac disease.
- the disorder is HIV-1 infection.
- a subject's serum is analyzed for the presence of HIV-1 gp120 and IgG-anti-HIV-1 gp120, the presence of both indicating active HIV-1 infection.
- a subject's serum is analyzed for the presence of either HIV-1 gp120 and IgG-anti-HIV-1 gp120, the absence of the HIV-1 gp120 and the presence of IgG-anti-HIV-1 gp120 antibody indicating HIV-1 infection or immunization.
- a subject's serum is analyzed for the presence of HIV-1 gp120 and IgG-anti-HIV-1 gp120, the absence of both indicating that the subject is neither HIV-1 infected nor immunized.
- a subject's serum is analyzed for the presence of IgA-anti-gliadin and IgA-anti-TGt, the presence of both indicating that the subject is afflicted with celiac disease.
- a subject's serum is analyzed for the presence of IgA-anti-gliadin, the presence of this antibody indicating the possibility that the subject is afflicted with celiac disease.
- This invention further provides a method of determining whether an antibody known to specifically bind to a first glycomer also specifically binds to a second glycomer, which method comprises: (a) contacting the antibody with the first or second microarray, wherein a plurality of glycomers, other than the first glycomer, are affixed at discrete loci in the microarray, and wherein the contacting is performed under conditions which would permit the antibody to specifically bind to the first glycomer if it were present in the microarray; and (b) determining whether any of the glycomers in the microarray, other than the first glycomer, has the antibody specifically bound thereto, thereby determining whether the antibody also specifically binds to a second glycomer.
- This invention further provides a method of determining whether an antibody known to specifically bind to a first insoluble protein also specifically binds to a second insoluble protein, which method comprises: (a) contacting the antibody with the first or second microarray, wherein a plurality of insoluble proteins, other than the first insoluble protein, are affixed at discrete loci in the microarray, and wherein the contacting is performed under conditions which would permit the antibody to specifically bind to the first insoluble protein if it were present in the microarray; and (b) determining whether any of the insoluble proteins in the microarray, other than the first insoluble protein, has the antibody specifically bound thereto, thereby determining whether the antibody also specifically binds to a second insoluble protein.
- This invention further provides a method of making a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, which method comprises contacting the nitrocellulose or Hydrogel support with the compounds under suitable conditions, whereby (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides a method of making a microarray comprising a plurality of nitrocellulose or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, which method comprises contacting the nitrocellulose or Hydrogel supports with the compounds under suitable conditions, whereby (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides a method of making the first article comprising contacting a nitrocellulose or Hydrogel support with dextran at discrete loci under suitable conditions.
- the method further comprises the step of affixing at least one compound to the dextran at each discrete locus, whereby the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides a method of making the second article comprising contacting a plurality of nitrocellulose or Hydrogel supports with dextran, whereby each support has dextran affixed to its surface at one or more discrete loci.
- the method further comprises the step of affixing at least one compound to the dextran at each discrete locus, whereby the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides six kits.
- the first kit comprises one of the instant microarrays and instructions for use.
- the second kit comprises one of the instant microarrays and a desiccant.
- the third kit comprises one of the instant microarrays immersed in an aqueous solution.
- the fourth kit is a kit for practicing the first diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the glycomer to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- the fifth kit is a kit for practicing the second diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the insoluble protein to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- the sixth kit is a kit for practicing the third diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the antibody or lectin to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- This invention further provides a first antibody capable of specifically binding to a glycomer present on the surface of a mammalian macrophage, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell.
- the antibody is a groove-type antibody.
- the antibody is designated 4.3.F1 (ATCC Accession No. PTA-3259).
- the antibody is designated 45.21.1 (ATCC Accession No. PTA-3260).
- This invention further provides a second antibody capable of specifically binding to a glycomer present on the surface of a mammalian intestinal epithelial cell, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell.
- the antibody is a cavity-type antibody.
- the antibody is designated 16.4.12E (ATCC Accession No. PTA-3261).
- This invention further provides a method of determining whether a subject is afflicted with a disorder characterized by the presence of a glycomer on the surface of macrophages in an afflicted subject, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell, comprising: (a) contacting a sample of the subject's macrophages with the first antibody; and (b) determining whether the antibody specifically binds to the macrophages in the sample, such binding indicating that the subject is afflicted with the disorder.
- the subject is human.
- the disorder is an immune disorder or an inflammatory disorder.
- This invention provides a method of determining whether a subject is afflicted with a disorder characterized by the presence of a glycomer on the surface of intestinal epithelial cells in an afflicted subject, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell, comprising: (a) contacting a sample of the subject's intestinal epithelial cells with the second antibody; and (b) determining whether the antibody specifically binds to the intestinal epithelial cells in the sample, such binding indicating that the subject is afflicted with the disorder.
- the subject is human.
- the disorder is an immune disorder or an inflammatory disorder.
- the disorder is celiac disease.
- each facet of this invention i.e., each of the instant compositions of matter and methods
- the glycomer, insoluble protein, lectin or antibody of the instant microarray is conjugated with a green fluorescent protein (GFP), and this conjugate is affixed to a nitrocellulose or Hydrogel support either via the GFP moiety or not.
- GFP green fluorescent protein
- Conjugation includes, without limitation, conjugation by covalent or noncovalent means.
- conjugation of a second protein with GFP is accomplished via formation of a fusion protein with the second protein.
- a fusion protein includes, for example, a protein encoded by a gene that comprises a GFP-encoding region and a non-GFP-encoding region.
- GFP includes, without limitation, whole GFP as well as fluorescent fragments thereof.
- GFP alone i.e., unconjugated form
- the fifth microarray comprises a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (a) at at least one discrete locus is affixed a compound associated with Bacillus anthracis and selected from the group consisting of a glycomer and a protein, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- the sixth microarray comprises a plurality of nitrocellulose or Hydrogel or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, wherein (a) at at least one discrete locus is affixed a compound associated with Bacillus anthracis and selected from the group consisting of a glycomer and a protein, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- the fourth method of detection is a method of detecting in a sample the presence of one or more agents associated with Bacillus anthracis which specifically bind to one or more glycomers, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; and (b) determining whether any glycomer in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the fifth method of detection is a method of detecting in a sample the presence of one or more agents associated with Bacillus anthracis which specifically bind to one or more proteins, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding protein in the microarray; and (b) determining whether any known protein in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- the sixth method of detection is a method of detecting in a sample the presence of one or more glycomers or proteins which specifically bind to one or more antibodies or lectins associated with Bacillus anthracis, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; and (b) determining whether any antibody or lectin in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- microarray technology described herein as applied to agents associated with Bacillus anthracis.
- this invention provides, for example, all such embodiments relating to methods of quantitative detection, diagnosis, binding detection, making microarrays, kits, and antibodies and glycomers identified using the instant methods, as applicable.
- This invention provides novel antigen- and antibody-based microarrays for monitoring and quantifying a broad spectrum of biological molecules and their molecular interactions.
- a microarray technique is used to spot thousands of antigens and/or antibodies on a solid surface. This strategy can be applied to any molecular target, including naturally occurring proteins, carbohydrates, lipids and nucleic acids, as well as synthetic compounds.
- the instant microarray is useful for monitoring the expression of specific antibodies and other cellular factors in body fluids, and is therefore useful for disease diagnosis and basic immunological investigation. When a large repertoire of distinct monoclonal antibodies are arrayed, an antibody library microarray is produced. Application of these microarrays for global analysis of gene expression at the translational and post-translational levels is envisioned.
- the Elvin A. Kabat Collection of antigens and antibodies at Columbia University is useful in practicing this technology.
- nitrocellulose-coating can serve as a suitable matrix for immobilizing polysaccharides, glycoprotein, glycolipid, protein and antibodies on a glass surface without chemical conjugation.
- fluorescence-conjugated dextran molecules were applied.
- a high-precision robot designed to produce cDNA microarrays (GMS 417 Arrayer, Genetic Microsystems, Inc., Woburn Mass.) was used to spot carbohydrate antigens onto a glass slide pre-coated with nitrocellulose polymer (ONCYTE Film-Slides, Grace Bio-Labs, Inc., Bend, Oreg.). Spots of antigens were printed with spot sizes at approximately 200 micron and 400 micron intervals, center-to-center. They were air dried and stored at room temperature before use. Conditions for long-term storage of the printed antigen/antibody microarrays were compared.
- the air-dried carbohydrate microarrays can be stored at room temperature for at least one year without significant inactivation of their immunological activities; and (2) the antibody microarrays can be stored in an aqueous solution at 4° C. for at least one year without significant decrease in their antigen-binding activity, as illustrated using antibodies with anti-carbohydrate specificity.
- Dextran preparations can serve as carrier molecules to conjugate other biologically active molecules.
- Such dextran-containing conjugates can be immobilized on a nitrocellulose-surface without further chemical conjugation. This method was demonstrated by immobilizing the fluorescence- ⁇ (1,6)dextran conjugates of different molecular weights, ranging from 35 kD to 2000 kD, on a nitrocellulose-coated glass slide. The fluorescence group is accessible to the anti-fluorescence antibodies in solution, thereby demonstrating specific binding. Methods for producing dextran-conjugates for surface immobilization follow.
- ⁇ (1,6)dextran, preparation N279 (B512) was dissolved in 0.01M NaAcetate buffer, pH 5.5, at 10 mg/ml and warmed in a 37° C. water bath for 30 minutes. NaIO 4 was then added to the final concentration of 1 ⁇ 10 ⁇ 2 M. The solution was mixed well and left to stand at room temperature for one hour in the dark. The preparation was dialyzed against 0.02M BBS (Borate buffered saline) pH 8.0, 4° C., overnight.
- 0.02M BBS Borate buffered saline
- Standard methods were applied to couple NHS-Biotin (BRL #5533LA) to target molecules, i.e., either protein or polysaccharide.
- target molecules i.e., either protein or polysaccharide.
- the biotinylated molecule was incubated with avidin at a proper molar ratio depending on the molecular weight of the target and its molar ratio with biotin.
- the molecules were then spotted on a surface that was precoated with biotin-dextran and blocked with BSA or gelatin. This strategy allows a flexible arrangement of antigen or antibody microarrays for a desired purpose, and avoids non-specific binding of target molecules on a surface.
- Small bioactive molecules containing amine group(s) can be coupled to amino-dextrans (Molecular Probes) by glutaraldehyde.
- Glutaraldehyde was added to the mixtures of the target molecule and amino-dextran (at proper molar ratios) to a final concentration of 0.2%. They were at room temperature for two hours. The reaction was stopped by addition of 1M ethanolamine at 6.1 ⁇ l/ml. The mixture was at room temperature for an additional two hours and then dialyzed against 1 ⁇ PBS or other proper solution, overnight. The dextran-small molecule conjugates were then spotted on nitrocellulose-coated slides. This method is suitable for generating microarrays having a large repertoire of small molecules and useful for high throughput drug screening or other biomedical investigations.
- Microbial polysaccharides, blood group substances and glycolipids were solubilized and stored in saline at a concentration of about 1 mg/ml at 4° C. A small droplet of chloroform was added to prevent microbes. In this simple way, most solutions can be stored for years. The agents were diluted in saline at required concentrations immediately before spotting.
- Soluble protein preparations were prepared at relatively high concentrations in 1 ⁇ PBS (mg/ml) with addition of 20% glycerol and frozen at ⁇ 80° C. They were diluted in 1 ⁇ PBS before use and stored at 4° C. for a short period of time (a few days).
- Antibody preparations were generally stored at 4° C. in 1 ⁇ PBS except in special cases.
- Some E. Coli -expressed protein antigens are water-insoluble.
- the preparations were purified in a denatured condition and stored them in the same solution at 4° C. The freezing process is avoided for these proteins. In most cases these preparations can be immobilized on a nitrocellulose matrix without special treatment. This method has been applied successfully in applicant's laboratory for hybridoma screening.
- the printed antigen/antibody microarrays were rinsed with 1 ⁇ PBS with 0.05% Tween 20 and then blocked by incubating the slides in 1% BSA in PBS containing 0.05% NaN 3 at 37° C. for 30 minutes. The microarrays were then incubated at room temperature with fluorescent-antibody conjugate at proper titration in 1% BSA PBS containing 0.05% NaN 3 and 0.05% Tween 20. Slides were rinsed with 1 ⁇ PBS with 0.05% Tween 20 five times, air-dried at room temperature and then scanned for fluorescent signals.
- a ScanArray 5000 Standard Biochip Scanning System (GSI Lumonics, Inc. and Packard BioChip Technologies, Inc.) which is equipped with multiple lasers, emission filters, ScanArray Acquisition Software and QuantArray Microarray Analysis Software, was used to scan the stained antigen microarray, quantify spot-associated fluorescent-signals and analyze data.
- a technical problem that has limited the application of the nitrocellulose-coated glass slide is its association with “white color” and non-specific fluorescent signals upon scanning. This problem is solved using the method that follows. (a) After staining a microarray glass slide, allow it to air-dry for a few minutes (at this stage, the nitrocellulose-coated region is white in color). (b) Soak the slide in 100% ethanol for 1-2 minutes until the white color of the nitrocellulose-coated region disappears and the entire slide becomes transparent. (c) Quickly spin the slide to remove extra ethanol. (d) Scan the slide when it is completely transparent. After storage for a few days or longer, depending on the humidity level in the air, the slide may turn back to the white color. One may repeat the above process to make the slide transparent again if necessary.
- the antigen/antibody microarray can be stained with antibodies, antigens or other reactors that are conjugated with non-fluorescent dyes.
- the commonly used alkaline phosphatase (AP) and peroxidase are useful alternatives.
- Sensitivity is one of the critical parameters that determine the diagnostic value of antigen microarrays.
- dextran preparations were arrayed on nitrocellulose-coated glass slides in concentrations ranging from 100 ⁇ g/ml to 3.3 ng/ml. They were stained with fluorescence-labeled anti-dextran mAbs, either 4.3.F1 or 16.4.12E, at a concentration of 1 ⁇ g/ml. In both cases, the captured fluorescent signals (intensities) detected were positively correlated to the antigen concentrations.
- 4.3.F1 was only detectable when the concentrations of N279, LD7 and B1299S are higher than 0.4, 20 or 100 ⁇ g/ml, respectively (spots of antigens with concentrations lower than 0.4 ⁇ g/ml were not shown in FIG. 1). Signal saturation was not observed even at the highest concentration of 100 ⁇ g/ml, showing the technical potential for improving the sensitivity of antigen microarrays.
- Glycoconjugate technology was used to produce an “epitope-specific antigen microarray”.
- a naturally occurring antigen may be composed of multiple antigenic determinants. Frequently, one or a few of them serve as predominant antigenic determinants for host recognition.
- Antibodies specific for some carbohydrate epitopes of a microbial polysaccharide can be more protective than those reacting with others.
- glycoproteins displaying ⁇ (1,6)-linked glucoses i.e., isomaltotriose-coupled BSA (IM3-BSA) or its KLH-conjugate (IM3-KLH)
- IM3-BSA isomaltotriose-coupled BSA
- IM3-KLH KLH-conjugate
- mAb 16.4.12E cavity-type
- mAb 4.3.F1 groove-type
- glycoproteins can be immobilized on a nitrocellulose-coated glass slide and their antigenic determinants remain accessible to antibodies in solution.
- Neoglycolipids i.e., glycolipid conjugates
- glycolipid conjugates were used to produce epitope-specific microarrays, wherein stearylamine-isomaltosyl oligosaccharide conjugates, ST-IM3, ST-IM5 and ST-IM7, were applied (data not shown)
- Such glycolipid conjugates are homogeneic, since each lipid molecule can only be coupled by a single oligosaccharide.
- the sugar chain can be conjugated on to multiple sites of a protein molecule, generating a heterogenic population of antigenic determinants. Both sugar epitope and the amino acid residues adjacent to it may be structurally involved in forming these antigenic determinants.
- a panel of anti-dextran mAbs were immobilized at a concentration of 0.5 mg/ml on a set of glass slides. These included (a) a nitrocellulose-coated glass slide (ONCYTE Film-Slides, Grace Bio-Labs, Inc., Bend, Oreg.); (b) a poly-lysine treated slide (POLY-PREPTM, Sigma); (c) a silane-treated glass slide (SILANE-PREPTM, Sigma); and (d) an un-treated, pre-cleaned glass slide. These slides were then reacted with fluorescence-tagged dextran preparations of distinct structures.
- the antibodies investigated include monoclonal antibodies of different isotypes (IgM, IgG and IgA).
- a well-established antigen-antibody system i.e., dextrans and anti-dextran monoclonal antibodies (mAbs) [10, 11] was used for these investigations.
- mAbs antigen-antibody system
- the former is specific for the terminal non-reducing end structure of ⁇ (1,6)dextran; the latter recognizes the internal linear chain of the polysaccharide.
- FIG. 2 shows an example of this approach.
- the antigen-based microarray can be applied for detection and characterization of a wide range of microbial infections.
- the host usually responds with the formation of antibodies which can be detected by a modified version of any of the methods used for antigen detection.
- the formation of antibodies and their time course depends on the antigenic stimulation provided by the infection. Recognition of these patterns provides evidence of recent or past infection.
- Microarrays of a large panel of antigens allow detection of many specificities in a single assay and thus allow a rapid diagnosis of infections. The diagnostic power of the instant microarrays will only increase as more microbial antigens and/or their antigenic determinants are characterized and applied.
- FIG. 2 a small scale antigen microarray with about 50 antigens was produced (FIG. 2) and tested with human sera from normal individuals and celiac patients. These specimens were diluted at 1:20 in 1% BSA-PBS with 0.025% Tween 20 and applied to the microarray. The bound human antibodies were visualized by application of a second antibody specific for human IgG or IgA that was conjugated with a fluorescent molecule (an anti-human IgG Cy3 and an anti-human IgA Cy5 ). The positive staining of the microspots of these arrayed antigens by the serum specimens ranged from 6% (three of fifty spots were detected) to 12% (six of fifty spots were detected). The antigens detected were mainly microbial polysaccharides, including Klebsiella polysaccharide type 7, 13, 14, 21 and 33, Dudmans Rhizobium Trifelli TA1 and Levan.
- Klebsiella polysaccharide type 7, 13, 14, 21 and 33 Dud
- the instant microarrays are significantly different from known cDNA microarray and oligo-chip technologies, which target only nucleic acids.
- Applicant has employed high throughput microarray technology to develop a novel strategy for detecting, quantifying and characterizing proteins, carbohydrates and other biological molecules, and useful in the new areas of post-genomic research, namely proteomics and glycomics.
- this technology is designed to detect and quantify a large repertoire of distinct biological molecules in a single assay.
- this technology is useful for detecting thousands of distinct molecules using a small amount of biological specimen, such as a drop of blood or other bodily fluid. This technology can be extended to the genome-wide scanning of protein expression and post-translational modification.
- the FITC-conjugated ⁇ (1,6) dextrans of moleuclar weight 20 kDa, 70 kDa, and 2,000 kDa, FITC-inulin, a biotinylated anti-human IgG antibody, an alkaline phosphatase-conjugated anti-human IgM, and streptavidin conjugates, were purchased from Sigma (St. Louis, Mo.).
- Antibodies for cell type/lineage analysis including antibodies specific for murine CD11b/MAC1, MAC3, TCR- ⁇ , TCR- ⁇ , CD3, CD4, CD5, CD8, CD19, B220, Syndecan-1, a mouse IgG3 isotype standard (A12-3), and a streptavidin conjugate of Texas Red, were from BD-PharMingen (San Diego, Calif.).
- a streptavidin-Cy3 conjugate was purchased from Amersham Pharmacia (Piscataway, N.J.), and a red fluorescence substrate of alkaline phosphatase, Vector Red, from Molecular Probes, Inc. (Burlingame, Calif.).
- a high-precision robot designed to produce cDNA microarrays was utilized to spot carbohydrate antigens onto the glass slides precoated with nitrocellulose polymer (FAST Slides; Schleicher & Schuell, Keene, N.H.).
- Carbohydrate antigens were dissolved in saline (0.9% NaCl) in concentrations as specified in the Figure legends. They were printed with spot sizes of ⁇ 150 ⁇ m and at 375- ⁇ m intervals, center to center. The printed carbohydrate microarrays were air-dried and stored at room temperature without desiccant before application.
- the printed carbohydrate microarrays were rinsed with PBS, pH 7.4, with 0.05% (vol/vol) Tween 20 and then blocked by incubating the slides in 1% (wt/vol) BSA in PBS containing 0.05% (wt/vol)NaN 3 at 37° C. for 30 minutes. They were then incubated at room temperature with antibodies at an indicated titration in 1% (wt/vol) BSA in PBS containing 0.05% (wt/vol) NaN 3 and 0.05% (vol/vol) Tween 20.
- Application of secondary antibodies or streptavidin conjugates is specified in figure legends.
- the stained slides were rinsed five times with PBS with 0.05%(vol/vol) Tween 20, air-dried at room temperature, and then scanned for fluorescent signals.
- the stained microarrays were scanned with a ScanArray 5000 Standard Biochip Scanning System (Packard BioChip Technologies, Inc., Billerica, Mass.) and data analyzed using Quant Array version 2.1 software associated with the system.
- ELISA and immunofluorescence staining were carried out as described (6, 11).
- the dextranase treatments were performed by a preincubation of tissue sections with dextranase(Sigma) at 0.5 unit/ml in 100 mM potassium PBS, pH 6.0, 37° C. for 60 minutes. This condition allows a complete removal of molecules of FITC- ⁇ (1,6) dextran that were specifically trapped by immune cells in the spleen sections of ⁇ (1,6) dextran-immunized mice (11).
- a model system for establishing carbohydrate microarray technology The dextrans and anti-dextran antibodies (1, 2) were applied to establish methods for immobilizing carbohydrate polymers on glass slides.
- Dextrans are polymers composed entirely of glucose, produced mainly by bacteria of the family Lactobacillaceae and of the genera Leuconostoc and Streptococcus.
- Dextran molecules derived from different strains may, however, differ significantly in their glycosidic linkage compositions. Unlike proteins that are linked solely by a peptide bond, carbohydrates utilize many possible glycosidic linkages so as to diversify their structures extensively.
- dextran preparations are predominantly or solely ⁇ (1,6)-linked, forming molecules with dominantly linear chain structures; others are composed of multiple glycosidic linkages, including ⁇ (1,6)-, ⁇ (1,3)-, ⁇ (1,2)-, and others, generating heavily branched molecules(3) (Table 1).
- Previous immunological studies (2, 4) have demonstrated that such structural characteristics are detectable by antibodies specific for different antigenic determinants or epitopes of dextran molecules. This system is, therefore, suitable for developing methods for immobilization of carbohydrate antigens and for investigating their immunological properties in a surface-immobilized configuration.
- FITC fluorescein isothiocyanate
- dextran preparations ranging from 20 kDa to 2,000 kDa and inulin of 3.3 kDa were all stably immobilized on the nitrocellulose-coated slide without chemical conjugation.
- the efficiency of their immobilization was, however, significantly influenced by the molecular weight.
- the larger dextran molecules were better retained than the smaller ones (FIGS. 6A, B).
- dextrtan preparations of different linkage compositions(3) and of different rations of terminal to internal epitopes (1, 4) were printed on nitrocellulose-coated glass slides. These preparations include N279, displaying both internal linear and terminal nonreducing end epitopes; B1299S, heavily branched and expressing predominantly terminal epitopes; and LD7, a synthetic dextran composed of 100% ⁇ (1,6)-linked internal linear chain structure.
- the dextran microarrays were incubated with monoclonal antibodies (mabs) of defined specificities, either a groove-type anti- ⁇ (1,6) dextran 4.3F1 (IgG3) (5) or a cavity-type anti- ⁇ (1,6) dextran 16.412E (IgA) (6).
- the former recognizes the internal linear chain of ⁇ (1,6) destrans; the latter is specific for the terminal nonreducing end structure of the polysaccharide.
- the groove-type mAb, 4.3F1 (refs 5,7) bound to the dextran preparations with predominantly linear chain structures, N279 and LD7, but bound poorly to the heavily branched ⁇ (1,6) dextran, B1299S.
- Both their nonreducing end structure, recognized by the cavity-type anti- ⁇ (1,6) dextrans, and the internal linear chain epitopes, bound by the groove-type anti- ⁇ (1,6) dextrans, are displayed on the surface after immobilization and are accessible to antibodies in an aqueous solution.
- a microbial infection may expose and release multiple antigenic substances to a host, eliciting a comprehensive host immune response, including a B cell response, which produces specific antibodies, and a T cell response, resulting in specific T cell activation and cytokine production. There is also an activation of macrophage, dendritic cells and other accessory cells, leading to production of differential profiles of cytokines and inflammation factors. Some microbial substances are lethal to a host upon their immediate release or after interacting with host cells or cellular factors. The interplay of different types of host cells and multiple protein factors and their interaction with the invading pathogen determine the progress and consequence of a microbial infection. For example, in an anthrax infection, the pathogen Bacillus anthracis may expose and release a number of antigens of distinct structural characteristics to a host, eliciting a comprehensive picture of a host response (FIG. 8).
- the microspot format of surface displaying biological molecules has the advantage of achieving a highly sensitive and simultaneous detection of multiple binding partners in solution. Since the amount of molecule in the solution phase that is required for saturating the surface immobilized microspots of molecules is considerably small, binding can be achieved with a relatively lower molar concentration of molecules in solution. In brief, it is believed that the smaller microspot is better than the bigger spot in its sensitivity of detection in an assay system (12,13).
- High-priority infectious agents that pose current risks to our national security include multiple microbial pathogens known as Category A pathogens, such as Bacillus anthracis (anthrax), Clostridium botulinum (botulism), Yersinia pestis (plague), Variola viruse (smallpox), Francisella tularensis (tularemia) and viral hemorrhagic fevers (Lassa virus, Ebola virus, Marburg virus and Lymphocytic Choriomeningitis virus).
- An assay system that allows detection and characterization of these pathogens in a single assay using limited clinical specimens is currently unavailable.
- Such emerging microbes could be either beneficial or harmful to public health depending on the nature of the microorganism as well as the way by which they are utilized. Therefore, in designing a high throughput immunoassay one must consider the detection of existing pathogens as well as their mutants or recombinant forms. This goal is achievable if a panel of antigens of a given microbe and/or their specific antibodies are applied to produce a diagnostic biochip to detect multiple molecular targets of the pathogen. Applicants have tested the feasibility of this proposal by printing a panel of HIV-1 proteins on a single chip to monitor the HIV-1 infections by different classes or clades of HIV-1 viruses (see FIGS. 11 and 12).
- An antigen biochip is designed to detect and quantify antibodies in body fluids. During infection, whether viral, bacterial, fungal, or parasitic, the host usually responds with formation of antibodies, which can be detected by modification of any of the methods used for antigen detection. The formation of antibodies and their time course depends on the antigenic stimulation provided by the infection. Recognition of these patterns provides us with evidence of recent or past infection. Establishing a biochip to display a large panel of microbial antigens and the host derived autoantigens will substantially extend the scope of biomedical research on the biological relationship between host and microorganism, as well as understanding the molecular mechanisms of infectious diseases. Both carbohydrate antigens and protein antigens can be of importance for the design and production of a diagnostic biochip.
- Carbohydrate structures of microbial origin including polysaccharides, glycolipids and glycoproteins, frequently serve as the main antigenic structures to which host cells recognize and mount a response (17).
- a single microbial antigen may, however, display multiple antigenic determinants, with one or a few of them predominating in a given infection.
- a relatively simple microbial polysaccharide, ⁇ (1,6) dextran N279 displays both the internal linear chain and terminal non-reducing end structures as distinct antigenic determinants.
- the polysaccharide was injected to a Balb/c mouse, it elicited a predominant antibody response directed to the internal linear chain epitope of ⁇ (1,6)dextran.
- the internal linear chain epitope is thus defined as a dominant antigenic determinant to the host.
- the antibodies elicited were solely or dominantly of the groove-type anti-dextran.
- the terminal non-reducing end structure is apparently the minor antigenic determinant.
- a dominant antigenic determinant should, therefore, be placed as a high priority to serve as a target for vaccine design or for developing an immunoassay for diagnosis.
- Identifying a minor antigenic determinant is, however, also important since there is the possibility that a dominant antigenic structure is not suitable for vaccination or diagnostic application; whereas, a minor antigenic determinant may serve as a molecular target for these applications.
- Some microbial antigens may share or mimic host components. This is known as antigenic cross-reactivity.
- a(1 ⁇ 8)NeuNAc in the capsule of the group B meningococcus and of E.coli K1 is found on glycoproteins and gangliosides of human tissues, complicating the application of the capsular polysaccharides for vaccination, especially in infants who have expression of polymeric forms of the carbohydrate structure.
- Gag p24 protein of HIV-1 elicits a dominant antibody response in most AIDS patients.
- Detecting anti-Gag antibodies has diagnostic value.
- These antibodies have no HIV-1 neutralization activity since Gag is not expressed on the surface of the HIV-1 virus.
- the antigen may be coupled with a carrier molecule, forming a highly antigenic conjugate molecule.
- IM3 isomaltotriose
- BSA or KLH can be coupled to BSA or KLH to produce a semi-synthetic glycoprotein to display the minor antigenic determinant of the polysaccharide, i.e., the terminal non-reducing end epitopes of ⁇ (1,6)dextran.
- Antigenic structures that are not expressed on the surface of a microorganism also have an important diagnostic value. For example, detection of antibodies that are specific for the surface antigen of hepatitis B (HBsAg) may indicate an early viral infection or a successful vaccination; detecting antibody specificities to multiple viral antigens, such as surface antigen (HBsAg) plus core antigen (HBcAg) or HBsAg plus a relevant e antigen (HBeAg) suggests an active infection or the progression of the disease (28,29).
- a microbial pathogen either a virus or a bacterium, may release multiple antigenic substances that trigger host antibody responses.
- the antibodies elicited are mainly those bound to the surface antigens and are predominantly IgM antibodies.
- IgG antibodies with different specificities, including anti-gp120 (envelope protein) and anti-Gag p55 polyproteins of HIV-1, can be detected in the serum of the patient.
- applying a combination of surface and non-surface antigens on a biochip for diagnosis can assist in the recognition of the stages or steps of an infection and provide information to predict disease progression and to evaluate the efficacy of a therapeutic agent or strategy.
- anthrax toxin is lethal upon its activation. This process involves multiple steps of molecular and cellular interactions of anthrax proteins, host cells and protein factors (1-3).
- the protective antigen of anthrax, named PA is an integrated component of the lethal toxin of Bacillus anthracis. It binds to a specific cellular receptor and forms toxic, cell bound complexes with edema factor (EF) and lethal factor (LF) (1-3).
- EF edema factor
- LF lethal factor
- an antigen-based biochip is designed to detect and quantify specific antibodies and therefore, diagnose an infection. This method is not for the detection and quantification of antigens that are released from an infectious agent. Detecting microbial antigens in serum or other body fluids is generally more difficult than detecting antibodies. The former has, however, higher diagnostic value than the latter. It is, therefore, necessary to establish a highly sensitive antibody-based microarray to detect microbial antigens.
- TI-dependent and TD-antigenic responses which are recognizable by in vitro immunoassay, include a series of humoral factors, such as antigen specific antibodies, their Ig-isotypes, cytokines and other inflammation factors.
- Cytokines are soluble proteins or glycoproteins, which play a critical role in controlling development or differentiation of lymphocytes and in regulating their anti-infection responses. For example, a microbial infection or vaccination may activate certain sub-types of T cells, either T helper 1 (Th1) cells or T helper 2 (Th2) cells. These specialized Th cells can produce unique profiles of cytotokines.
- IgA-antibodies at mucosal sites Induction of IgA-antibodies at mucosal sites is of critical importance. T cells and their cytokines have been shown to play a critical role in various stages of IgA response (33-35), including induction of Ig class switching of IgM to IgA and of terminal differentiation of IgA-committed B cells.
- Th2 cytokines such as IL-4, IL-5 and IL-6
- Th1 cytokine IFN- ⁇
- the carbohydrate microarray technology has certain technical advantages and disadvantages.
- An obvious advantage is that the purified polysaccharides are generally stable in various conditions, either as dried solid or in aqueous solution, at room temperature or at 4° C. in storage.
- protein-denaturing and/or conformational alteration in microarray printing and storage is a major challenge to the technology, there is no such serious concern for most (if not all) carbohydrate antigens.
- a disadvantage of the carbohydrate microarray technology is that methods for high throughput production of carbohydrate macromolecules or complex carbohydrates, which is equivalent to the PCR for amplifying DNA or the cloning and expression method for producing proteins, are yet to be developed.
- Classical methods to obtain pure carbohydrate antigens include (a) isolation and purification from biological materials, such as cells, tissues or biological fluids; (b) chemical synthesis; and (c) enzymatic in vitro synthesis.
- a Rapid progress in establishing high throughput technology for the in vitro synthesis of carbohydrate macromolecules or complex carbohydrate molecules is most likely unexpected.
- the availability of purified carbohydrate antigens is, therefore, a potential rate-limiting factor to the carbohydrate microarray industry.
- Our optimized methods for printing microarrays allows one: (i) to reduce amount of antigen needed for microarray printing; (ii) to increase the detection sensitivity and biochip capacity; (iii) to reduce the time that is necessary for a microarray printing cycle; (iv) to prevent cross-contaminations in printing microarrays; and (v) to reduce the cost of producing a diagnostic biochip substantially.
- FIG. 9 The general printing procedure is schematically illustrated in FIG. 9.
- a high-precision robot designed to produce cDNA microarrays was utilized to spot carbohydrate antigens onto glass slides that were pre-coated with nitrocellulose polymer.
- This biochip is designed to enable the simultaneous detection of all Category A infectious diseases. In its clinical application, two-step staining is required. A number of carefully selected pairs of antigen and antibody are be printed on slides for each pathogen.
- the immobilized antigen serves as a probe to detect antibody in solution; the surface displayed antibody is used to capture a specific antigen in the solvent.
- This assay is, therefore, capable of detection of both antigens and antibodies in a single assay. Since an immobilized antigen may display multiple antigenic determinants, a microspot of antigen may capture antibodies that recognize different antigenic determinants expressed by the antigenic molecule. This makes the biochip system highly sensitive.
- Each micro-glass slide contains eight well-separated sub-arrays of identical contents. There are 600 microspots per sub-array, with spot sizes of approximately 200 micron at 300 micron intervals, center-to-center. A single slide is, therefore, designed to enable eight detections;
- Each 600-spot sub-array is composed of carbohydrate and protein antigens, as well as antibodies specific to microbial antigens.
- the immobilized antigens will allow for the detection of human antibodies elicited by an infection; whereas immobilized antibodies are for the detection of microbial antigens;
- each antigen/antibody will be printed at 0.5-1.0 mg/ml and at one to ten dilution of the initial concentration for the second concentration. Each preparation at a given concentration will be repeated three times; and
- Antibody isotype standard curves Human antibodies of IgG, IgA and IgM isotype of known concentrations will serve as standard curves for antibody detection and normalization.
- This biochip is designed to enable the rapid diagnosis of the Category A infectious diseases, which requires only a single step of staining in clinical diagnosis. The time required for a biochip assay is, therefore, substantially shorter.
- Competitive immunoassay is used for rapid diagnosis.
- a competitive immunoassay requires an antigen/antibody pair. Either antigen or antibody can be immobilized on the solid surface, which will then interact with an antigen or antibody in solution. The immobilized antigen and tagged antibody in solution forms a specific probe to detect both antigen and antibody in clinical specimens. The free-antigen or antibody competitively inhibits the binding of the tagged antibody to the antigen immobilized on the solid surface. Key characteristics of this “competitive” one-step biochip that differ from Diagnostic Biochip A are summarized below:
- a panel of carefully selected microbial antigens, whose specific antibodies are available, will be printed on the chip with the method described above.
- the free antigens or antibodies can compete with the labeled antigen or antibody to bind the immobilized antigens or antibodies. Given that antibodies are generally more stable than other protein molecules in solution and are suitable for standardized production, printing antigen on a series of glass slides and using fluorescent-tagged antibodies for staining is preferred. If a clinical specimen in question contains a specific antibody for the target antigenic determinant or the antigen, the binding of the tagged antibody to the antigen will be competitively inhibited.
- Diagnostic Biochip B is a highly sensitive and specific biochip system. Its specificity is at the level of a single antigenic determinant.
- Diagnostic Biochip C is composed of a large repertoire of carbohydrate and protein antigens as well as antibodies. This is a largely extended Diagnostic Biochip A. This biochip makes it possible to diagnose and characterize a wide range of microbial infections using a few microliters of serum specimen. This microarray has the printing capacity to include most common pathogens. Practically, it is limited by the availability of specific antigen preparations and their antibodies. 1000-2000 distinct antigens and antibodies can be printed on the chip. This enables a simultaneous detection of about 300 microbes, which include about 50-100 human pathogens. General properties of the master microarray are summarized as follows:
- Each antigen has four dilutions (0.5 mg/ml to begin with) and each dilution has three repeats.
- This biochip is composed of about 4,000 microspots of antigen and antibody preparations. Each antigen or antibody preparation of a given dilution was printed with four repeats in a vertical line of microspots on the biochip. This allows us to visually observe and statistically analyze the reproducibility of microarray printing and staining. The significance and sensitivity of antibody detection for each antigen at a given antigen concentration can also be statistically calculated. Some preparations, for example the gp120 glycoprotein of HIV-1 as highlighted in a square in FIG. 11, were printed from left to right in a series dilution of one to five, beginning at 0.5-1.0 mg/ml and with four dilutions thereafter. These biochips were stained with the normal or HIV-1 infected human serum specimens with the methods described above. Pictures of the ScanArray visualization of the multi-color fluorescent staining of biochips are shown in FIG. 11.
- a large repertoire of antibody specificities were recognized in the normal and HIV infected individuals; (c) the specificity of this system is illustrated by recognizing the epitope-binding specificities of monoclonal anti-dextran antibodies and by specific detection of human serum antibodies for the gp120 glycoproteins and gag p24 of HIV-1 in AIDS patients; (d) a large repertoire of microbial antigens can be patterned on a single micro-glass slide, reaching the capacity to include most common and conditional pathogens; and (e) a biochip-based high throughput technology requires a strong bioinformatic presence to support it. While one may need a day to perform a biochip assay for a given clinical specimen, one may need many days to process the large amount of data produced by the biochip analysis. Developing advanced computer algorithms to facilitate this process is of equal importance with improving the hardware of the biochip technology.
- a method currently used for cytokine detection either ELISA-based assays or radioimmunoassays, takes advantage of the Sandwich-antibody assay. Specifically, the first cytokine-specific antibody is immobilized on a solid surface to capture cytokine in solution and then the second anti-cytokine antibody is applied to detect the surface-immobilized cytokine. The second anti-cytokine can be biotinylated, allowing signal amplification with a labeled Streptavidin. These methods are highly sensitive but limited in detecting a cytokine on a one-by-one base.
- An antibody microarray for a full-panel scanning of human cytokines was prepared. Polyclonal and monoclonal antibodies specific for human cytokines are currently available through various resources, providing a strong base for developing an antibody microarray to enable a highly sensitive, high throughput, full-panel cytokine scan.
- a large collection of carbohydrate containing macromolecules are printed on the nitrocellulose-coated slides and then the carbohydrate microarrays are stained with antibody preparations or lectins to probe the microspots that display the antigenic determinants in question.
- the monoclonal and polyclonal antibodies elicited by a microbial antigen or by a pathogen, as well as serum specimens of an infected individual are all useful reagents for these analyses.
- a positively stained microspot indicates the presence of a target molecule or antigenic determinant. Further characterization of this antigen preparation could lead to the identification of a suitable diagnostic molecule for a given infectious disease.
- Carbohydrate structures present in B. anthracis are potential molecular targets for vaccine development and for diagnostic application. These carbohydrate structures include glycoproteins and polysaccharides. Glycoproteins are expressed by the dormant spore of B. anthracis and are recognizable by specific lectins, such as Glycine max (41). Since the spore surface interacts with the host initially in an anthrax infection, these structures are likely the targets for host recognition and antibody responses. They are therefore important for both vaccination and diagnosis. Polysaccharides are expressed by the germinating spores of B. anthracis, which are detected by monoclonal antibodies raised against the cell wall Gal-NAG polysaccharide of the pathogen (22).
- the exo- and/or cell wall Gal-NAG polysaccharide which is present in the culture medium for growing B. anthracis (4), can be isolated from the cell wall of the microbe (22,42). Given that the Gal-NAG polysaccharide is universally present among and specific for strains of Bacillus anthracis (22), its presence in solution and its structural stability, makes this molecule a potential target for the identification of B. anthracis and for developing an anthrax vaccine.
- Gal-NAG polysaccharide (a) it is 12,000 Da in molecular weight and contains galactose, N-acetylglucosamine, and N-acetylmannosamine in an approximate molar ratio of 3:2:1 (22) or 10:2:1. This slight difference in molar ratio is attributed to differences in the hydrolysis conditions applied (47); (b) it is pyruvylated although the sugar residue and position of pyruvylation are yet to be determined (47); (c) it is most likely B.
- anthracis specific and expressed by both germinating spores and the vegetative bacillus (22); (d) it shows antigenic determinants which are cross-reactive to Pneumococcus type 14 polysaccharide (43) ; (e) it has no human blood group substances A, B, or H activity (43); and (f) anti-serum elicited by the anthrax polysaccharide has, however, cross-reactivities with a preparation of hydrolyzed blood group substance A that contains the type IT Gal-GlcNAc sequences (Gal ⁇ 1 ⁇ 4GlcNAc) (see ref. 43, page 452 for a description of the study by Ivanovicx (1940)).
- the Gal-NAG polysaccharide expresses potent antigenic determinants to mice and humans since the pyruvylated Gal-NAG structure is not present in the host; (ii) the polysaccharide itself is, however, poorly antigenic in solution since it is a T-independent antigen with relatively low molecular weight (1.2 KDa). Given this consideration, early observations that the polysaccharide was not protective to animals challenged by B. anthracis can be attributed to the nature of poor immunogenicity in its native configuration; (iii) its Gal-NAG core structure is similar to a core structure of blood group type II chain, Gal ⁇ 1 ⁇ 4GlcNAc.
- the anthrax polysaccharide may contain a non-pyruvylated antigenic determinant mimicking those of the Pneumococcus type 14 polysaccharide. This leads us to conclude, therefore, that the cell wall polysaccharide of B. anthracis contains more than one antigenic determinant.
- a carbohydrate microarray was designed to maximize the surface display of its potential antigenic structures using the following method: (a) print the polysaccharide on a microchip to display its antigenic determinants in the native configuration; (b) isolate the pyruvylated and non-pyruvylated fractions of the polysaccharide and apply them on the microarray as described by Mesnage et al. (47). This allows investigation of the potential dominant role of the pyruvylated sugar structure in its antigenicity; and (c) synthesize a panel of oligosaccharide-protein conjugates.
- Detecting microbial antigens in serum or other body fluids is useful in the diagnosis of an infectious disease but generally it is difficult. It is, therefore, necessary to establish a highly sensitive antibody-based microarray to detect microbial antigens. In addition, such an antibody-based microarray will allow us to monitor a microbial pathogen in the environment as well as in host body fluids. Identification of highly specific antigens and antibodies for each pathogen is critical for the development of a diagnostic biochip.
- IgM antibodies twelve distinct specificities of IgM antibodies (12/48) and thirty-five IgG anti-carbohydrate antibodies (35/48) were identified.
- Carbohydrate molecules that were positively stained include twenty polysaccharides (20/24), eleven complex carbohydrates of cellular origin (11/19) and four semi-synthetic glycoconjugates (4/5).
- anti-carbohydrate antibodies of IgM isotype twelve distinct specificities were identified. The majority (7/12) were bound to Klebsiella polysaccharides. This is similar to our previous observation that antibodies bound to Klebsiella polysaccharides were most frequently found in the repertoire of human myeloma anti-carbohydrate antibodies (48-52).
- the repertoire of human IgG anti-carbohydrate antibodies is, however, broader than those of IgM isotype.
- microbial polysaccharides 20/24
- polysaccharides of microbial pathogens E. coli -K92 and -K100
- Pneumococcus type-C -VIII, -IX, -SIV, -XIV and -27
- Group B Meningococcus H. Influenza Type A
- This antigen microarray was then applied to characterize monoclonal antibodies (FIG. 14, panels III and IV) to critically evaluate their antigenic or epitope-binding specificities and cross-reactivities.
- Antigenic cross-reactivity between microbial polysaccharide ⁇ (1, 6)dextran and a preparation of Chondroitin sulfate B polysaccharide that was derived from the intestinal mucosa of porcine was demonstrated. This has led to the recognition of a novel cross-reactive molecular marker of microbes and host cell (11).
- these experiments demonstrated that semi-synthetic glycoproteins are applicable for the construction of a carbohydrate microarray. This is of critical importance since it enables the application of rationally designed synthetic oligosaccharides for microarray construction and allows a critical examination of the specificity and cross-reactivity of carbohydrate-mediated molecular recognition.
- the flexible 8-chamber biochip system is sufficient for this type of initial screening of a panel of molecular targets.
- all the available antigen preparations of the eight Category-A pathogens can be printed at various dilutions in a single sub-array chamber.
- a specific antibody for example, a mouse monoclonal antibody bound to the anthrax polysaccharide, can be applied on the sub-array biochip to react with all the antigens on the chip. It may also be applied in a series of dilutions on different sub-array chambers. This simple experiment allows us to critically evaluate (a) antibody binding specificity and cross-reactivity; (b) the affinity of antigen-antibody interaction; and (c) the quality of the printed antigen and method for immobilizing the antigen.
- an antigen/antibody pair is qualified by the 8-chamber biochip analysis, a further evaluation is conducted using a large-scale biochip, which displays both microbial antigens and those from human and other mammalian species.
- the highly specific pairs of antigens and antibodies are candidates for the diagnosis of corresponding microbial infections.
- Those who have cross-reactivities with human tissue antigens may be also useful for printing microarrays. As summarized above, identification of such cross-reactivities may lead to a better understanding of the biological relationship of microbes and their hosts, as well as the pathogenesis mechanisms of an infectious disease.
- Different categories of proteins can be used to produce the diagnostic protein microarray. For example, (a) both membrane-bound and secretory proteins of a pathogen, which may trigger the initial immune response in an infection, making them ideal targets for early diagnosis and vaccination; (b) non-surface expressed proteins, which could be useful in identifying and characterizing the progressive stages of an infection; and (c) the candidate genes that are unique to a given pathogen, namely the species-specific or stain-specific molecular targets, thereby enabling highly specific detection on the final biochip.
- TMHMM http://www.cbs.dtu.dk/services/TMHMM-2.0/
- NetOGlyc 2.0 http://www.cbs.dtu.dk/services/NetOGlyc/
- PredictProtein http://www.embl-heidelberq.de/predict protein/predictprotein.html
- 3D-PSSM Web Server V 2.6.0 http://www.bmm.icne t.uk/ ⁇ 3dpssm/) for protein fold recognition.
- COGnitor program takes an amino acid sequence and extrapolates its function by comparing the unknown protein's sequence of amino acids to amino acid sequences from other genes of characterized function in a series of genomes (54). Genes that are highly conserved in evolution would be identifiable using the COGnitor program; those that are unique to a given organism could be non-recognizable by a COGnitor search. Proteins that are not recognized by the COGnitor program are probably high priority candidates for diagnostic application since the proteins they encode are most likely species-specific antigens. For the genes that are recognized and classified by the program, additional steps of investigation must be taken to define whether they are suitable targets for a diagnostic use.
- this protein contains both a transmembrane region, as well as a large extracellular component.
- the protein is on the surface of the bacteria, and is an ideal candidate to be printed on a microarray because it may play a role in initiating a primary immune response. Therefore, even if Okinaka et al did not characterize the gene, we could use this software to identify it as an ideal surface target that could induce a primary immune response.
- the COGnitor program can be used to identify the species-specific genes/proteins for printing the diagnostic protein chips.
- the amino acid sequences of all the 46 annotated genes of Px01 plasmid of B. anthracis through the COGnitor program. We present the results from this test in Table 2.
- the COG database includes 74,059 classified protein sequences from the genomes of 43 species of both prokaryotic and eukaryotic organisms (but excludes the human genome), a “No Cog” result suggests that the protein in question is more likely to be species or strain-specific to the pathogen. At the very least, one can claim that it is highly unlikely for a “No Cog” protein to contain a known evolutionarily conserved ancient domain that exists across many species' genomes. Being able to select against genes that exhibit such conserved domains is a welcome tool, for this could help to lower the probability of selecting a protein that may yield ambiguous results on the final biochip due to cross reactivity.
- the genes of the most unique lethal nature, as well as a series of surface antigens, are not recognized by the COGnitor program because they match no other species' genes.
- One example of an ideal gene to select has been presented, namely the px01-54 protein of B. anthracis. This protein is expressed on the surface of the organism according to Okinaka et al. (16), spans a membrane according to the TMHMM program, and is not recognized by the COGnitor program, making it more likely to be unique to the species.
- HydroGelTM slides are produced by Packard BioScience for printing protein microarrays. We investigated whether Hydrogel can serve as an alternative substrate for producing carbohydrate microarrays and for producing HIV diagnostic protein microarrays.
- Printing proteins and carbohydrate-containing macromolecules on hydrogel can be performed using Cartesian's PIXSYS 5500A Microarryer (CHIPMAKER 4), using a contact arraying procedure.
- CHIPMAKER 4 Cartesian's PIXSYS 5500A Microarryer
- Protein preparations including antibodies, BSA, Avidin and HIV-1 gp120, RT and gag proteins, can be quantitatively immobilized on the hydrogel, providing fine spots of about 150 microns in diameter and thus making it possible to produce a high density protein microarray.
- Carbohydrate preparations including polysaccharides, glycosaminoglycans, glycoproteins, semi-synthetic glycoconjugates and glycolipids, can be quantitatively immobilized on the hydrogel, providing fine spots of about 200 microns in diameter and thus making it possible to produce a high density carbohydrate microarray.
- Hydrogel-based protein and carbohydrate microarrays are advantageous due to their low fluorescent background.
- a disadvantage of the Hydrogel substrate is its absorption of relative lower amounts of materials on the biochip.
- the fluorescent signals detected on Hydrogel-slides are much lower than those detected on the nitrocellulose slides.
- the nitrocellulose-based biochip favors detection of IgG antibodies but not IgM antibodies in solution.
- the former is an immunoglobulin (Ig) monomer; and the latter is an Ig pentamer.
- Ig immunoglobulin
- Such bias is not seen in the Hydrogel-based biochips. This finding is of significance since it provides information to improve the nitrocellulose surface for producing a diagnostic biochip.
- An infectious agent may expose and release multiple antigenic substances to a host, eliciting specific antibody responses.
- Many antigen-antibody binding assays are currently in use for clinical diagnosis of infectious and non-infectious diseases. These include the classical direct immunoassays, such as, immunodiffusion, immunoelectrophoresis, agglutination and immunoprecipitation, and recently developed methods, including immunofluorescence, radioimmunoassay (RIA), enzyme-immunoassay (EIA) and western blot.
- RIA radioimmunoassay
- EIA enzyme-immunoassay
- a number of category A pathogens Bacillus anthracis, Clostridium botulinum, Yersinia pestis, and viral hemorrhagic fevers
- other emerging infectious diseases Lyme disease and West Nile Virus infection
- the antigen/antibody-based biochips will play a significant role in the surveillance of emerging infectious diseases (FIG. 17).
- Both carbohydrate antigens and protein antigens are important for the production of a diagnostic biochip. As shown in FIG. 17, the presence of a polysaccharide in Bacillus anthracis has been recognized for some time 11,12,13 . It is specific for B. anthracis, a useful molecular target for the identification of the pathogen. This structure is, however, masked before spore germination, casting doubt on its potential for vaccination use. A protein antigen of B. anthracis, the protective antigen (PA) is a well-recognized vaccine target. PA is an integrated component of the lethal toxin of Bacillus anthracis.
- detecting a microbial antigen and/or its specific antibodies in bodily fluids are important in diagnosis of infectious diseases and in surveillance of emerging infectious diseases. This goal is achieved by an antigen/antibody-based microarray of high sensitivity, large capacity, and extensive antigenic diversity.
- This section is directed to a central technical difficulty in the technology of proteomic microarrays—the structural and conformational instability of protein on-chip.
- Our procedures include a) a high throughput technology to screen for the antigen preparations that are applicable for our proposed microarray platform; b) the technology for the production and long-lasting preservation of protein microarrays; and c) Green Chip Technology to facilitate protein chip development.
- Our method of protein chip fabrication is a non-covalent protein immobilization on a nitrocellulose-coated micro-glass slide. It uses a nitrocellulose-surface to immobilize an antigen, similar to the Western Blot assay, but has no treatment to denature the protein before its application. A protein microspot is, therefore, printed on the chip without any chemical or physical treatment to interfere with its native structure.
- Each microglass slide contains eight well-separated sub-arrays of identical contents. Its microarray capacity is 600 microspots per subarray. A single slide is, therefore, designed to enable eight microarray analyses. Antibodies can be applied on separate subarrays in a serial dilution as in an ELISA assay.
- Each microglass slide contains eight-well separated sub-arrays of identical contents. There are 600 microspots per subarray, with spot sizes of approximately 200 microns and at 300-micron intervals, center-to-center. A single slide is, therefore, designed to enable eight detections.
- a 600-spot subarray is composed of pathogen-specific protein antigens in question as well as a few selected carbohydrate antigens to serve as control spots. These selected carbohydrate antigens have been characterized on the chip. Their specific antibodies are seen frequently in body fluids of normal individuals;
- each antigen will be printed at 0.5-1.0 mg/ml and also at a one to ten dilution of the initial concentration for the second concentration. Each preparation at a given concentration will be repeated three times; and
- Antibody isotype standard curves Human or murine antibodies of IgG, IgA and IgM isotype of known concentrations will serve as standard curves for antibody detection and normalization.
- a) Negative elimination A preparation of mixed monoclonal or polyclonal antibodies is applied to stain a subarray. Antibodies derived from the same species can be mixed together to stain a sub-array and a tagged secondary antibody can reveal their specific binding on antigen spots. To take the advantage of the above 8-chamber design, these antibodies are applied in serial dilutions to permit an estimation of their detection sensitivity and specificities;
- the protein may be conjugated to a carrier molecule (such as BSA) to improve its immobilization. If it is ELISA negative but Western positive to a corresponding antibody, the protein may be solubilized in a denaturing solution before printing on the chip.
- microarray biochip composed of about 4,000 microspots of antigens.
- carbohydrate antigens we printed a large panel of protein antigens.
- each antigen or antibody preparation of a given dilution was printed with four repeats in a vertical line of micro-spots on the biochip. This allowed us to visually observe and statistically analyze the reproducibility of microarray printing and staining. The significance and sensitivity of antibody detection for each antigen at a given antigen concentration can also be statistically calculated.
- Antibodies of distinct epitope-binding specificities are frequently elicited in the course of a microbial infection.
- the ELISA-based immunoassays are preferential to the detection of antibodies that recognize the native antigenic determinants;
- the Western blot assays generally directed to the protein structures that are denatured/partial denatured and immobilized on a nitrocellulose membrane or other surfaces with hydrophobic characteristics.
- the “Western type” of antigenic structures also has large potential in protein chip application since many antigens on Western blot/nitrocellulose strips are stable and suitable for long-term preservation.
- the protein microarray assay requires preservation of protein structures (a general belief in the field). Protein on-chip stability has been considered a critical issue for the development of long-lasting protein microarrays. To address this question of protein stability, we analyzed in a model system, the HIV-1 protein chip (see FIG. 18).
- FIG. 18 shows the results from protein microarrays that were printed, air-dried, and stored at room temperature. In one set, slides were stained at day 2 and another set in 11 months after printing. Serum specimens applied for the day 2 staining are identical to those for the 11 month-old slides. This allows a comparative analysis of protein antigenic reactivities on the chips that were stored for different time range, either for two days or for eleven months. Each bar represents the mean of four detections (Ratio of intensity over background). Data were calculated and statistically analyzed as described 9 .
- protein microarrays can be treated in three different ways, including lyophilizing, desiccation, and hydration, and stored for a various periods of time, ranging from two days to two years.
- This method can be applied to many molecular targets whose nucleotide sequences and/or structural information are available. This method is, therefore, designed to extend the repertoire of pathogen signatures for the production of diagnostic microarrays.
- PA protective antigen
- Efficacy of protein immobilization on a nitrocellulose-coated microslide depends on the physicochemical property of protein molecules. Since only noncovalent molecular interactions are involved, a common influencing factor is the molecular weight (MW) of a target molecule. In some circumstances, protein antigens or pathogen-specific antigenic determinants are too small to be immobilized on the chip without altering their antigenic reactivities. We, therefore, fuse a target molecule to a carrier protein molecule to improve its surface adhering property. In this case, we select a fluorescent carrier molecule, the green fluorescent protein (GFP). GFP was originally isolated from the biolyminescent jellyfish Aequorea Victoria 44 .
- the protein as well as its variants, have been successfully expressed in various other organisms and have been used as a detection system.
- the two variants that are readily available as purified proteins are EGFP (enhanced green fluorescent protein) and GFPuv (UV-optimized GFP variant). Their excitation maxima are 488 and 395 nm, respectively, while their emission maxima are 507 and 509 nm, respectively.
- PA is the central component of the three-part lethal toxin of Bacillus anthracis. It binds to a specific cellular receptor and forms toxic, cell bound complexes with edema factor (EF) and lethal factor (LF) 14-16 . It was named PA since it acted protective when an animal was injected with the protein and then challenged by the lethal pathogen B. anthracis. PA itself is a good antigen for eliciting antibody responses in a number of mammalian species, making it an important vaccine against anthrax 45 . The crystal structure of monomeric PA at 2.1 ⁇ resolution and the water-soluble heptamer at 4.5 ⁇ resolution have been resolved (FIG. 21) 46 . PA is, therefore, an ideal molecule model for studying the relationship between protein structure and its antigenic reactivity.
- EF edema factor
- LF lethal factor
- a) Construction of expression vectors, protein induction and purification Construct a panel of twelve GFP-PA fusion proteins as outlined in FIG. 22. Briefly, six sets of PCR primers have been designed according the published nucleotide sequences of PA (on the PX01 plasmid) and the domain structure of the protein. Use a cDNA clone containing the full-length PA as a template for PCR amplification to produce six PCR fragments, including a full-length PA, an N-terminal truncated PA (PA 63 ), and domain 1 to 4. These PCR fragments are subcloned into an E.
- coli expression vector pGFPuv cDNA Vector (BD/Clontech), to express corresponding GFP fusion proteins.
- the expressed fusion protein will be accumulated intracellularly as GFP alone.
- a His-tag can be cloned either at the N-terminal or the C-terminal of a recombinant protein, allowing protein purification using Ni-NTA column/resin under either denatured or native condition as described by the manufacture (QIAGEN Inc., USA). This will enable the binding of protein on Ni-NTA ELISA plate and Western blot using anti-His antibodies.
- Additional methods of purification include: i) the native condition of purification; ii) denaturing conditions; and iii) the GFPuv protein is resistant to the 8M Urea, which serves as one of the alternative methods for GFP-fusion protein purification.
- the ELISA-based immunoassays preferentially detect antibodies that recognize the native antigenic determinants; the Western blot assays are directed to the protein structures that are denatured/partially denatured and immobilized on a nitrocellulose membrane or other surfaces with hydrophobic characteristics. “Western-like” antigenic structures have high potential in protein chip application since they are generally stable and suitable for long-term preservation. Given the complexity of protein structure and the question regarding their antigenic reactivity, we use the protective antigen (PA) of B. anthracis as a model and example for other important microbial antigens.
- PA protective antigen
- This section is directed to the high throughput production of the oligosaccharide-based, epitope-specific carbohydrate microarrays.
- This invention makes it possible to produce a glycochip whereby a single type of glycoconjugate, the oligosaccharide-polyacrylomide conjugate, is utilized to display a large repertoire of oligosaccharides of distinct structures.
- ⁇ Gal anti- ⁇ Gal system As a model to establish the technology of the oligosaccharide-based, epitope-specific carbohydrate microarrays. Since ⁇ Gal is a key antigenic determinant that is responsible for the hyperacute rejection in animal to human xenotransplantation, the microarrays produced by this investigation are valuable for monitoring such anti-xenoantigenic responses.
- Glycoconjugates utilized in this study include: (i) DW450 phenyl ⁇ -Galactopyranosyl-(1-3) b-D-galactopyranosyl-(1-4)-1-thio-b-D-glucopyranoside; (ii) DW451 ⁇ -Galactosyl ⁇ 2; (iii) DW452 ⁇ -Galactosyl ⁇ 3; (iv) DW453 ⁇ -Galactosyl ⁇ 4; (v) DW454 polylactose (1/2.5); (vi) DW455 ⁇ -Gal polymer A; (vii) DW456 ⁇ -Gal polymer B; (viii) DW457 ⁇ -Gal polymer C; (ix) DW458 ⁇ -Gal polymer D; (x) DW459 ⁇ -Gal polymer E; and (xi) DW460 ⁇ -Gal polymer F.
- Results shown in FIG. 23A demonstrate that the ⁇ Gal-sugar epitopes are displayed by the PAGE-conjugates and are specifically detected by the lectin Banderiraea Simplicifolla BS-1.
- Glycoconjugates utilized in this study include: (i) DW450 phenyl ⁇ -Galactopyranosyl-(1-3) b-D-galactopyranosyl-(1-4)-1-thio-b-D-glucopyranoside; (ii) DW451 ⁇ -Galactosyl-2; (iii) DW452 ⁇ -Galactosyl-3; (iv) DW453 ⁇ -Galactosyl-4; (v) DW454 polylactose (1/2.5); (vi) DW455 ⁇ -Gal polymer A; (vii) DW456 ⁇ -Gal polymer B; (viii) DW457 ⁇ -Gal polymer C; (ix) DW458 ⁇ -Gal polymer D; (x) DW459 ⁇ -Gal polymer E; and (xi) DW460 ⁇ -Gal polymer F.
- Results shown in FIG. 23B illustrate that the ⁇ Gal-sugar epitopes are displayed by the PAGE-conjugates and are specifically detected by a preparation of affinity purified human anti- ⁇ Gal antibodies.
- This experiment provides direct information regarding the use of this sugar chip in detecting human anti- ⁇ Gal antibodies. Therefore, this sugar chip itself is a means for monitoring the hyperacute rejection in animal-to-human xenotransplantation that is mainly mediated by human anti- ⁇ Gal antibodies. The potential of this epitope-specific sugar chip is, however, far beyond this specific application.
- Results shown in FIG. 29 demonstrate that the ⁇ -Gal-sugar epitopes are displayed by the polyacrylamide-conjugates and are specifically detected by the lectin Banderiraea Simplicifolla BS-1.
- the molecular interaction between Lectin BS-1 and the ⁇ -Gal-sugar epitopes is epitope-density dependent.
- Such sugar chain specific molecular recognition can only take place when the molar ratio of oligosaccharide:carrier is greater than 1:2.5.
- Microorganisms express carbohydrate-containing macromolecules of different molecular configurations, including polysaccharides, glycolipids and glycoproteins.
- Carbohydrate structures play critical roles in the entry and colonization of microbes, their host recognition, and induction of immune responses 1-5 . They are, therefore, important molecular targets for vaccine development.
- a notable example is vaccination with the protein-conjugates of Haemophilus influenza type b polysaccharide that resulted in the decline in the incidence of H. influenza meningitis and other infections in infants and children 6,7 . Presence of polysaccharides and glycoproteins in B. anthracis has been recognized for some time 8-10 .
- the spore surface interacts with the host.
- a loosely fitting exosporium composed of protein, lipid, and carbohydrate is observed outside the spore coat.
- Two exosporium-specific major glycoproteins have been described for B. cereus 11, 12 .
- Staining of spores of B. cereus and B. anthracis by specific lectins suggested the presence of carbohydrate structures on the surface of their spores 10 . Information regarding their carbohydrate structures is, however, currently unavailable.
- spores After entry into the host, spores are taken up by macrophages and are transported to the regional lymph nodes that typically drain the site of inoculation 13, 14 . Germination of B. anthracis spores may occur intracellularly, such as in the phagolysosome of alveolar macrophages or extracellularly in the presence of serum and elevated CO 2 . Whether and how the intracellular germinating spores circumvent the antimicrobial environment of the phagolysosome is unknown. During germination, the antigenic determinant(s) of somatic polysaccharide, the cell wall Gal-NAG polysaccharide of B. anthracis is exposed 9 .
- the capsule is a polymer of ⁇ -D-glutamic acid with molecular weights between 20 and 55 kDa in vitro and estimated to be 215 kDa in vivo 15 . This structure is poorly immunogenic to the host 16 .
- the capsule may inhibit host defense through inhibition of phagocytosis of the vegetative cells by macrophages.
- the capsule is thus considered to be one of the two major contributing factors to the virulence of B. anthracis 17-20 .
- Vegetative bacillus releases multiple factors, such as toxins, cellular protein factors, and soluble polysaccharides.
- factors such as toxins, cellular protein factors, and soluble polysaccharides.
- proteins and polysaccharides in the culture media of growing B. anthracis has long been recognized.
- potential vaccine candidates of B. anthracis were evaluated in animal models 8 . Different molecular fractions were injected into animals, and then these immunized animals were challenged with lethal dosages of B. anthracis spores.
- the protein fractions provided a strong protection for the immunized animals.
- the protective antigen abbreviated PA, is an integrated component of the lethal toxin of B. anthracis.
- EF edema factor
- LF lethal factor
- Neutralization antibodies to PA or a polyvalent factor that inhibits the formation of the complex may protect animals from lethal attack by the toxin 23 .
- a considerable number of polysaccharides are also present in the culture media growing the bacteria.
- Anthrax vaccination was the first effective bacterial vaccination in history 24 .
- Two types of anthrax vaccines are currently in use for humans: A) the spores of the toxigenic, nonencapsulated B. anthracis STI-1 strain 25-27 and B) the cell-free PA-based vaccines consisting of aluminum hydroxide-adsorbed supernatant material from cultures of the toxigenic, nonencapsulated B. anthracis strain V770-NPI-R 28 or alum-precipitated culture filtrate from the Sterne strain.
- Hybridoma and monoclonal antibody technology has provided a powerful means to explore potential molecular targets for diagnosis and vaccine development.
- Ezzell et al. were able to establish two IgM monoclonal antibodies that were directed at an epitope associated with the cell wall Gal-NAG polysaccharide 9 .
- Electron microscopy showed that both mabs interacted with the cell wall of vegetative cells, as well as with the cortex of spores. Neither mAb reacted with encapsulated vegetative cells, such as those from infected guinea pigs, nor did they react with intact spores.
- the oligosaccharides of this glycoprotein had N-acetyl-galactosamine at the reducing end, rhamnose and a component not yet identified.
- the rhamnose residue is seen in the microbial polysaccharide at relatively high frequency and is frequently recognized by a host as a part of a dominant antigenic structure 12, 33-38 .
- B. cereus strain 4342 from the American Type Culture Collection (ATCC) since this strain and B. anthracis are monomorphic at multiple allozyme loci, being part of the same highly related cluster of isolates within the B. cereus lineage 42, 43 .
- ATCC American Type Culture Collection
- Schurch et al. 43 found recently that B. cereus strain 4342 was sensitive to the ⁇ phage, which is distinct from most other B. cereus strains so far studied but is identical to strains of B. anthracis.
- Rabbit IgG antibodies purified by the Protein A column were applied at concentrations of 0.5 and 5 ⁇ g/ml. As determined in our preliminary investigation, their anti-Pn23 activities were detected at these antibody dilutions. The spores were removed from their antibody mixtures by centrifuge and the spore-free antibody solutions were applied for an ELISA assay to measure their anti-Pn23-polysaccharide activities.
- the anti-rabbit serum was added to the tubes of spore 246, 4342, and a PBS-control. They were mixed by vigorously shaking at 4° C. overnight. The mixed compounds were centrifuged for 30 minutes at 4000 rpm at 4° C. and the supernatants were collected and were saved at 4° C.
- ELISA plates were coated with Pn23 5 ⁇ l/ml in 0.02M BBS, 100 ⁇ l/well at 37° C. for 2 hours. Next, the blocking reaction with 2% NBC-PBS was performed, 200 ⁇ l/well at 37° C. for 1 hour. The supernatants were added at 100 ⁇ l/well at 37° C. for 90 minutes.
- Anti-rabbit IgG AP was added at a dilution of 1:5000 in 2% NBC-PBS, 100 ⁇ l/well at 37° C. for 60 minutes. OD readings were taken at 405 nm, one hour after the substrates were added. The same experiment was repeated three times and results were expressed as the relative ELISA binding activities of each assay.
- the anti-Pn23 activities of the rabbit anti-anthrax spore serum that were incubated with PBS were listed as 100% activity for this comparison in FIG. 28.
- subtilis (299121); 59/96 aa psiti O Disulfide bond formation protein DsbB 138 174200 174493 2 97 Small DNA binding, pagR-like; B. anthracis (AF031382); 63/98 aa positi K Predicted transcriptional regulators 109 131939 132238 2 99 Similar to small DNA binding proteins, pagR; plasmid pXO1, B. antraci K Predicted transcriptional regulators 121 153605 153937 2 110 Adenine phosphoribosyl trasferase, apt; plasmid pXO1; B.
- anthracis (A F Adenine/guanine phosphoribosyltransferases and related PRPF 129 163846 164238 1 130 Truncated transposase for IS1627; B. anthracis (U30712); 93/137 aa po L Putative tranposase 118 149232 149864 2 150 Unknown function; plasmid pXO1; B. anthracis (LI3841) No Cog No Cog 87 101962 102444 2 160 Unknown function, putative thioredoxin (137 aa), yoll; B.
- subtilis Z9911 OC Thiol-disulfide isomerase thioredoxins 120 152064 152636 1 190 Putative transposase (401 aa); S. pyogenes (AF064540); 108/192 aa p L Transpose 115 142410 142991 2 193 Resolvase (191 aa), Tn1546-like; Enterococcus faecium (Q06237); 125 L Site-specific recombinases, DNA invertase Pin homologs 111 136229 136843 2 204 Hypothetical protein in the protective antigen domain, ypa; plasmid pXO No Cog No Cog 127 162232 162876 2 214 Putative transposase for IS1627; plasmid pXO1; B.
- antracis U30712
- L Putative transposase 141 175663 176307 2 Thermonuclease precursor (TNASE)/micrococcal nuclease (231 aa);
- subtilis (U93875); 213/251 aa po No Cog No Cog 96 116307 117131 1 274 Putative transposase for IS1627; plasmid pXO1; B. anthracis Sterne Le L Putative transposase 91 109000 109842 1 280 Hypothetical protein (193 aa), ywoA in ngrB-spollQ intergene region; B. I Membrane-associated phospholipid phosphatase 94 112516 113403 1 296 UDP-glucose-pyrophosphorylase (292 aa), glaB; B.
- subtilis Q05852; 2 M UDP-gluose pyrophosphorylase 18 25124 26071 1 315 Intergrase/recombinase protein (311 aa); thermoautotrophicum (AE0 L Integrase 103 123018 123971 1 317 Probable integrase/recombinase (296 aa), ripX; B. subtilis (P46352); 93 L Integrase 39 48912 29889 2 325 Transposase (478 aa), IS231E; B.
- thringiensis (Q02403); 282/299 aa L Predicted transposase 112 138540 139523 2 327 Spore germination response gerXC; plasmid pXO1; B. anthracis (AF10 No Cog No Cog 114 141002 142081 2 359 Spore germination response, gerXB; plasmid pXO1; B.
- anthracis AF10 No Cog No Cog 132 167948 169033 1 361 Putative integrase (356 aa); Streptococcus mutans (AF065141); 206/34 S Uncharacterized BCR 136 172285 17380 1 364 Response regulator aspartate phosphatase C (393 aa), rapC; B.
- subtilis (D50453); 126/238 aa positive (52%0 and 527117 aa positive (44%) 93 111374 112474 1 366 Hyaluronate synthase (419 aa), hasA; Streptococcus pyogenes (L2118: M Glycosyltransferases, probably involved in cell wall biogenesis 86 100777 101922 2 381 Hypothetical protein (402 aa), yrkO; B. subtilis (D84432); 199/376 aa po R Uncharacterized membrane protein 54 67634 68815 1 393 S-layer precursor/surface protein (814 aa); B.
- subtilis Z99122 M Predicted UDP-glucose 6-dehydrogenase 23 31621 33006 2 461 Potential cooling region (609 aa); Clostridium difficile (X98606); 249/390 L Retron-type reverse transcriptase 81 95978 97363 1 461 Ras- and transposon-related protein (225 aa), yocA; B. subtilis (AF0278 M Membrane proteins related to metalloendopeptidases 119 150042 151469 1 475 trans-acting positive regulator, atxA; plasmid pXO1, B.
- anthracis (L1384 No Cog No Cog 59 74068 75501 1 477 Secretory protein kinase (474 aa)m kln; C. limicola (U77780); 186/310 aa N Type IV secretory pathway, VirB11 components, and related AT 35 42103 43539 1 478 Transposase (478 aa), IS231E; B. thuringiensis (Q02403); 455/478 aa L Predicted transposase 36 43808 45262 2 484 Transposase (478 aa), IS231E; B.
- thuringiensis Q02403; 347/468 aa L Predicted tranposase 113 139480 140958 2 492 Spore germination response, gerXA; plasmid pXO1; B. anthracis (AF10 No Cog No Cog 7 6544 8190 2 548 Reverse transcriptase (574 aa), IS629; E.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Abstract
This invention provides novel nitrocellulose-based or Hydrogel-based microarrays and methods of making and using them (1) to detect the presence of one or more agents in a sample, (2) to determine the amount of one or more agents in a sample, (3) to determine whether a subject is afflicted with a disorder, and (4) to determine whether an agent known to specifically bind to a first compound also specifically binds to a second compound. This invention also provides kits which comprise the instant microarrays. This invention further provides antibodies capable of specifically binding to a glycomer present both on the surface of a mammalian macrophage or intestinal epithelial cell, and on a bacterial cell. Finally, this invention provides diagnostic methods using the instant antibodies.
Description
- This invention is a continuation-in-part and claiming the benefit of U.S. Ser. No. 10/280,376, filed Oct. 24, 2002, a continuation-in-part and claiming the benefit of PCT International Application No. PCT/US02/11612, filed Apr. 10, 2002, the contents of which are hereby incorporated by reference into this application.
- [0002] The invention described herein was made with Government support under grant number AI45326 from the National Institutes of Health. Accordingly, the United States Government has certain rights in this invention.
- Throughout this application, various references are cited. Disclosure of these references in their entirety is hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
- Genomics
- The Human Genome Project is rapidly approaching its end: the complete mapping and sequencing of the human genome, and the identification of all genes therein. Emerging from this effort is a new generation of biotechnologies, collectively known as “functional genomics”. These technologies, including DNA chips (1) and cDNA microarrays (2, 3), make use of the sequence information and genetic materials provided by the human genome project, combine advanced laser and fluorescence sensor technology, and take advantage of computer-aided large-scale data management systems. Differing from classical molecular biology methods which focus on a specific gene or its product, these new approaches monitor the expression of genes on a genome-wide scale, and identify their characteristic overall patterns. The scope of biological investigation has therefore been expanded from the study of a single gene or protein to the study of numerous genes and/or proteins simultaneously.
- Proteomics
- Proteins are the final gene products, acting as fundamental elements of living organisms. However, the amount of mRNA expression does not always indicate the level of its encoded protein in a cell. The protein molecule has its own life span and kinetics of metabolism. There are specialized cellular machineries, such as the ubiquitin-dependent and -independent pathways of protein degradation, allowing rapid turnover of a protein when its function is no longer required. The fate of a newly synthesized protein is also significantly influenced by post-translational modifications, such as phosphorylation, glycosylation, acetylation or myristylation, at specific amino acid residues. Such molecular modifications are frequently regulated differentially and/or developmentally, establishing a specific function, or playing a structural role, for a given protein. Thus, it has been generally accepted that a better understanding of the genome's function will not be possible without protein analysis. Developing technologies for a genome-wide analysis of protein expression and post-translational modification represents a major challenge to the scientific community (4, 5).
- Glycomics
- Carbohydrate-containing macromolecules are the secondary products of genes. Their synthesis requires multiple enzymatic reactions and many steps of intracellular trafficking, transportation and modification. Multiple genes contribute to the synthesis of cellular elements containing complex carbohydrates. “Glycomics”, a new scientific discipline, has emerged to create a comprehensive understanding of the structure, function, synthesis and genetic regulation of cellular carbohydrate molecules.
- Carbohydrates are abundant on cell surfaces, existing as either membrane-bound glycoconjugates or secreted substances. These molecules play fundamental structural and protective roles. They are also abundant intracellularly, and serve as an active and dynamic energy reservoir.
- Recent studies further demonstrated that many important signaling and regulatory processes are mediated by the interaction of carbohydrate-ligands and their receptors (6, 7). Abnormal expression of carbohydrate moieties may occur in cells that are undergoing malignant transformation. These moieties may therefore serve as molecular targets for tumor diagnosis or therapy.
- The carbohydrate molecules of microorganisms are important in establishing the biological relationships of microbes and their hosts (7-9). These relationships especially include the host recognition of microorganisms and the induction of an immune response by a microbial antigen. The carbohydrate moieties of microbial antigens frequently serve as the key structures for immune recognition (10). Identifying such determinants is of fundamental importance for understanding the molecular mechanisms of host recognition and immune responses.
- Existing Technologies
- Technologies suitable for monitoring protein expression on a genome-wide scale and for characterizing a wide range of ligand-receptor interactions such as protein-protein reactions, carbohydrate-protein reactions and the interaction of synthetic small molecules and cellular components have yet to be developed. Current methods for specifically detecting and quantifying a protein or a microbial polysaccharide include antigen/antibody based-immunoassays. These assays include (a) classical direct immunoassays, such as immunodiffusion, immunoelectrophoresis, agglutination and immunoprecipitation assays, and (b) recently developed methods such as immunofluorescence, radioimmunoassay (RIA), enzyme-immunoassay (EIA) and western blot assays. These approaches exploit the specificity of antigen-antibody interactions. However, they are designed for analyzing only one agent at a time, and are therefore limited as to the number of molecules that can be analyzed in a single assay.
- In sum, a single technology useful for the simultaneous study of numerous molecules, be they protein, carbohydrate or combinations thereof, is sorely needed to advance both proteomics and glycomics.
- This invention provides six microarrays and two articles useful for making same. The first microarray comprises a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- The second microarray comprises a plurality of nitrocellulose or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, wherein (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- The first article comprises a nitrocellulose or Hydrogel support having dextran affixed to its surface at discrete loci. In one embodiment the dextran is α(1, 6) dextran.
- The third microarray comprises the first article, wherein at least one compound is affixed to the dextran at each discrete locus, the composition of compounds at each discrete locus differing from the composition of compounds at at least one other discrete locus.
- The second article comprises a plurality of nitrocellulose or Hydrogel supports, each support having dextran affixed to its surface at one or more discrete loci. In one embodiment the dextran is α(1, 6) dextran.
- The fourth microarray comprises the second article, wherein at least one compound is affixed to the dextran at each discrete locus, the composition of compounds at each discrete locus differing from the composition of compounds at at least one other discrete locus.
- The fifth microarray comprises a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (a) at at least one discrete locus is affixed a compound associated withBacillus anthracis and selected from the group consisting of a glycomer and a protein, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- The sixth microarray comprises a plurality of nitrocellulose or Hydrogel or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, wherein (a) at at least one discrete locus is affixed a compound associated withBacillus anthracis and selected from the group consisting of a glycomer and a protein, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention provides six methods for detecting the presence of agents in a sample. The first method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known glycomers, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; and (b) determining whether any known glycomer in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- The second method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known insoluble proteins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known insoluble protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding insoluble protein in the microarray; and (b) determining whether any known insoluble protein in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- The third method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known antibodies or lectins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; and (b) determining whether any known antibody or lectin in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- The fourth method is a method of detecting in a sample the presence of one or more agents associated withBacillus anthracis which specifically bind to one or more glycomers, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; and (b) determining whether any glycomer in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- The fifth method is a method of detecting in a sample the presence of one or more agents associated withBacillus anthracis which specifically bind to one or more proteins, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding protein in the microarray; and (b) determining whether any known protein in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- The sixth method is a method of detecting in a sample the presence of one or more glycomers or proteins which specifically bind to one or more antibodies or lectins associated withBacillus anthracis, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; and (b) determining whether any antibody or lectin in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- This invention further provides three quantitative methods. The first method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known glycomers, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known glycomer is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; (b) for each known glycomer in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- The second method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known insoluble proteins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known insoluble protein is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding insoluble protein in the microarray; (b) for each known insoluble protein in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- The third method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known antibodies or lectins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known antibody or lectin is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; (b) for each known antibody or lectin in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- This invention further provides three diagnostic methods. The first method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known glycomer, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known glycomer in the microarray; and (b) determining whether the known glycomer in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- The second method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known insoluble protein, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known insoluble protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known insoluble protein in the microarray; and (b) determining whether the known insoluble protein in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- The third method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known antibody or lectin, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known antibody or lectin in the microarray; and (b) determining whether the known antibody or lectin in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- This invention further provides a method of determining whether an antibody known to specifically bind to a first glycomer also specifically binds to a second glycomer, which method comprises: (a) contacting the antibody with the first or second microarray, wherein a plurality of glycomers, other than the first glycomer, are affixed at discrete loci in the microarray, and wherein the contacting is performed under conditions which would permit the antibody to specifically bind to the first glycomer if it were present in the microarray; and (b) determining whether any of the glycomers in the microarray, other than the first glycomer, has the antibody specifically bound thereto, thereby determining whether the antibody also specifically binds to a second glycomer.
- This invention further provides a method of determining whether an antibody known to specifically bind to a first insoluble protein also specifically binds to a second insoluble protein, which method comprises: (a) contacting the antibody with the first or second microarray, wherein a plurality of insoluble proteins, other than the first insoluble protein, are affixed at discrete loci in the microarray, and wherein the contacting is performed under conditions which would permit the antibody to specifically bind to the first insoluble protein if it were present in the microarray; and (b) determining whether any of the insoluble proteins in the microarray, other than the first insoluble protein, has the antibody specifically bound thereto, thereby determining whether the antibody also specifically binds to a second insoluble protein.
- This invention further provides a method of making a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, which method comprises contacting the nitrocellulose or Hydrogel support with the compounds under suitable conditions, whereby (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides a method of making a microarray comprising a plurality of nitrocellulose or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, which method comprises contacting the nitrocellulose or Hydrogel supports with the compounds under suitable conditions, whereby (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides a method of making the first article comprising contacting a nitrocellulose or Hydrogel support with dextran at discrete loci under suitable conditions.
- This invention further provides a method of making the second article comprising contacting a plurality of nitrocellulose or Hydrogel supports with dextran, whereby each support has dextran affixed to its surface at one or more discrete loci.
- This invention further provides six kits. The first kit comprises one of the instant microarrays and instructions for use. The second kit comprises one of the instant microarrays and a desiccant. The third kit comprises one of the instant microarrays immersed in an aqueous solution.
- The fourth kit is a kit for practicing the first diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the glycomer to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- The fifth kit is a kit for practicing the second diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the insoluble protein to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- The sixth kit is a kit for practicing the third diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the antibody or lectin to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- This invention further provides a first antibody capable of specifically binding to a glycomer present on the surface of a mammalian macrophage, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell.
- This invention further provides a second antibody capable of specifically binding to a glycomer present on the surface of a mammalian intestinal epithelial cell, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell.
- This invention further provides a method of determining whether a subject is afflicted with a disorder characterized by the presence of a glycomer on the surface of macrophages in an afflicted subject, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell, comprising: (a) contacting a sample of the subject's macrophages with the first antibody; and (b) determining whether the antibody specifically binds to the macrophages in the sample, such binding indicating that the subject is afflicted with the disorder.
- Finally, this invention provides a method of determining whether a subject is afflicted with a disorder characterized by the presence of a glycomer on the surface of intestinal epithelial cells in an afflicted subject, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell, comprising: (a) contacting a sample of the subject's intestinal epithelial cells with the second antibody; and (b) determining whether the antibody specifically binds to the intestinal epithelial cells in the sample, such binding indicating that the subject is afflicted with the disorder.
- FIG. 1
- This Figure shows a carbohydrate microarray and its application in characterizing the epitope-binding specificity of monoclonal antibodies (“mAb”). Dextran preparations of defined structural characteristics, including N279, LD7, B1299S and B1355S, were immobilized on a nitrocellulose-coated micro-glass slide in serial dilutions and stained with anti-α(1,6)dextran antibodies. These antibodies were either a groove-type antibody, i.e., 4.3.F1, or a cavity-type antibody, i.e., 16.4.12E, and were conjugated with fluorescence. Their distinct epitope-binding specificities were visualized by scanning the carbohydrate microarray using a GMS 418 microarray scanner.
- FIG. 2
- This Figure shows an antigen-based microarray and its application in studying the cross-reactivity of monoclonal antibodies. Forty-nine distinct antigen preparations, including microbial polysaccharides, blood group substances and other glycoconjugates, were arrayed on slides and incubated with fluorescence-labeled mAbs. FIG. 2A: anti-DEX 4.3.F1; FIG. 2B: anti-DEX 16.4.12E. Intensity values of cross-reacting spots were compared with those of specific binding to α(1,6)dextran N279. N279 was applied as a series of 1:5 dilutions of a 100 μg/ml solution (a). Other antigens were applied as 500 μg/ml. Identical antigens are arrayed in FIG. 2A and FIG. 2B.
- FIG. 3
- This Figure shows the detection of a cell population in the small intestine of an adult mouse by a groove-type anti-α(1,6)dextran antibody 4.3.F1 (IgG3), which showed cross-reactivity to a chondroitin sulfate B preparation. The cryostat sections of small intestine were stained either by mAb 4.3.F1 (IgG3) or by an IgG3 isotype control mAb obtained from BD PharMingen. The two mabs were fluorescent conjugates. Sections were co-stained with DAPI for the cell nucleus to visualize the overall tissue structure. The 4.3.F1-positive cells were seen in the lamina propria of the small intestine. FIGS.3A-3D: mAb 4.3.F1; FIGS. 3E-3H: isotype control.
- FIG. 4
- This Figure shows that groove-type and cavity-type anti-α(1,6)dextran monoclonal antibodies recognize distinct cellular markers: a groove-type mAb 45.21.1 (IgA) identifies a cell population in the lamina propria of the small intestine (FIGS. 4C and 4F), and a cavity-type mAb 16.4.12E (IgA) stains the epithelial cells in the crypts of the small intestine (FIGS. 4B and 4E). An IgA isotype control mAb purchased from BD PharMingen was applied as a background control (FIGS. 4A and 4D).
- FIG. 5
- This Figure shows the recognition of a cell population in the human small intestinal tissue using anti-α(1,6)dextran antibodies. The intestinal section of a normal (FIGS. 5A and 5B) and of a celiac individual (FIGS. 5C and 5D) were stained with the fluorescence-conjugate of mAb 16.4.12E (FIGS. 5B and 5D) and co-stained with DAPI to reveal the intestinal structures (FIGS. 5A and 5C).
- FIG. 6
- This Figure shows the immobilization of polysaccharides on a nitrocellulose-coated glass slide. Panel A: Image of the carbohydrate microarray (microarrays of dextrans and inulin) spots before and after washing. Panel B: Quantitative illustration of the relation of fluorescence intensity and the concentration of printed carbohydrate microarrays before and after washing. Fluorescent conjugates of dextrans or inulin were dissolved in saline (0.9% NaCl) and spotted at an initial concentration of 10 mg/ml and then diluted in serial dilutions of 1:5. The microarray slides were scanned before and after washing. The data of six repeats of the same experiment is statistically analyzed and presented. Legend: ▪: 2000 k; ▴: 70 k; : 20 k; ♦: Inulin.
- FIG. 7
- This Figure shows the immunological characterization of surface-immobilized dextran molecules. Panel A: Microarray binding curves of a groove-type anti-Dex 4.3F1 (IgG3/Kappa) and a cavity-type anti-dextran 16.4.12E (IgA/Kappa) to dextran molecules of distinct structure. Dextran molecules were printed with an initial concentration of 0.1 mg/ml and diluted by a 1:5 series titration. The printed arrays were washed to remove unbound antigens and then stained with biotinylated anti-dextran, either 4.3F1 or 16.4.12E, at a concentration of 1 μg/ml, and then stained with Cy3-streptavidin at 1:500 dilutions. The readout of the experiment (i.e., fluorescent intensity of the microspot) reflects the amounts of antigen immobilized and epitopes displayed for antibody recognition. The cavity-type mAb 16.4.12E bound to N279 and B12995, but not LD7. By contrast, the groove-type mAb 4.3F1 bound to the dextran preparations N279 and LD7, but bound poorly to B1299S. Panel B: ELISA binding curve of anti-Dex 4.3F1 and 16.4.12E. Dextran preparations were coated on an ELISA plate at an initial concentration of 10 μg/ml and then diluted by a 1:5 series titration in 0.02 M borate-buffered saline, pH 8.0. The antigen-coated plates were incubated with biotinylated anti-dextrans at a concentration of 1 μg/ml. The bound antibodies were revealed with an alkaline phosphatase (AP)-streptavidin conjugate and AP substrate. Legend: ♦: N279; □: LD7; ▴: B-1299S. Left Panel: 4.3F1 (Groove-type); Right Panel: 16.4.12 (Cavity-Type).
- FIG. 8
-
- FIG. 9
- This Figure shows a simple and efficient procedure for producing a carbohydrate microarray. Microspotting: Carbohydrate antigens were printed using Cartesian Technologies' PIXSYS 5500C (Irvine, Calif.) with
STEALTH 3 pins. Supporting substrate: FAST Slides (Industrial partner A, Schleicher & Schuell, Keene, N.H.). The printed carbohydrate microarrays were air dried and stored at room temperature without desiccant before application. Immuno-staining: Immediately before use, the microarrays were rinsed with phosphate-buffered saline (PBS). The staining procedure utilized is essentially identical to regular immunoflourescent staining of tissue sections. Microarray-scanning: A ScanArray 5000 Standard Biochip Scanning System and its QuantArray software (Packard Biochip Technologies, Inc.) were applied for scanning and data capturing. - FIG. 10
- This Figure shows a schematic of the 8-chamber sub-arrays.
- FIG. 11
- This Figure shows probing of the repertoires of human serum antibodies using Antigen Chip 4000. Left: HIV negative normal serum. Right: Serum of an HIV-1 infected individual. For each microarry analysis, 10 ml of serum were applied on an antigen chip at 1:10 dilutions. Anti-human antibodies with distinct fluorescent tags were applied to recognize and quantify the bound human IgG, IgM and IgA. In this Figure, human IgG was stained in Red/Cy5 and human IgM in Green/Cy3. The two images of contrasting colors were overlaid. IgA human antibodies were detected on the same chip with an anti-human IgAFITC (data was not shown).
- FIG. 12
- This Figure shows the scanning of human antibodies specific for a large panel of HIV proteins using a protein-based microarray biochip. Serum specimens of four normal individuals and six AIDS patients were characterized by a protein biochip that displays a large panel of HIV-1 proteins. Each preparation was printed four times on the same biochip. For each assay, 10 μl of serum were applied at 1:10 dilutions on a single chip. Human IgG that was captured by the immobilized antigens was recognized and quantified by a Cy3-labeled second antibody. Data of each group, normal and HIV-infected individuals, were statistically analyzed. Results were presented as the mean value of the ratio of fluorescent intensity over the background of given microspots (Histogram). Their standard division was also shown. Significant variations that were observed in the HIV-1 infected group may reflect the diversity of the HIV-1 specific antibody responses, as well as the level of antigenic cross-reactivities of HIV-1 proteins that were expressed by different clades or strains of HIV-1 virus.
- FIG. 13
- This Figure shows a schematic of a hypothetical structural and immunological relationships of the type II backbone structure of blood group substances, type XIV pneumococcal polysaccharide and the cell wall Gal-NAG polysaccharide.
- FIG. 14
- This Figure shows a carbohydrate microarray characterization of human and murine antibodies. Forty-eight distinct antigen preparations were arrayed on slides at antigen concentrations of 0.5 mg/ml and 0.02 mg/ml. They were incubated with combined human serum specimens at a concentration equivalent to 1:100 dilutions of each specimen or with binotinylated mouse monoclonal antibodies at 1 mg/ml. The human IgM captured by microarrays was visualized using an anti-human IgM-AP conjugate and the color developed using Vector Red. The human IgG anti-carbohydrates were detected using a biotinylated anti-human IgG. A Cy3-Streptoavidin conjugate was then applied to visualize the human IgG or murine monoclonal antibodies bound on microarray. The readout of the experiment, i.e., fluorescent intensity of the microspot, reflects the amounts of antigen immobilized and epitopes displayed for antibody recognition. Data of four repeats of microarray staining are summarized in Table 2.
- FIG. 15
- This Figure shows the prediction of protein structure using TMHMM version 2.0 (55 of the Third Series of Experiments): PX01-54 ofB. anthracis encodes a S-layer protein, a novel molecular target for anthrax diagnosis and vaccination.
- FIG. 16
- This Figure shows biochip detection of human antibody reactivities to either anthrax polysaccharide or Pneumococcus type XIV polysaccharide in mixed human serum specimen which confirms that these antigen preparations are applicable for producing diagnostic microarrays.
- FIG. 17
- This Figure shows a schematic of diagnosis and surveillance of emerging infectious diseases using antigen arrays. An emerging infection may attack human as well as animal populations. Detecting specific antibodies in their bodily fluids using antigen microarrays is a powerful means for the diagnosis and surveillance of emerging infectious diseases. Left: schematic of the life cycle ofBacillus anthracis; Right: host antibodies elicited by an infection are important molecular targets for the diagnosis and surveillance of emerging infectious diseases.
- FIG. 18
- This Figure shows long-lasting antigenic reactivities of protein microarrays in some but not all preparations.
- FIG. 19
- This Figure shows that clustering analysis identified reproducible global pattern of antigenic reactivities on biochips.
- FIG. 20
- This Figure shows that purified GFPuv protein is stably immobilized on the nitrocellulose-coated slide (upper row) but is less stable on a poly-Lys treated DNA ready slide (bottom row). A preparation of purified GFPuv was spotted on slide at 0.5 mg/ml (left side) and 0.05 mg/ml (right side). Scanning was performed 1) at the same day after spotting; 2) after overnight air-drying the slide; and 3) after washing the slide extensively in a buffer containing 0.1
% Tween 20 1× PBS. - FIG. 21
- This Figure shows the structure of PA and its four domains: PA is a long, flat molecule of
dimensions 100ט50×30 Å. and is composed of four domains 46. Domain 1 (residues 1-258) comprises a b-sandwich with jelly-roll topology, several small helices, and a pair of adjacent calcium ions coordinated by residues in a variant of the EF-hand motif. Domain 2 (residues 259-487) has a b-barrel core with modified Greek-key topology and elaborate excursions, including a large flexible loop between strands 2b2 and 2b3 that is implicated in membrane insertion. Domain 3 (residues 488-595) has a four-stranded mixed b-sheet, two smaller sheets and four helices; it adopts the same fold as ferredoxins and resembles domain A of toxic-shock-syndrome toxin-1. Domain 4 (residues 596-735) has an initial hairpin and helix, followed by a b-sandwich with an immunoglobulin-like fold.Domains domain 4 has limited contact with the other 3 domains. D1 is the N-terminal domain, contains two calcium ions and the cleavage site for activating proteases. D2 contains a large flexible loop for membrane insertion. D3 is a small domain of unknown function. D4 is the C-terminal receptor-binding domain. (Domain description from Petosa et al. Nature Vol. 305(1997); image generated from the structure of protective antigen using NCBI's Cn3D version 4.0). - FIG. 22
- This Figure shows a schematic of a molecular approach to construct GFP fusion proteins of PA and its derivatives. Primers for PCR reactions are designed based on sequence information of each domain target. Restriction sites are selected to avoid digesting the PA chains or its domains. Following are primer sequences of PA derived portion: Integral PA (nt bases 143,799-146,073): 5′ ATGGTTCTTTAGCTTTCTG (19 mer, Start: 143,409); 3′ CCTAGAATTACCTTATCCTATC (22 mer, Stop: 146,085). P63 (nt bases 144,376-146,070): 5′ GCGAAGTACAAGTGCTGG (18 mer, Start: 144,363); 3′ TTGAATGTGCAATTGTCCTC (20 mer, Stop: 146,321). PA Domain 1 (nt bases 143,866-144,639): 5′ TCAGGCAGAAGTTAAACAGG (20 mer, Start: 143,859); 3′ GATAAGCTGCCACAAGGG (18 mer, Stop: 144,643). PA Domain 2 (nt bases 144,640-145,326): 5′ TGGCAGCTTATCCGATTG (18 mer, Start: 144,632); 3′ GCAGTTGTTTCTTGAATTTGCG (22 mer, Stop: 145,331). PA Domain 3 (nt bases 145,327-145,650): 5′ CAAGAAACAACTGCACGTATC (21 mer, Start: 145,318); 3′ CTTCTCTATGAGCCTCCTTAAC (22 mer, Stop: 145,720). PA Domain 4 (nt bases 145,651-146,070): 5′ TATCAAGAATCA GTTAGCG (19 mer, Start: 145,548); 3′ ACCTTATCCTATCTCATAGCC (21 mer, Stop: 146,076).
- FIG. 23A
- This Figure shows lectin staining of α-Gal specific oligosaccharides displayed by the neoglycocojugates.
- FIG. 23B
- This Figure shows that α-Gal-sugar chains are displayed by the PAGE-based neoglycocojugates and are detected by the human anti-α-Gal antibodies.
- FIG. 24
- This Figure shows a carbohydrate microarray characterization of antibody fingerprints in rabbit serum-specimens. Panel A: A microarray staining of rabbit anti-anthrax spore anti-serum revealed a broad spectrum of antibody specificities; Panel B: Clustering analysis of antibody profiles of an un-immunized (subject 1) and two anthrax spore-immunized rabbit antibodies, one obtained from an U.S. company (subject 2) and another from an U.K.-based company (subject 3).
- FIG. 25
- This Figure shows dimension reduction analysis to reveal anthrax specific anti-carbohydrate activities. Panel A: Anti-anthrax antiserum-U.S.; Panel B: Anti-anthrax antiserum-U.K. Slashed open circles represent the diagnostic index of antigens relevant toB. anthraces, including the anthrax cell-wall polysaccharide, Pn14-polysaccharide which is cross-reactive to anthrax cell-wall polysaccharide, anthrax protective protein (PA) and the Pn23-polysaccharide, which is proposed by this investigation as a cross-reactive antigen to the sugar structure(s) of anthrax spores. Black spots represent the diagnostic index of antigens that are not relevant to B. anthracis based on our current understanding and available information. The two lines are set to 2 times the standard deviation from the mean value of the corresponding chip. Spots distributed outside the lines are statistically significant. The only slashed open circle outside the green lines is Pn23 polysaccharide, which is commonly seen in the two anti-anthrax spore responses from different subjects. The dimension reduction analysis algorithm was developed in our laboratory. In principle, we applied the microarray signals detected in non-immunized/uninfected serum specimens as the “filters” to subtract the microarray signals that exist in both the experimental condition and the control condition.
- FIG. 26
- This Figure shows ELISA confirmation of the cross-reactivities of rabbit anti-anthrax spore antibodies to Pn23-polysaccharide but not Pneumococcus type 14 (Pn14). Polysaccharides were coated on an ELISA plate at concentration of 10 μg/ml in 0.02M BBS. The initial concentration of rabbit sera were 1/250 with serial 1:5 dilution titrated in 2% NBC-PBS/tween20. Panel A: ELISA binding curves of non-immunized rabbit serum (rabbit-D); and Panel B: anthrax spore immunized rabbit serum (rabbit-G). Panel C: ELISA value for anti-anthrax spore antibodies of rabbit serum at OD 405 nm at serum dilution of 1/250.
- FIG. 27
- This Figure shows the structural unit of Pn23 polysaccharide (from van Steijn et al.41). Glcp represents the p ring form of glucose, Galp represents the p ring form of galactose, and Rhap represents the p ring form of 6-deoxy-mannose. Linkages between the sugars have two possible anomeric designators: a (alpha) or b (beta), and are indicated in the structure. D or L stands for two possible absolute designators. The numbers presented between the two linked sugars specify which carbon molecules form the disaccharide bonds. Since the two numbers are presented between the two sugars that are bonded, the number that is closest to the respective sugar represents the carbon number of the sugar that forms the linkage. For example, in the adjacent molecule,
carbon 1 from the glucose molecule is linked tocarbon 4 of the galactose molecule. - FIG. 28
- This Figure shows the antigenic cross-reactivities of anti-anthrax spore antibodies to Pn23 polysaccharide that were substantially reduced by pre-absorption of the rabbit anti-sera with the spores ofB. cereus 4342.
- FIG. 29
- This Figure shows lectin staining of α-Gal specific oligosaccharides displayed by the neoglycoconjugates.
- FIG. 30
- This Figure shows non-covalent absorption to immobilize proteins and polysaccharides on a nitrocellulose-coated microchip.
- Definitions
- As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below.
- “Affixed” shall mean attached by any means. In one embodiment, affixed shall mean attached by a covalent bond. In another embodiment, affixed shall mean attached non-covalently.
- “Agent” shall mean any chemical entity, including, without limitation, a glycomer, a protein, an antibody, a lectin, a nucleic acid, a small molecule, and any combination thereof.
- “Antibody” shall mean (a) an immunoglobulin molecule comprising two heavy chains and two light chains and which recognizes an antigen; (b) polyclonal and monoclonal immunoglobulin molecules; and (c) monovalent and divalent fragments thereof. Immunoglobulin molecules may derive from any of the commonly known classes, including but not limited to IgA, secretory IgA, IgG and IgM. IgG subclasses are also well known to those in the art and include, but are not limited to, human IgG1, IgG2, IgG3 and IgG4. Antibodies can be both naturally occurring and non-naturally occurring. Furthermore, antibodies include chimeric antibodies, wholly synthetic antibodies, single chain antibodies, and fragments thereof. Antibodies may be human or nonhuman. Nonhuman antibodies may be humanized by recombinant methods to reduce their immunogenicity in man.
- “Aqueous solution” shall mean any solution in which water is a solvent. Examples of aqueous solutions include water and water-based buffer solutions.
- “Associated withBacillus anthracis” shall mean physically derived from Bacillus anthracis, present on or within Bacillus anthracis, a derivative or degradation product of Bacillus anthracis or a portion thereof, and/or able to bind to any or all of the forementioned. Examples of agents associated with Bacillus anthracis include, without limitation, any anti-Bacillus anthracis antibody and an immunogenic oligosaccharide present on the surface of Bacillus anthracis.
- “Complex carbohydrate” shall mean a carbohydrate polymer comprising more than two types of saccharide monomer units. Examples of complex carbohydrates include blood group substances such as Lewis X and Lewis Y.
- “Composition of compounds” at a discrete locus shall mean the identity of the one or more compounds at that locus. For example, if
locus 1 has compounds A and B, andlocus 2 has compounds A and C, then the composition of compounds atlocus 1 differs from that atlocus 2. - “Compound” shall mean any molecule. Compounds include, but are not limited to, proteins, nucleic acids, glycomers, lipids and small molecules.
- “Dextran” shall mean a branched polymer of glucose consisting mainly of α(1,6)-glycosidic linkages.
- “Discrete locus” shall mean a point, region or area for the affixation of a compound which does not overlap with another such point, region or area, and which may further be separated from another such point, region or area by physical space.
- “Glycomer” shall mean any carbohydrate-containing moiety. Glycomers include, without limitation, (a) complex carbohydrates, (b) polysaccharides, (c) oligosaccharides and (d) glycoconjugates. “Glycoconjugates” include, without limitation, glycoproteins, glycolipids and glycopolymers. In one embodiment of the glycomer, the carbohydrate moiety thereof is conjugated, either covalently or noncovalently, to polyacrylamide.
- “Insoluble protein” shall mean any protein which does not solubilize in aqueous solution. Examples of insoluble proteins include trans-membrane proteins.
- “Lectin” shall mean a protein that is capable of agglutinating erythrocytes, binding sugars, and/or stimulating mitosis. Examples of lectins include concavalin A.
- “Microarray” shall mean (a) a solid support having one or more compounds affixed to its surface at discrete loci, or (b) a plurality of solid supports, each support having one or a plurality of compounds affixed to its surface at discrete loci. The instant microarrays can contain all possible permutations of compounds within the parameters of this invention. For example, the instant microarray can be an all-glycomer microarray, an all-insoluble protein microarray, an all-antibody microarray, a disease-specific microarray, a species-specific microarray, or a tissue-specific microarray.
- “Nitrocellulose or Hydrogel support” shall mean any solid support having nitrocellulose or Hydrogel affixed to its surface. Nitrocellulose or Hydrogel supports include, without limitation, nitrocellulose-coated or Hydrogel-coated chips (e.g. silicone chips), slides (e.g. glass slides), filters, plates and beads.
- “Polysaccharide” shall mean a carbohydrate polymer comprising either one or two types of saccharide monomer units. Examples of polysaccharides include bacterial cell surface carbohydrates.
- “Sample”, when used in connection with the instant methods, includes, but is not limited to, any body tissue, skin lesion, blood, serum, plasma, cerebrospinal fluid, lymphocyte, urine, exudate, or supernatant from a cell culture.
- “Specifically bind” shall mean the binding of a first entity to a second entity based on complementarity between the three-dimensional structures of each. In one embodiment, specific binding occurs with a KD of less than 10−5. In another embodiment, specific binding occurs with a KD of less than 10−8. In a further embodiment, specific binding occurs with a KD of less than 10−11.
- “Subject” shall mean any organism including, without limitation, a mouse, a rat, a dog, a guinea pig, a ferret, a rabbit and a primate. In the preferred embodiment, the subject is a human being.
- Embodiments of the Invention
- This invention provides six microarrays and two articles useful for making same. The first microarray comprises a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- The second microarray comprises a plurality of nitrocellulose or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, wherein (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- The first article comprises a nitrocellulose or Hydrogel support having dextran affixed to its surface at discrete loci. In one embodiment the dextran is α(1,6) dextran.
- The third microarray comprises the first article, wherein at least one compound is affixed to the dextran at each discrete locus, the composition of compounds at each discrete locus differing from the composition of compounds at at least one other discrete locus.
- The second article comprises a plurality of nitrocellulose or Hydrogel supports, each support having dextran affixed to its surface at one or more discrete loci. In one embodiment the dextran is α(1,6) dextran.
- The fourth microarray comprises the second article, wherein at least one compound is affixed to the dextran at each discrete locus, the composition of compounds at each discrete locus differing from the composition of compounds at at least one other discrete locus.
- In one embodiment of the first and third microarrays, the nitrocellulose or Hydrogel support is selected from the group consisting of a chip, a slide, a filter, and a plate. In one embodiment of the second and fourth microarrays, the nitrocellulose or Hydrogel support is selected from the group consisting of a chip, a slide, a filter, a plate, and a bead.
- In one embodiment of the above microarrays, the number of discrete loci is at least 100. In another embodiment, the number of discrete loci is at least 1000. In a further embodiment, the number of discrete loci is at least 10,000. In a further embodiment, the number of discrete loci is at least 50,000.
- In one embodiment of the first and second microarrays, a glycomer is affixed at at least one locus. In another embodiment, an insoluble protein is affixed at at least one locus. In another embodiment, a lectin is affixed at at least one locus. In a further embodiment, an antibody is affixed at at least one locus. In a further embodiment, the microarray has affixed to its surface two or more compounds selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody. In a further embodiment, the microarray has further affixed to its surface a compound selected from the group consisting of a soluble protein, a nucleic acid and a small molecule.
- In one embodiment of the third and fourth microarrays, a glycomer is affixed to the dextran at at least one locus. In another embodiment, an insoluble protein is affixed to the dextran at at least one locus. In another embodiment, a lectin is affixed to the dextran at at least one locus. In a further embodiment, an antibody is affixed to the dextran at at least one locus. In another embodiment, the microarray has affixed to the dextran two or more compounds selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody. In another embodiment, the microarray has affixed to its surface a compound selected from the group consisting of a soluble protein, a nucleic acid and a small molecule.
- In one embodiment of the instant microarrays, at each locus is affixed only one compound. In another embodiment, at at least one locus is affixed a plurality of compounds.
- This invention provides six methods for detecting the presence of agents in a sample. The first method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known glycomers, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; and (b) determining whether any known glycomer in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- The second method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known insoluble proteins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known insoluble protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding insoluble protein in the microarray; and (b) determining whether any known insoluble protein in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- The third method is a method of detecting in a sample the presence of one or more agents which specifically bind to one or more known antibodies or lectins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; and (b) determining whether any known antibody or lectin in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- In one embodiment of the above methods, the agent is an antibody which correlates with a disease. In a further embodiment of the first method, the agent is an antibody which correlates with an inflammatory disease. In additional embodiments of the above methods, the agent is an antibody which correlates with an infection or the presence of a tumor.
- In one embodiment of the instant methods, the method comprises detecting the presence of a plurality of agents in the sample, each of which binds to either a plurality of glycomers, a plurality of insoluble proteins, or a plurality of lectins or antibodies, as applicable. In another embodiment of the instant methods, the method comprises determining the amount of a plurality of agents in the sample, each of which binds to either one glycomer, one insoluble protein or one lectin or antibody, as applicable.
- “Determining” whether an agent is bound to a compound in a microarray can be performed according to methods well known in the art. Such methods include, but are not limited to, fluorescence, radioimmunoassay, and immunolabeling detection.
- In the instant methods of detection, several embodiments are provided which include, without limitation, the following: (a) one agent in a sample binds to one compound on the instant microarray; (b) one agent in a sample is detected that binds to more than one compound on the microarray; (c) the collective presence of a plurality of agents in a sample is detected, wherein each such agent binds to one or more compounds on the microarray; and (d) each of a plurality of agents in a sample is individually detected, wherein each such agent binds to one or more compounds on the microarray.
- This invention further provides three quantitative methods. The first method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known glycomers, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known glycomer is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; (b) for each known glycomer in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- The second method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known insoluble proteins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known insoluble protein is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding insoluble protein in the microarray; (b) for each known insoluble protein in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- The third method is a method of determining the amount of one or more agents in a sample, each of which specifically binds to one or more known antibodies or lectins, which method comprises: (a) contacting the sample with the first or second microarray, wherein each known antibody or lectin is affixed at at least one discrete locus, and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; (b) for each known antibody or lectin in the microarray, determining the amount of agent specifically bound thereto; and (c) comparing the amounts so determined to a known standard, thereby determining the amount of the one or more agents in the sample.
- In one embodiment of the instant quantitative methods, the agent is an antibody which correlates with a disease. In a further embodiment of the first method, the agent is an antibody which correlates with an inflammatory disease. In additional embodiments of the above methods, the agent is an antibody which correlates with an infection or the presence of a tumor.
- In one embodiment of the instant quantitative methods, the method comprises determining the amount of a plurality of agents in the sample, each of which binds to either a plurality of glycomers, a plurality of insoluble proteins, or a plurality of lectins or antibodies, as applicable. In another embodiment of the instant quantitative methods, the method comprises determining the amount of a plurality of agents in the sample, each of which binds to either one glycomer, one insoluble protein or one lectin or antibody, as applicable.
- “Determining” the amount of an agent which is bound to a compound in a microarray can be performed according to well known methods in the art. The “known standards” useful for the instant quantitative methods include, for example, correlations between known concentrations of agents in a control sample and their corresponding values as determined using the instant microarray.
- In the instant quantitative methods, several embodiments are provided which include, without limitation, the following: (a) one agent in a sample binds to one compound on the instant microarray; (b) one agent in a sample is quantitated that binds to more than one compound on the microarray; (c) the collective amount of a plurality of agents in a sample are quantitated, wherein each such agent binds to one or more compounds on the microarray; and (d) each of a plurality of agents in a sample is individually quantitated, wherein such agent binds to one or more compounds on the microarray.
- This invention further provides three diagnostic methods. The first method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known glycomer, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known glycomer in the microarray; and (b) determining whether the known glycomer in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- The second method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known insoluble protein, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known insoluble protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known insoluble protein in the microarray; and (b) determining whether the known insoluble protein in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- The third method is a method of determining whether a subject is afflicted with a disorder characterized by the presence or absence in an afflicted subject of an agent which specifically binds to a known antibody or lectin, which method comprises: (a) contacting a suitable sample from the subject with the first or second microarray, wherein the known antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit the agent, if present in the sample, to specifically bind to the known antibody or lectin in the microarray; and (b) determining whether the known antibody or lectin in the microarray has the agent specifically bound thereto, thereby determining whether the subject is afflicted with the disorder.
- In one embodiment of the instant diagnostic methods, the subject is human. In one embodiment of the first method, the disorder is an inflammatory disorder. In another embodiment of the first method, the inflammatory disorder is celiac disease. In one embodiment of the third method, the disorder is HIV-1 infection.
- The following are specific examples of the instant diagnostic methods. In the first example, a subject's serum is analyzed for the presence of HIV-1 gp120 and IgG-anti-HIV-1 gp120, the presence of both indicating active HIV-1 infection. In the second example, a subject's serum is analyzed for the presence of either HIV-1 gp120 and IgG-anti-HIV-1 gp120, the absence of the HIV-1 gp120 and the presence of IgG-anti-HIV-1 gp120 antibody indicating HIV-1 infection or immunization. In the third example, a subject's serum is analyzed for the presence of HIV-1 gp120 and IgG-anti-HIV-1 gp120, the absence of both indicating that the subject is neither HIV-1 infected nor immunized. In the fourth example, a subject's serum is analyzed for the presence of IgA-anti-gliadin and IgA-anti-TGt, the presence of both indicating that the subject is afflicted with celiac disease. Finally, in the fifth example, a subject's serum is analyzed for the presence of IgA-anti-gliadin, the presence of this antibody indicating the possibility that the subject is afflicted with celiac disease.
- This invention further provides a method of determining whether an antibody known to specifically bind to a first glycomer also specifically binds to a second glycomer, which method comprises: (a) contacting the antibody with the first or second microarray, wherein a plurality of glycomers, other than the first glycomer, are affixed at discrete loci in the microarray, and wherein the contacting is performed under conditions which would permit the antibody to specifically bind to the first glycomer if it were present in the microarray; and (b) determining whether any of the glycomers in the microarray, other than the first glycomer, has the antibody specifically bound thereto, thereby determining whether the antibody also specifically binds to a second glycomer.
- This invention further provides a method of determining whether an antibody known to specifically bind to a first insoluble protein also specifically binds to a second insoluble protein, which method comprises: (a) contacting the antibody with the first or second microarray, wherein a plurality of insoluble proteins, other than the first insoluble protein, are affixed at discrete loci in the microarray, and wherein the contacting is performed under conditions which would permit the antibody to specifically bind to the first insoluble protein if it were present in the microarray; and (b) determining whether any of the insoluble proteins in the microarray, other than the first insoluble protein, has the antibody specifically bound thereto, thereby determining whether the antibody also specifically binds to a second insoluble protein.
- This invention further provides a method of making a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, which method comprises contacting the nitrocellulose or Hydrogel support with the compounds under suitable conditions, whereby (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides a method of making a microarray comprising a plurality of nitrocellulose or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, which method comprises contacting the nitrocellulose or Hydrogel supports with the compounds under suitable conditions, whereby (a) at at least one discrete locus is affixed a compound selected from the group consisting of a glycomer, an insoluble protein, a lectin and an antibody, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides a method of making the first article comprising contacting a nitrocellulose or Hydrogel support with dextran at discrete loci under suitable conditions.
- In one embodiment of this method, the method further comprises the step of affixing at least one compound to the dextran at each discrete locus, whereby the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides a method of making the second article comprising contacting a plurality of nitrocellulose or Hydrogel supports with dextran, whereby each support has dextran affixed to its surface at one or more discrete loci.
- In one embodiment of this method, the method further comprises the step of affixing at least one compound to the dextran at each discrete locus, whereby the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- This invention further provides six kits. The first kit comprises one of the instant microarrays and instructions for use. The second kit comprises one of the instant microarrays and a desiccant. The third kit comprises one of the instant microarrays immersed in an aqueous solution.
- The fourth kit is a kit for practicing the first diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the glycomer to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- The fifth kit is a kit for practicing the second diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the insoluble protein to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- The sixth kit is a kit for practicing the third diagnostic method, which comprises: (a) a microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (i) at at least one discrete locus is affixed the antibody or lectin to which the agent present or absent in an afflicted subject specifically binds, and (ii) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus; and (b) instructions for use.
- This invention further provides a first antibody capable of specifically binding to a glycomer present on the surface of a mammalian macrophage, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell. In one embodiment, the antibody is a groove-type antibody. In another embodiment, the antibody is designated 4.3.F1 (ATCC Accession No. PTA-3259). In a further embodiment, the antibody is designated 45.21.1 (ATCC Accession No. PTA-3260).
- This invention further provides a second antibody capable of specifically binding to a glycomer present on the surface of a mammalian intestinal epithelial cell, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell. In one embodiment, the antibody is a cavity-type antibody. In another embodiment, the antibody is designated 16.4.12E (ATCC Accession No. PTA-3261).
- This invention further provides a method of determining whether a subject is afflicted with a disorder characterized by the presence of a glycomer on the surface of macrophages in an afflicted subject, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell, comprising: (a) contacting a sample of the subject's macrophages with the first antibody; and (b) determining whether the antibody specifically binds to the macrophages in the sample, such binding indicating that the subject is afflicted with the disorder. In one embodiment the subject is human. In another embodiment, the disorder is an immune disorder or an inflammatory disorder.
- This invention provides a method of determining whether a subject is afflicted with a disorder characterized by the presence of a glycomer on the surface of intestinal epithelial cells in an afflicted subject, which glycomer, or structural mimic thereof, is also endogenous to, and present on the surface of, a bacterial cell, comprising: (a) contacting a sample of the subject's intestinal epithelial cells with the second antibody; and (b) determining whether the antibody specifically binds to the intestinal epithelial cells in the sample, such binding indicating that the subject is afflicted with the disorder. In one embodiment the subject is human. In another embodiment, the disorder is an immune disorder or an inflammatory disorder. In a further embodiment, the disorder is celiac disease.
- In one embodiment of each facet of this invention (i.e., each of the instant compositions of matter and methods), the glycomer, insoluble protein, lectin or antibody of the instant microarray is conjugated with a green fluorescent protein (GFP), and this conjugate is affixed to a nitrocellulose or Hydrogel support either via the GFP moiety or not. “Conjugation” as used herein includes, without limitation, conjugation by covalent or noncovalent means. In a further embodiment, conjugation of a second protein with GFP is accomplished via formation of a fusion protein with the second protein. As used herein, “a fusion protein” includes, for example, a protein encoded by a gene that comprises a GFP-encoding region and a non-GFP-encoding region. As used herein, GFP includes, without limitation, whole GFP as well as fluorescent fragments thereof. In a further embodiment of each facet of this invention, GFP alone (i.e., unconjugated form), is bound to the instant microarray.
- The fifth microarray comprises a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (a) at at least one discrete locus is affixed a compound associated withBacillus anthracis and selected from the group consisting of a glycomer and a protein, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- The sixth microarray comprises a plurality of nitrocellulose or Hydrogel or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, wherein (a) at at least one discrete locus is affixed a compound associated withBacillus anthracis and selected from the group consisting of a glycomer and a protein, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
- The fourth method of detection is a method of detecting in a sample the presence of one or more agents associated withBacillus anthracis which specifically bind to one or more glycomers, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; and (b) determining whether any glycomer in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- The fifth method of detection is a method of detecting in a sample the presence of one or more agents associated withBacillus anthracis which specifically bind to one or more proteins, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding protein in the microarray; and (b) determining whether any known protein in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- The sixth method of detection is a method of detecting in a sample the presence of one or more glycomers or proteins which specifically bind to one or more antibodies or lectins associated withBacillus anthracis, which method comprises: (a) contacting the sample with the fifth or sixth microarray, wherein each antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; and (b) determining whether any antibody or lectin in the microarray has an agent specifically bound thereto, thereby detecting the presence of the one or more agents in the sample.
- Also envisioned in this invention are all embodiments of the microarray technology described herein as applied to agents associated withBacillus anthracis. Specifically, this invention provides, for example, all such embodiments relating to methods of quantitative detection, diagnosis, binding detection, making microarrays, kits, and antibodies and glycomers identified using the instant methods, as applicable.
- This invention will be better understood from the Experimental Details that follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.
- Experimental Details
- First Series of Experiments
- This invention provides novel antigen- and antibody-based microarrays for monitoring and quantifying a broad spectrum of biological molecules and their molecular interactions. A microarray technique is used to spot thousands of antigens and/or antibodies on a solid surface. This strategy can be applied to any molecular target, including naturally occurring proteins, carbohydrates, lipids and nucleic acids, as well as synthetic compounds. The instant microarray is useful for monitoring the expression of specific antibodies and other cellular factors in body fluids, and is therefore useful for disease diagnosis and basic immunological investigation. When a large repertoire of distinct monoclonal antibodies are arrayed, an antibody library microarray is produced. Application of these microarrays for global analysis of gene expression at the translational and post-translational levels is envisioned. The Elvin A. Kabat Collection of antigens and antibodies at Columbia University is useful in practicing this technology.
- I. Materials, Methods and Results
- (A) Method for Antigen/Antibody Immobilization
- It is experimentally demonstrated here that nitrocellulose-coating can serve as a suitable matrix for immobilizing polysaccharides, glycoprotein, glycolipid, protein and antibodies on a glass surface without chemical conjugation. A set of commercially available glass slides, including those coated with nitrocellulose (ONCYTE Film-Slides, Grace Bio-Labs, Inc., Bend, Oreg.), poly-L-lysine (POLY-PREP™, Sigma), aminoalkylsilane (SILANE-PREP™, Sigma) and regular micro-glass slides, were compared for their capacity to immobilize macromolecules of distinct structural properties. In the initial experiments, fluorescence-conjugated dextran molecules were applied. An extended panel of antigen preparations, including polysaccharide, glycoprotein, glycolipid, protein and antibody, were then investigated. Examples of these investigations are shown in FIGS. 1 and 2.
- (B) Printing and Long-Term Storage of Antigen/Antibody Microarrays
- A high-precision robot designed to produce cDNA microarrays (GMS 417 Arrayer, Genetic Microsystems, Inc., Woburn Mass.) was used to spot carbohydrate antigens onto a glass slide pre-coated with nitrocellulose polymer (ONCYTE Film-Slides, Grace Bio-Labs, Inc., Bend, Oreg.). Spots of antigens were printed with spot sizes at approximately 200 micron and 400 micron intervals, center-to-center. They were air dried and stored at room temperature before use. Conditions for long-term storage of the printed antigen/antibody microarrays were compared. The results show that (1) the air-dried carbohydrate microarrays can be stored at room temperature for at least one year without significant inactivation of their immunological activities; and (2) the antibody microarrays can be stored in an aqueous solution at 4° C. for at least one year without significant decrease in their antigen-binding activity, as illustrated using antibodies with anti-carbohydrate specificity.
- (C) Proper Macromolecules for Coupling Smaller Bioreactive Molecules and Displaying them on a Solvent-Accessible Surface
- Dextran preparations, especially α(1, 6)dextrans, can serve as carrier molecules to conjugate other biologically active molecules. Such dextran-containing conjugates can be immobilized on a nitrocellulose-surface without further chemical conjugation. This method was demonstrated by immobilizing the fluorescence-α(1,6)dextran conjugates of different molecular weights, ranging from 35 kD to 2000 kD, on a nitrocellulose-coated glass slide. The fluorescence group is accessible to the anti-fluorescence antibodies in solution, thereby demonstrating specific binding. Methods for producing dextran-conjugates for surface immobilization follow.
- (1) Mild Sodium Periodate Oxidization of Dextran to Create Highly Reactive Aldehyde Functional Groups (CHO)
- α(1,6)dextran, preparation N279 (B512), was dissolved in 0.01M NaAcetate buffer, pH 5.5, at 10 mg/ml and warmed in a 37° C. water bath for 30 minutes. NaIO4 was then added to the final concentration of 1×10−2 M. The solution was mixed well and left to stand at room temperature for one hour in the dark. The preparation was dialyzed against 0.02M BBS (Borate buffered saline) pH 8.0, 4° C., overnight.
- (2) Mild Oxidization of Carbohydrate Structure of IgG to Create CHO Group for Surface Immobilization
- The above protocol was also applied to produce active CHO groups in carbohydrate molecules that exist naturally in the C region of IgG molecules. Such CHO-activated IgG is then covalently linked to the amino group of an amino-dextran molecule that was immobilized on a nitrocellulose-coated glass slide. Preparations of amino-dextrans are commercially available (Molecular Probes, Eugene). This method of IgG immobilization uses a carbohydrate structure attached in the Fc region of IgG, which is away from the antibody combining sites of antibody molecule, and thus preserves the antibodies' binding activity.
- (3) Coupling of Biotin-LC-Hydrazide to the Oxidized Dextran
- The above oxidized dextran was diluted 10-fold in 0.1M NaAcetate, pH 5.5. A ⅓ volume of 5 mM Biotin-LC-Hydrazide was added dropwise. The mixture was shaken at room temperature for one hour. The reaction was terminated by addition of 0.5 ml of 1M Tris HCl, pH 7.5, and the mixture was then dialyzed against Tris buffer (0.1M Tris pH 7.5, 0.1 M NaCl, 2.0mM MgCl2). The biotinylated dextrans are then ready to be immobilized on nitrocellulose-coated glass slides so that their biotin-groups are accessible to other molecules in solution.
- (4) Surface Immobilization of Biotinylated Molecules
- Standard methods were applied to couple NHS-Biotin (BRL #5533LA) to target molecules, i.e., either protein or polysaccharide. The biotinylated molecule was incubated with avidin at a proper molar ratio depending on the molecular weight of the target and its molar ratio with biotin. The molecules were then spotted on a surface that was precoated with biotin-dextran and blocked with BSA or gelatin. This strategy allows a flexible arrangement of antigen or antibody microarrays for a desired purpose, and avoids non-specific binding of target molecules on a surface.
- (5) Glutaraldehyde-Conjugation to Generate Dextran-Small Molecule Conjugates
- Small bioactive molecules containing amine group(s) can be coupled to amino-dextrans (Molecular Probes) by glutaraldehyde. Glutaraldehyde was added to the mixtures of the target molecule and amino-dextran (at proper molar ratios) to a final concentration of 0.2%. They were at room temperature for two hours. The reaction was stopped by addition of 1M ethanolamine at 6.1 μl/ml. The mixture was at room temperature for an additional two hours and then dialyzed against 1× PBS or other proper solution, overnight. The dextran-small molecule conjugates were then spotted on nitrocellulose-coated slides. This method is suitable for generating microarrays having a large repertoire of small molecules and useful for high throughput drug screening or other biomedical investigations.
- (D) Solutions for Preparing Macromolecules of Distinct Physicochemical Properties
- (1) Solution Storage
- Microbial polysaccharides, blood group substances and glycolipids were solubilized and stored in saline at a concentration of about 1 mg/ml at 4° C. A small droplet of chloroform was added to prevent microbes. In this simple way, most solutions can be stored for years. The agents were diluted in saline at required concentrations immediately before spotting.
- (2) Protein Antigens
- Soluble protein preparations were prepared at relatively high concentrations in 1× PBS (mg/ml) with addition of 20% glycerol and frozen at −80° C. They were diluted in 1× PBS before use and stored at 4° C. for a short period of time (a few days). Antibody preparations were generally stored at 4° C. in 1× PBS except in special cases. SomeE. Coli-expressed protein antigens are water-insoluble. The preparations were purified in a denatured condition and stored them in the same solution at 4° C. The freezing process is avoided for these proteins. In most cases these preparations can be immobilized on a nitrocellulose matrix without special treatment. This method has been applied successfully in applicant's laboratory for hybridoma screening.
- (E) Staining and Scanning of Antigen/Antibody Microarrays
- (1) General Application Protocol
- Immediately before use, the printed antigen/antibody microarrays were rinsed with 1× PBS with 0.05
% Tween 20 and then blocked by incubating the slides in 1% BSA in PBS containing 0.05% NaN3 at 37° C. for 30 minutes. The microarrays were then incubated at room temperature with fluorescent-antibody conjugate at proper titration in 1% BSA PBS containing 0.05% NaN3 and 0.05% Tween 20. Slides were rinsed with 1× PBS with 0.05% Tween 20 five times, air-dried at room temperature and then scanned for fluorescent signals. A ScanArray 5000 Standard Biochip Scanning System (GSI Lumonics, Inc. and Packard BioChip Technologies, Inc.) which is equipped with multiple lasers, emission filters, ScanArray Acquisition Software and QuantArray Microarray Analysis Software, was used to scan the stained antigen microarray, quantify spot-associated fluorescent-signals and analyze data. - (2) Special Application Protocols
- (a) Method for Improving Signal Detection
- A technical problem that has limited the application of the nitrocellulose-coated glass slide is its association with “white color” and non-specific fluorescent signals upon scanning. This problem is solved using the method that follows. (a) After staining a microarray glass slide, allow it to air-dry for a few minutes (at this stage, the nitrocellulose-coated region is white in color). (b) Soak the slide in 100% ethanol for 1-2 minutes until the white color of the nitrocellulose-coated region disappears and the entire slide becomes transparent. (c) Quickly spin the slide to remove extra ethanol. (d) Scan the slide when it is completely transparent. After storage for a few days or longer, depending on the humidity level in the air, the slide may turn back to the white color. One may repeat the above process to make the slide transparent again if necessary.
- (b) Staining Antigen/Antibody Microarrays using Non-Fluorescent Dyes
- The antigen/antibody microarray can be stained with antibodies, antigens or other reactors that are conjugated with non-fluorescent dyes. The commonly used alkaline phosphatase (AP) and peroxidase are useful alternatives. One may practice this method as follows. (a) Stain an antigen microarray with a human serum sample at the proper dilution as described above. (b) After washing, stain the slide with an AP-conjugated anti-human IgG antibody at the proper dilution. (c) Wash the slide and develop the color by adding AP substrate BCIP alone or BCIP plus NBT. (d) Stop the reaction by adding a Tris-EDTA solution (20 mM Tris, pH 7.5, 5 mM EDTA). (e) Rinse the slide with distilled water and then scan it with a non-flourescent slide scanner, or observe the color reaction under a regular microscope.
- (F) Sensitivity of Antigen Microarrays
- Sensitivity is one of the critical parameters that determine the diagnostic value of antigen microarrays. In preliminary experiments (FIG. 1), dextran preparations were arrayed on nitrocellulose-coated glass slides in concentrations ranging from 100 μg/ml to 3.3 ng/ml. They were stained with fluorescence-labeled anti-dextran mAbs, either 4.3.F1 or 16.4.12E, at a concentration of 1 μg/ml. In both cases, the captured fluorescent signals (intensities) detected were positively correlated to the antigen concentrations. For example, 4.3.F1 was only detectable when the concentrations of N279, LD7 and B1299S are higher than 0.4, 20 or 100 μg/ml, respectively (spots of antigens with concentrations lower than 0.4 μg/ml were not shown in FIG. 1). Signal saturation was not observed even at the highest concentration of 100 μg/ml, showing the technical potential for improving the sensitivity of antigen microarrays.
- (G) Epitope-Specific Antigen Microarray
- Glycoconjugate technology was used to produce an “epitope-specific antigen microarray”. A naturally occurring antigen may be composed of multiple antigenic determinants. Frequently, one or a few of them serve as predominant antigenic determinants for host recognition. Antibodies specific for some carbohydrate epitopes of a microbial polysaccharide can be more protective than those reacting with others. There are also cross-reactive antigenic determinants that may be shared among strains or even species of microorganisms. Such cross-reactivities may cause difficulty in typing corresponding infectious agents. Thus, it is useful to define the fine specificities of antibodies elicited by an infection or by vaccination.
- To produce an epitope-specific microarray, preparations of glycoproteins displaying α(1,6)-linked glucoses, i.e., isomaltotriose-coupled BSA (IM3-BSA) or its KLH-conjugate (IM3-KLH), were applied in a microarray experiment. These conjugates have the terminal non-reducing end epitope of α(1,6)dextran in common but differ in their protein carriers. As expected, mAb 16.4.12E (cavity-type), but not mAb 4.3.F1 (groove-type), bind to the microspots of IM3-protein conjugates (FIGS. 1E and 2E). Thus, glycoproteins can be immobilized on a nitrocellulose-coated glass slide and their antigenic determinants remain accessible to antibodies in solution.
- Neoglycolipids, i.e., glycolipid conjugates, were used to produce epitope-specific microarrays, wherein stearylamine-isomaltosyl oligosaccharide conjugates, ST-IM3, ST-IM5 and ST-IM7, were applied (data not shown) Such glycolipid conjugates are homogeneic, since each lipid molecule can only be coupled by a single oligosaccharide. Unlike a glycoprotein conjugate, the sugar chain can be conjugated on to multiple sites of a protein molecule, generating a heterogenic population of antigenic determinants. Both sugar epitope and the amino acid residues adjacent to it may be structurally involved in forming these antigenic determinants.
- (H) Antibody Microarrays
- Experiments were performed to develop antibody-based microarrays. A panel of anti-dextran mAbs were immobilized at a concentration of 0.5 mg/ml on a set of glass slides. These included (a) a nitrocellulose-coated glass slide (ONCYTE Film-Slides, Grace Bio-Labs, Inc., Bend, Oreg.); (b) a poly-lysine treated slide (POLY-PREP™, Sigma); (c) a silane-treated glass slide (SILANE-PREP™, Sigma); and (d) an un-treated, pre-cleaned glass slide. These slides were then reacted with fluorescence-tagged dextran preparations of distinct structures. Only the nitrocellulose-slides showed spots of specific fluorescent signals. Thus, anti-dextran mAbs arrayed on the nitrocellulose-glass slide retained their antigen binding specificities. As described above, the antibody microarrays can be stored at room temperature in an air-dried condition for a few months and maintain their antibody-binding activity. The antibodies investigated include monoclonal antibodies of different isotypes (IgM, IgG and IgA).
- II. Application of Antigen-Antibody Biochip Technology for Basic Research and Clinical Investigation
- (A) Mapping Antibody Combining Sites by Applying Antigen/Antibody Microarrays
- A well-established antigen-antibody system, i.e., dextrans and anti-dextran monoclonal antibodies (mAbs) [10, 11], was used for these investigations. A panel of purified dextran preparations of different linkage compositions and of different ratios of terminal/internal epitopes [10] were immobilized on nitrocellulose-coated glass slides and then incubated with monoclonal antibodies of defined specificities, either the cavity-type or the groove-type anti-dextrans [12]. The former is specific for the terminal non-reducing end structure of α(1,6)dextran; the latter recognizes the internal linear chain of the polysaccharide. When a cavity-type mAb, 16.4.12E, was applied on the glass slide, it bound to the immobilized α(1,6)dextran preparations having branches, but not those with only internal linear chain structures. By contrast, a groove-type mAb, 4.3.F1, bound to the dextran preparations dominated by linear chain structures, but not to the heavily branched α(1,6)dextrans (FIG. 1). Thus, the use of polysaccharides of defined structure in microarrays is an important strategy for studying antibody specificities and for characterizing immune responses to microbial infections.
- As described above, methods to produce epitope-specific microarrays were also established, allowing characterization of the fine specificity of antibodies. Considering the presence of both the internal chain epitopes and the terminal non-reducing end epitopes in many polysaccharides, application of both polysaccharide macromolecules and their oligosaccharide conjugates on the instant microarrays will significantly enhance the power of the system, including its sensitivity, specificity and the detecting repertoires of antigenic determinants.
- (B) Investigation of the Specificity and Cross-Reactivity of Antibodies/Receptors
- An advantage of the instant microarray is that it provides a high throughput strategy to characterize the specificity and cross-reactivity of an antibody or a lectin molecule. FIG. 2 shows an example of this approach. A collection of about 50 carbohydrate-containing antigens, including microbial polysaccharides, blood group substances and other glyco-conjugates, were arrayed on the nitrocellulose-coated slide. They were then stained with anti-dextran mAbs, 4.3.F1, or 16.4.12E. As shown in FIG. 2, certain cross-reactive signals were detected for a few antigen preparations, being spots 2a, 3a and 6a for mAb 4.3.F1, and 2a, 3a, 4a, 6a, 1e, and 2e for 16.4.12E. Antigens arrayed at these locations are: 2a.
Klebsiella polysaccharide type 11; 3a. Klebsiella type 13; 4a. Klebsiella type 21; 6a. Chondroitin sulfate B polysaccharide; 1 e. IM3-BSA and 2e. IM3-KLH. - As discussed above, the binding of 16.4.12E (cavity-type), but not 4.3.F1 (groove-type), to IM3-BSA (1e) and IM3-KLH (2e) reflects the epitope-specific binding activities of these two monoclonal antibodies. Their binding to other antigens is, however, unexpected. The fluorescent intensities of cross-reactivities are much weaker than the binding to α(1,6)dextran N279. They were detected at a high antigen concentration (500 μg/ml), corresponding to or lower than the signals of specific bindings at much lower antigen concentrations (0.8 to 4 μg/ml). On an ELISA plate, such weak cross-reactivities are not detectable (data not shown). The cross-reactivities to CS-B polysaccharide (FIG. 2A and FIG. 2B), is interesting since CS-B is not a microbial antigen and was prepared from the intestinal mucosa of porcine. Further investigation of such reactivity led to the discovery of Dex-IdX as a cell type-specific marker in mouse and human (FIGS.3-5).
- (C) Clinical Application of Antigen Microarrays
- The antigen-based microarray can be applied for detection and characterization of a wide range of microbial infections. During infection, whether viral, bacterial, fungal or parasitic, the host usually responds with the formation of antibodies which can be detected by a modified version of any of the methods used for antigen detection. The formation of antibodies and their time course depends on the antigenic stimulation provided by the infection. Recognition of these patterns provides evidence of recent or past infection. Microarrays of a large panel of antigens allow detection of many specificities in a single assay and thus allow a rapid diagnosis of infections. The diagnostic power of the instant microarrays will only increase as more microbial antigens and/or their antigenic determinants are characterized and applied.
- To demonstrate this principle, a small scale antigen microarray with about 50 antigens was produced (FIG. 2) and tested with human sera from normal individuals and celiac patients. These specimens were diluted at 1:20 in 1% BSA-PBS with 0.025
% Tween 20 and applied to the microarray. The bound human antibodies were visualized by application of a second antibody specific for human IgG or IgA that was conjugated with a fluorescent molecule (an anti-human IgGCy3 and an anti-human IgACy5). The positive staining of the microspots of these arrayed antigens by the serum specimens ranged from 6% (three of fifty spots were detected) to 12% (six of fifty spots were detected). The antigens detected were mainly microbial polysaccharides, includingKlebsiella polysaccharide type - The majority of the positive staining was of human IgG antibodies, although IgAs were also detected. This investigation has demonstrated that the instant microarray has the sensitivity to detect specific antibodies in human serum. Given the current capacity of microspotting technology in the art, about twenty thousand antigens can be arrayed on a single glass slide. It is expected, therefore, that this microarray is capable of characterizing a wide range of microbial infections using very limited samples in a single experiment.
- III. Discussion
- The instant microarrays are significantly different from known cDNA microarray and oligo-chip technologies, which target only nucleic acids. Applicant has employed high throughput microarray technology to develop a novel strategy for detecting, quantifying and characterizing proteins, carbohydrates and other biological molecules, and useful in the new areas of post-genomic research, namely proteomics and glycomics.
- Differing from current immunoassays which detect specific molecules one-by-one, this technology is designed to detect and quantify a large repertoire of distinct biological molecules in a single assay. Combining a high throughput microarray technique and a sensitive confocal fluorescent scanning method, this technology is useful for detecting thousands of distinct molecules using a small amount of biological specimen, such as a drop of blood or other bodily fluid. This technology can be extended to the genome-wide scanning of protein expression and post-translational modification.
- 1. Ramsay, G., DNA chips: state-of-the art. Nature Biotechnology, 1998. 16(1): p. 40-4.
- 2. Brown, P. O. and D. Botstein, Exploring the new world of the genome with DNA microarrays. Nature Genetics, 1999. 21(1 Suppl): p. 33-7.
- 3. DeRisi, J. L., V. R. Iyer, and P. O. Brown, Exploring the metabolic and genetic control of gene expression on a genomic scale. Science, 1997. 278(5338): p. 680-6.
- 4. Lueking, A., et al., Protein microarrays for gene expression and antibody screening. Analytical Biochemistry, 1999. 270(1): p. 103-11.
- 5. Ge, H., UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. Nucleic Acids Research, 2000. 28(2): p. e3.
- 6. Varki, A., Biological roles of oligosaccharides: all of the theories are correct. Glycobiology, 1993. 3(2): p. 97-130.
- 7. Feizi, T., Carbohydrate recognition systems in innate immunity. Advances in Experimental Medicine & Biology, 1998. 435: p. 51-4.
- 8. Feizi, T. and R. W. Loveless, Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences. American Journal of Respiratory & Critical Care Medicine, 1996. 154(4 Pt 2): p. S133-6.
- 9. Zareba, T. W., et al., Binding of extracellular matrix proteins by enterococci. Curr Microbiol, 1997. 34(1): p. 6-11.
- 10. Wang, D. and E. A. Kabat, Carbohydrate Antigens (Polysaccharides), in Structure of Antigens, M.H.V.V. Regenmortal, Editor. 1996, CRC Press: Boca Raton New York London Tokyo. p. 247-276.
- 11. Wang, D., et al., The repertoire of antibodies to a single antigenic determinant. Molecular Immunology, 1991. 28(12): p. 1387-97.
- 12. Cisar, J., et al., Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran. J. Exp. Med., 1975. 142: p. 435-459.
- 13. Matsuda, T. and E. A. Kabat, Variable region cDNA sequences and antigen binding specificity of mouse monoclonal antibodies to isomaltosyl oligosaccharides coupled to proteins T-dependent analogues of α(1,6)dextran. J. Immunol., 1989. 142: p. 863-870.
- 14. Chen, H. T., S. D. Makover, and E. A. Kabat, Immunochemical studies on monoclonal antibodies to stearyl-isomaltotetraose from C58/J and a C57BL/10 nude mouse. Mol. Immunol., 1987. 24: p. 333-338.
- 15. Wang, D., et al., Two families of monoclonal antibodies to α(1,6)dextran, VH19.1.2 and VH9.14.7, show distinct patterns of Jk and JH minigene usage and amino acid substitutions in CDR3. J. Immunol., 1990. 145: p. 3002-3010.
- Second Series of Experiments
- I. Materials and Methods
- A. Carbohydrate Antigens and Antibodies
- Carbohydrate-containing macro-molecules applied in FIG. 7, and anti-α(1,6) dextran mabs, 16.4.12E (IgA/kappa) (6), 4.3F1 (IgG3/kappa)(5), and 45.21.1 (IgA/kappa)(8), were adopted from the collection of the late Professor Elvin A. Kabat of Columbia University. Purified proteins of 4.3F1, 45.21.1 and 16.4.12E were obtained by a procedure of affinity purification as described(9). The biotinylated or FITC-conjugated anti-dextran antibodies were prepared in our laboratory following standard protocols(10). The FITC-conjugated α(1,6) dextrans of
moleuclar weight 20 kDa, 70 kDa, and 2,000 kDa, FITC-inulin, a biotinylated anti-human IgG antibody, an alkaline phosphatase-conjugated anti-human IgM, and streptavidin conjugates, were purchased from Sigma (St. Louis, Mo.). Antibodies for cell type/lineage analysis, including antibodies specific for murine CD11b/MAC1, MAC3, TCR-α, TCR-β, CD3, CD4, CD5, CD8, CD19, B220, Syndecan-1, a mouse IgG3 isotype standard (A12-3), and a streptavidin conjugate of Texas Red, were from BD-PharMingen (San Diego, Calif.). A streptavidin-Cy3 conjugate was purchased from Amersham Pharmacia (Piscataway, N.J.), and a red fluorescence substrate of alkaline phosphatase, Vector Red, from Molecular Probes, Inc. (Burlingame, Calif.). - B. Printing Carbohydrate Microarrays
- A high-precision robot designed to produce cDNA microarrays (GMS 417 Arrayer; Genetic Microsystems, Inc., Woburn, Mass.) was utilized to spot carbohydrate antigens onto the glass slides precoated with nitrocellulose polymer (FAST Slides; Schleicher & Schuell, Keene, N.H.). Carbohydrate antigens were dissolved in saline (0.9% NaCl) in concentrations as specified in the Figure legends. They were printed with spot sizes of ˜150 μm and at 375-μm intervals, center to center. The printed carbohydrate microarrays were air-dried and stored at room temperature without desiccant before application.
- C. Staining and Scanning of Carbohydrate Microarrays
- Immediately before use, the printed carbohydrate microarrays were rinsed with PBS, pH 7.4, with 0.05% (vol/vol)
Tween 20 and then blocked by incubating the slides in 1% (wt/vol) BSA in PBS containing 0.05% (wt/vol)NaN3 at 37° C. for 30 minutes. They were then incubated at room temperature with antibodies at an indicated titration in 1% (wt/vol) BSA in PBS containing 0.05% (wt/vol) NaN3 and 0.05% (vol/vol)Tween 20. Application of secondary antibodies or streptavidin conjugates is specified in figure legends. The stained slides were rinsed five times with PBS with 0.05%(vol/vol)Tween 20, air-dried at room temperature, and then scanned for fluorescent signals. The stained microarrays were scanned with a ScanArray 5000 Standard Biochip Scanning System (Packard BioChip Technologies, Inc., Billerica, Mass.) and data analyzed using Quant Array version 2.1 software associated with the system. - D. Elisa and in Situ Immunofluorescence
- ELISA and immunofluorescence staining were carried out as described (6, 11). The dextranase treatments were performed by a preincubation of tissue sections with dextranase(Sigma) at 0.5 unit/ml in 100 mM potassium PBS, pH 6.0, 37° C. for 60 minutes. This condition allows a complete removal of molecules of FITC-α(1,6) dextran that were specifically trapped by immune cells in the spleen sections of α(1,6) dextran-immunized mice (11).
- II. Results and Discussion
- A model system for establishing carbohydrate microarray technology. The dextrans and anti-dextran antibodies (1, 2) were applied to establish methods for immobilizing carbohydrate polymers on glass slides. Dextrans are polymers composed entirely of glucose, produced mainly by bacteria of the family Lactobacillaceae and of the genera Leuconostoc and Streptococcus. Dextran molecules derived from different strains may, however, differ significantly in their glycosidic linkage compositions. Unlike proteins that are linked solely by a peptide bond, carbohydrates utilize many possible glycosidic linkages so as to diversify their structures extensively. Some dextran preparations are predominantly or solely α(1,6)-linked, forming molecules with dominantly linear chain structures; others are composed of multiple glycosidic linkages, including α(1,6)-, α(1,3)-, α(1,2)-, and others, generating heavily branched molecules(3) (Table 1). Previous immunological studies (2, 4) have demonstrated that such structural characteristics are detectable by antibodies specific for different antigenic determinants or epitopes of dextran molecules. This system is, therefore, suitable for developing methods for immobilization of carbohydrate antigens and for investigating their immunological properties in a surface-immobilized configuration.
- We applied the fluorescein isothiocyanate (FITC)-conjugated polysaccharides as probes to investigate whether nitrocellulose-coated glass slides can be used to immobilize microspots of carbohydrate polymers without covalent conjugation. FITC-α(1,6) dextran preparations of different molecular weights and a structurally distinct polysaccharide, inulin, were printed on the glass slides using a microprinting device to produce a carbohydrate microarray (FIG. 6A). Their fluorescent signals were then captured and quantified by a microscanning system that was developed for scanning complementary DNA (cDNA) microarrays. By analyzing the fluorescent intensities retained on the slides after extensive washing, we demonstrated that dextran preparations ranging from 20 kDa to 2,000 kDa and inulin of 3.3 kDa were all stably immobilized on the nitrocellulose-coated slide without chemical conjugation. The efficiency of their immobilization was, however, significantly influenced by the molecular weight. The larger dextran molecules were better retained than the smaller ones (FIGS. 6A, B).
- To investigate whether immobilized carbohydrate macromolecules preserve their antigenic determinants or epitopes, dextrtan preparations of different linkage compositions(3) and of different rations of terminal to internal epitopes (1, 4) were printed on nitrocellulose-coated glass slides. These preparations include N279, displaying both internal linear and terminal nonreducing end epitopes; B1299S, heavily branched and expressing predominantly terminal epitopes; and LD7, a synthetic dextran composed of 100% α(1,6)-linked internal linear chain structure. The dextran microarrays were incubated with monoclonal antibodies (mabs) of defined specificities, either a groove-type anti-α(1,6) dextran 4.3F1 (IgG3) (5) or a cavity-type anti-α(1,6) dextran 16.412E (IgA) (6). The former recognizes the internal linear chain of α(1,6) destrans; the latter is specific for the terminal nonreducing end structure of the polysaccharide. As shown in FIG. 7A (left), the groove-type mAb, 4.3F1 (
refs 5,7) bound to the dextran preparations with predominantly linear chain structures, N279 and LD7, but bound poorly to the heavily branched α(1,6) dextran, B1299S. By contrast, when the cavity-type mAb 16.4.12E (FIG. 7A, right) was applied, it bound to the immobilized dextran preparations having branches (N279 and B1299S) but not those with only internal linear chain structure (LD7). These patterns of antigen-antibody reactivities are characteristically identical to those recognized by an ELISA binding assay (FIG. 7B) and other classical quantitative immunoassays for either the groove-type (4, 5, 7) or the cavity type (4, 6) of anti-dextran mabs. We conclude, therefore, that dextran molecules immobilized on a nitrocellulose-coated glass slide have their immunological properties well preserved. Both their nonreducing end structure, recognized by the cavity-type anti-α(1,6) dextrans, and the internal linear chain epitopes, bound by the groove-type anti-α(1,6) dextrans, are displayed on the surface after immobilization and are accessible to antibodies in an aqueous solution. - 1. Wang, D. & Kabat, E. A. Carbohydrate antigens (polysaccharides);Structure of Antigens, Vol. 3 (ed. M.H.V.V. Regenmortal) 247-276 (CRC Press, Boca Raton Fla.; 1996).
- 2. Wang, D. et al., The repertoire of antibodies to a single antigenic determinant.Mol. Immunol. 28, 1387-1397 (1991).
- 3. Jeanes, A. Immunochemical and related interactions with dextrans reviewed in terms of improved structural information.Mol. Immunol. 23, 999-1028 (1986).
- 4. Cisar, J., Kabat, E. A., Dörner, M. M. & Liao, J. Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran.J. Exp. Med. 142, 435-459 (1975).
- 5. Wang, D. et al., Two families of monoclonal antibodies to α(1,6) dextran, VH19.1.2 and VH9.14.7, show distinct patterns of JK and JH minigene usage and amino acid substitutions in CDR3. J. Immunol. 145, 3002-3010 (1990).
- 6. Matsuda, T. & Kabat, E. A. Variable region cDNA sequences and antigen binding specificity of mouse monoclonal antibodies to isomaltosyl oligosaccharides coupled to proteins. T-dependent analogues of α(1,6)dextran.J. Immunol. 142, 863-870 (1989).
- 7. Chen, H. T., Makover, S. D. & Kabat, E. A. Immunochemical studies on monoclonal antibodies to stearyl-isomaltotetraose from C58/J and a C57BL/10 nude mouse.Mol. Immunol. 24, 333-338 (1987).
- 8. Sharon, J., Kabat, E. A. & Morrison, S. L. Association constants of hybridoma antibodies specific for α(1-6) linked dextran determined by affinity electrophoresis.Mol. Immunol. 19, 389-397 (1982).
- 9. Lai, E. & Kabat, E. A. Immunochemical studies of conjugates of isomaltosyl oligosaccharides to lipid: productions nd characterization of mouse hybridoma antibodies specific for stearyl-isomaltosyl oligosaccharides.Mol. Immunol. 22, 1021-1037 (1985).
- 10. O'Shannessy, D. J., Dobersen, M. J. & Qarles, R. H. A novel procedure for labeling immunoglobulins by conjugation to oligosaccharide moieties.Immunol. Lett. 8, 273-277 (1984).
- 11. Wang, D., Wells, S. M., Stall, A. M. & Kabat, E. A. reaction of germinal centers in the T-cell-independent response tot he bacterial polysaccharide α(1-6)dextran.Proc. Natl. Acad. Sci. USA 91, 2502-(1994).
- Third Series of Experiments
- I. Introduction
- A microbial infection may expose and release multiple antigenic substances to a host, eliciting a comprehensive host immune response, including a B cell response, which produces specific antibodies, and a T cell response, resulting in specific T cell activation and cytokine production. There is also an activation of macrophage, dendritic cells and other accessory cells, leading to production of differential profiles of cytokines and inflammation factors. Some microbial substances are lethal to a host upon their immediate release or after interacting with host cells or cellular factors. The interplay of different types of host cells and multiple protein factors and their interaction with the invading pathogen determine the progress and consequence of a microbial infection. For example, in an anthrax infection, the pathogenBacillus anthracis may expose and release a number of antigens of distinct structural characteristics to a host, eliciting a comprehensive picture of a host response (FIG. 8).
- To better understand the pathogenesis mechanisms of an infectious disease, it is crucially important to monitor the full-spectrum of the multi-parameter host responses and identify the characteristic patterns of the response. Monitoring such a complex host response and host-microbe interaction has long been a challenge to biomedical scientists and clinicians. Many antigen-antibody binding assays are currently in use for clinical diagnosis of infectious and non-infectious diseases. These include the classical direct immunoassays, such as, immunodiffusion, immunoelectrophoresis, agglutination and immunoprecipitation, and recently developed methods, including immunofluorescence, radioimmunoassay (RIA), enzyme-immunoassay (EIA) and western blot. These approaches take advantage of the specificity of antigen-antibody interaction but are designed to operate on a one-by-one basis.
- Rapid progress of the genome sequencing projects has led to the development of a generation of high throughput technologies for biological and medical research. These include the nucleic acid-based microarrays (6,7) or DNA chips (8), and the protein-based microarrays (9,10). Our recent efforts have been focusing on the development of a carbohydrate and protein-based microarray technology to extend the scope of biomedical research on carbohydrate-mediated molecular recognition and anti-infection responses (see
reference 11 and next section for our most recent progress). - The microspot format of surface displaying biological molecules has the advantage of achieving a highly sensitive and simultaneous detection of multiple binding partners in solution. Since the amount of molecule in the solution phase that is required for saturating the surface immobilized microspots of molecules is considerably small, binding can be achieved with a relatively lower molar concentration of molecules in solution. In brief, it is believed that the smaller microspot is better than the bigger spot in its sensitivity of detection in an assay system (12,13).
- (A) Category A Pathogens and their Genomic Information
- High-priority infectious agents that pose current risks to our national security include multiple microbial pathogens known as Category A pathogens, such asBacillus anthracis (anthrax), Clostridium botulinum (botulism), Yersinia pestis (plague), Variola viruse (smallpox), Francisella tularensis (tularemia) and viral hemorrhagic fevers (Lassa virus, Ebola virus, Marburg virus and Lymphocytic Choriomeningitis virus). An assay system that allows detection and characterization of these pathogens in a single assay using limited clinical specimens is currently unavailable.
- A great deal of genomic information is available for numerous pathogens (14-16), providing many opportunities to the field of infectious disease research. The identification of candidates from a large repertoire of genes, including a large panel of genes whose function is unknown, for developing diagnostic protein biochip s is, however, a current challenge. As detailed below, we have established a strategy to facilitate the selection and identification of genes that have potential to serve as novel molecular targets for vaccination and diagnosis. Information provided by whole genome sequencing of microbes may also boost progress in the molecular engineering of artificial species of desired characteristics. There is also concern that the release of laboratory amplified genetic material to the environment may facilitate the natural occurrence of recombinant or newly evolved microbial species or strains. Such emerging microbes could be either beneficial or harmful to public health depending on the nature of the microorganism as well as the way by which they are utilized. Therefore, in designing a high throughput immunoassay one must consider the detection of existing pathogens as well as their mutants or recombinant forms. This goal is achievable if a panel of antigens of a given microbe and/or their specific antibodies are applied to produce a diagnostic biochip to detect multiple molecular targets of the pathogen. Applicants have tested the feasibility of this proposal by printing a panel of HIV-1 proteins on a single chip to monitor the HIV-1 infections by different classes or clades of HIV-1 viruses (see FIGS. 11 and 12).
- (B) Antigen-Based Biochip
- An antigen biochip is designed to detect and quantify antibodies in body fluids. During infection, whether viral, bacterial, fungal, or parasitic, the host usually responds with formation of antibodies, which can be detected by modification of any of the methods used for antigen detection. The formation of antibodies and their time course depends on the antigenic stimulation provided by the infection. Recognition of these patterns provides us with evidence of recent or past infection. Establishing a biochip to display a large panel of microbial antigens and the host derived autoantigens will substantially extend the scope of biomedical research on the biological relationship between host and microorganism, as well as understanding the molecular mechanisms of infectious diseases. Both carbohydrate antigens and protein antigens can be of importance for the design and production of a diagnostic biochip.
- Carbohydrate structures of microbial origin, including polysaccharides, glycolipids and glycoproteins, frequently serve as the main antigenic structures to which host cells recognize and mount a response (17). A single microbial antigen may, however, display multiple antigenic determinants, with one or a few of them predominating in a given infection. For example, a relatively simple microbial polysaccharide, α(1,6) dextran N279, displays both the internal linear chain and terminal non-reducing end structures as distinct antigenic determinants. When the polysaccharide was injected to a Balb/c mouse, it elicited a predominant antibody response directed to the internal linear chain epitope of α(1,6)dextran. The internal linear chain epitope is thus defined as a dominant antigenic determinant to the host. The antibodies elicited were solely or dominantly of the groove-type anti-dextran. In this case, the terminal non-reducing end structure is apparently the minor antigenic determinant. A dominant antigenic determinant should, therefore, be placed as a high priority to serve as a target for vaccine design or for developing an immunoassay for diagnosis.
- Identifying a minor antigenic determinant is, however, also important since there is the possibility that a dominant antigenic structure is not suitable for vaccination or diagnostic application; whereas, a minor antigenic determinant may serve as a molecular target for these applications. Some microbial antigens may share or mimic host components. This is known as antigenic cross-reactivity. For examples, a(1→8)NeuNAc in the capsule of the group B meningococcus and ofE.coli K1 is found on glycoproteins and gangliosides of human tissues, complicating the application of the capsular polysaccharides for vaccination, especially in infants who have expression of polymeric forms of the carbohydrate structure. There are also circumstances that a dominant antigenic structure can be useful for diagnosis but not for vaccination. For example, the Gag p24 protein of HIV-1 elicits a dominant antibody response in most AIDS patients. Detecting anti-Gag antibodies has diagnostic value. These antibodies, however, have no HIV-1 neutralization activity since Gag is not expressed on the surface of the HIV-1 virus. Even for the envelope protein, gp120 of HIV-1, which is surface displayed and accessible to antibody recognition, there are only a few epitopes of the glycoprotein to which antibodies can be effective in virus neutralization (18).
- With current immunological advances, converting a minor antigenic determinant into a dominant one is technically achievable. For example, the antigen may be coupled with a carrier molecule, forming a highly antigenic conjugate molecule. As demonstrated with a model antigenic system α(1,6)dextran, an isomaltotriose (IM3), which is derived from the polysaccharide α(1,6)dextran, can be coupled to BSA or KLH to produce a semi-synthetic glycoprotein to display the minor antigenic determinant of the polysaccharide, i.e., the terminal non-reducing end epitopes of α(1,6)dextran. When this glycoconjugate was injected to Balb/c, a dominant antibody response to the terminal antigenic determinant is induced. Immunization with such an artificial semi-synthetic glycoconjugate is now well known as the conjugate vaccine. A notable example is vaccination with the protein-conjugates ofHaemophilus influenza type b polysaccharide that resulted in the decline in the incidences of H. influenza meningitis and other infections in infants and children (19,20). The presence of polysaccharides and glycoproteins in Bacillus anthracis has been recognized for some time (4, 21,22). Whether these carbohydrate structures are suitable targets for anthrax vaccination is, however, an open question.
- Recognition of cross-reactive antigenic determinants is frequently shown to be of biological and medical significance. There are a number of documented cases in which microbial antigens mimic the structures of host components, assisting a microbe to escape from a host's immune defense (23,26). Such mimicking microbial antigens may also induce autoimmune disorders and contribute to the pathogenesis of an infectious disease (23,27). Identification and characterization of such antigenic structures may lead to a better understanding of the molecular mechanisms of infectious diseases.
- Antigenic structures that are not expressed on the surface of a microorganism also have an important diagnostic value. For example, detection of antibodies that are specific for the surface antigen of hepatitis B (HBsAg) may indicate an early viral infection or a successful vaccination; detecting antibody specificities to multiple viral antigens, such as surface antigen (HBsAg) plus core antigen (HBcAg) or HBsAg plus a relevant e antigen (HBeAg) suggests an active infection or the progression of the disease (28,29). A microbial pathogen, either a virus or a bacterium, may release multiple antigenic substances that trigger host antibody responses. In an early infection, as an initial immune response, the antibodies elicited are mainly those bound to the surface antigens and are predominantly IgM antibodies. With the progression of an infectious disease, for example in an AIDS patient a few months post-serum conversion, a large panel of IgG antibodies with different specificities, including anti-gp120 (envelope protein) and anti-Gag p55 polyproteins of HIV-1, can be detected in the serum of the patient. Thus, applying a combination of surface and non-surface antigens on a biochip for diagnosis can assist in the recognition of the stages or steps of an infection and provide information to predict disease progression and to evaluate the efficacy of a therapeutic agent or strategy.
- Development of drugs or therapeutic strategies against microbial infection requires a better understanding of the pathogenic mechanisms of an infectious disease. For example, the anthrax toxin is lethal upon its activation. This process involves multiple steps of molecular and cellular interactions of anthrax proteins, host cells and protein factors (1-3). The protective antigen of anthrax, named PA, is an integrated component of the lethal toxin ofBacillus anthracis. It binds to a specific cellular receptor and forms toxic, cell bound complexes with edema factor (EF) and lethal factor (LF) (1-3). This understanding leads to the development of a polyvalent inhibitor-based therapeutic strategy to protect a host from lethal attack by the toxin (5). Technically, it is of crucial importance to identify the structural moieties or epitopes that play key roles in forming the toxic complex or in the interaction of PA and its macrophage receptor. Generally speaking, the epitopes of a protein or a glycomer that interact with or are recognized by their partners are surface exposed and are, therefore, recognizable by specific antibodies. Identifying such antigen-antibody pairs is of crucial importance. Such pairs could serve as specific probes for the screening of smaller molecules to identify drug candidates that may block the effect of the anthrax toxin. Development of an antigenic structure-based biochip of large capacity and diversity would facilitate efforts to identify such key structural elements and screen for their specific antibodies for drug development.
- Thus, for the purpose of diagnosis, vaccination and drug development, it is important to recognize the dominant and minor antigenic determinants for a specific anti-infection antibody response to characterize the specificity and cross-reactivity of an antigenic structure; and to have a full-panel scanning of the repertoires of antibody specificities elicited by an infection. Such investigation has been impossible owing to a lack of a high throughput, multi-parameter assay system. Developing a carbohydrate and protein-based biochip to present a large repertoire of antigenic structures, including those displaying a single antigenic determinant on each microspot, would substantially facilitate these investigations.
- (C) Antibody-Based Biochip
- In principle, an antigen-based biochip is designed to detect and quantify specific antibodies and therefore, diagnose an infection. This method is not for the detection and quantification of antigens that are released from an infectious agent. Detecting microbial antigens in serum or other body fluids is generally more difficult than detecting antibodies. The former has, however, higher diagnostic value than the latter. It is, therefore, necessary to establish a highly sensitive antibody-based microarray to detect microbial antigens.
- The complexity of a host anti-infection response further challenges the development of a multi-parameter immunoassay for characterizing infectious diseases. During an infection, a large panel of antigenic substances of distinct structural characteristic, including protein, polysaccharide, glycolipid, glycoproteins and nucleic acid, may be released to trigger the host immune response. These substances may differ significantly in their immunological properties and, therefore, elicit characteristic patterns of host responses. For example, protein antigens fail to elicit antibody responses in mice lacking a thymus but polysaccharides and other macromolecules with repetitive antigenic determinants can induce unimpaired antibody responses in these mice (30-32). The former are termed T-dependent (TD) antigens and the latter are T-independent (TI) antigens. The differences of TI- and TD-antigenic responses, which are recognizable by in vitro immunoassay, include a series of humoral factors, such as antigen specific antibodies, their Ig-isotypes, cytokines and other inflammation factors.
- To better understand infectious disease, the full spectrum of anti-infection responses must be studied. These include specific antibody responses as well as the antigen-non-specific cytokine responses and other host responses. Cytokines are soluble proteins or glycoproteins, which play a critical role in controlling development or differentiation of lymphocytes and in regulating their anti-infection responses. For example, a microbial infection or vaccination may activate certain sub-types of T cells, either T helper 1 (Th1) cells or T helper 2 (Th2) cells. These specialized Th cells can produce unique profiles of cytotokines. Th1 secrete IL-2, IL-3, TNF-α and IFN-γ; Th2 secrete IL-3, IL-4, IL-5, IL-6, IL-9, IL-10 and some TNF-α. For anti-infection responses, induction of IgA-antibodies at mucosal sites is of critical importance. T cells and their cytokines have been shown to play a critical role in various stages of IgA response (33-35), including induction of Ig class switching of IgM to IgA and of terminal differentiation of IgA-committed B cells. Many researchers believe that IgA responses are highly Th-2 dependent (36-39), since there is evidence that Th2 cytokines, such as IL-4, IL-5 and IL-6, are required to induce terminal differentiation of IgA-committed B cells. By contrast, the Th1 cytokine, IFN-γ, antagonizes IL-4 in its IgA induction.
- Our current efforts focus on the development of high throughput post-genomic technologies to extend the scope of biomedical research on human infectious diseases and the human immune response. A carbohydrate and protein-based microarray has been prepared, making it possible to display a large collection of antigens on a single biochip for probing the repertoires of antibody specificities and for studying carbohydrate and protein mediated molecular recognition on a large scale. This microarray platform has achieved the sensitivity to detect a broad range of human antibodies with as little as a few microliters of serum specimens and has reached the capacity to include antigenic preparations of most common pathogens. This technology is, therefore, readily applicable for large-scale production of an antigen/antibody microarray. In this invention, we describe the establishment of a detailed procedure for the industrial scale production of diagnostic biochips to enable simultaneous detection and characterization of a wide range of microbial infections, which include all listed Category A biological warfare agents. These include (a) the design and production of a carbohydrate-based microarray composed of microbial polysaccharides, its derivatives and a large panel of carbohydrate-containing macromolecules of distinct sugar structure; (b) a procedure to take advantage of the genomic information available for specific pathogens to design and produce proteomic microarrays to identify novel molecular targets for vaccination, diagnosis and drug development; (c) a method to produce an antibody-based microarray system to monitor microbial antigens in vivo and in vitro and to enable full-panel scanning of cytokines and other inflammation factors with limited amount of clinical specimens; and (d) the design and production of highly sensitive diagnostic biochips, including Diagnostic Biochip A and B for the rapid detection of all the biological warfare agents listed by the CDC as Category A pathogens arid Diagnostic Biochip C for simultaneous detection and characterization of a wide range of common infectious diseases, which are caused by about 200 human pathogens.
- II. Methods to Produce Large Capacity and High-Density Biochips (˜30,000 Microspots/Microchip)
- Compared with DNA- and protein-based microarrays, the carbohydrate microarray technology has certain technical advantages and disadvantages. An obvious advantage is that the purified polysaccharides are generally stable in various conditions, either as dried solid or in aqueous solution, at room temperature or at 4° C. in storage. Unlike protein microarrays, wherein protein-denaturing and/or conformational alteration in microarray printing and storage is a major challenge to the technology, there is no such serious concern for most (if not all) carbohydrate antigens. A disadvantage of the carbohydrate microarray technology is that methods for high throughput production of carbohydrate macromolecules or complex carbohydrates, which is equivalent to the PCR for amplifying DNA or the cloning and expression method for producing proteins, are yet to be developed. Classical methods to obtain pure carbohydrate antigens include (a) isolation and purification from biological materials, such as cells, tissues or biological fluids; (b) chemical synthesis; and (c) enzymatic in vitro synthesis. A Rapid progress in establishing high throughput technology for the in vitro synthesis of carbohydrate macromolecules or complex carbohydrate molecules is most likely unexpected. The availability of purified carbohydrate antigens is, therefore, a potential rate-limiting factor to the carbohydrate microarray industry.
- Our optimized methods for printing microarrays allows one: (i) to reduce amount of antigen needed for microarray printing; (ii) to increase the detection sensitivity and biochip capacity; (iii) to reduce the time that is necessary for a microarray printing cycle; (iv) to prevent cross-contaminations in printing microarrays; and (v) to reduce the cost of producing a diagnostic biochip substantially.
- (A) Printing Microspots of Smaller Sizes and High-Densities
- The general printing procedure is schematically illustrated in FIG. 9. A high-precision robot designed to produce cDNA microarrays was utilized to spot carbohydrate antigens onto glass slides that were pre-coated with nitrocellulose polymer. In addition, the following were also used:
- a)
STEALTH 3 pins for printingmicrospots 150 microns in diameter on nitrocellulose slides. This allows the arraying of 10,368 spots per FAST-slide with spot intervals of 250 micron, center-to-center; and - b) STEALTH 2.5 pins for printing spots at about 100 microns in diameter on the surface. 28,800 spots can be patterned on a single FAST slide. If each antigen preparation is printed as an array of four identical microspots, (See FIG. 12 below), 7,200 antigenic molecules can be included on a single slide. This system has, therefore, enough capacity to include most known human microbial pathogens and tumor-associated antigens.
- III. Diagnostic Biochips
- (A) Diagnostic Biochip A
- This biochip is designed to enable the simultaneous detection of all Category A infectious diseases. In its clinical application, two-step staining is required. A number of carefully selected pairs of antigen and antibody are be printed on slides for each pathogen. The immobilized antigen serves as a probe to detect antibody in solution; the surface displayed antibody is used to capture a specific antigen in the solvent. This assay is, therefore, capable of detection of both antigens and antibodies in a single assay. Since an immobilized antigen may display multiple antigenic determinants, a microspot of antigen may capture antibodies that recognize different antigenic determinants expressed by the antigenic molecule. This makes the biochip system highly sensitive. Its detection specificity is, however, at the level of the antigenic molecule but not at the level of a single antigenic determinant. In case an antigen expresses a cross-reactive antigenic determinant, its detection specificity will be reduced (See the design of diagnostic biochip B for further discussion).
- (1) 8-chamber sub-arrays (See FIG. 10):
- Each micro-glass slide contains eight well-separated sub-arrays of identical contents. There are 600 microspots per sub-array, with spot sizes of approximately 200 micron at 300 micron intervals, center-to-center. A single slide is, therefore, designed to enable eight detections;
- (2) Contains:
- (a) Microspots: Each 600-spot sub-array is composed of carbohydrate and protein antigens, as well as antibodies specific to microbial antigens. The immobilized antigens will allow for the detection of human antibodies elicited by an infection; whereas immobilized antibodies are for the detection of microbial antigens;
- (b) Repeats and dilutions: Each antigen/antibody will be printed at 0.5-1.0 mg/ml and at one to ten dilution of the initial concentration for the second concentration. Each preparation at a given concentration will be repeated three times; and
- (c) Antibody isotype standard curves: Human antibodies of IgG, IgA and IgM isotype of known concentrations will serve as standard curves for antibody detection and normalization.
- (3) Assay mechanisms:
- (a) Detection of antibodies: use of immobilized antigens to capture antibodies in solution, which are then recognized by the tagged anti-human antibodies. In principle, this is an indirect immunoassay;
- (b) Detection of microbial antigens: use of immobilized antibodies to capture antigens in solution and application of the tagged antibodies specific for the corresponding antigens to identify the captured antigens. This is known as a “Sandwich” immunoassay.
- (4) Application and staining procedure:
- Use of 0.5-1.0 microliters of serum specimens for the detection of a) specific antibodies in body fluids and b) presence of antigens in vivo and in vitro. Two steps of staining and approximately 5 hrs is required to complete the biochip analysis.
- (5) Specificity & sensitivity:
- a highly sensitive biochip system with specificity at the level of an antigenic molecule.
- (B) Diagnostic Biochip B
- This biochip is designed to enable the rapid diagnosis of the Category A infectious diseases, which requires only a single step of staining in clinical diagnosis. The time required for a biochip assay is, therefore, substantially shorter. Competitive immunoassay is used for rapid diagnosis. A competitive immunoassay requires an antigen/antibody pair. Either antigen or antibody can be immobilized on the solid surface, which will then interact with an antigen or antibody in solution. The immobilized antigen and tagged antibody in solution forms a specific probe to detect both antigen and antibody in clinical specimens. The free-antigen or antibody competitively inhibits the binding of the tagged antibody to the antigen immobilized on the solid surface. Key characteristics of this “competitive” one-step biochip that differ from Diagnostic Biochip A are summarized below:
- (1) Chip contents:
- A panel of carefully selected microbial antigens, whose specific antibodies are available, will be printed on the chip with the method described above.
- (2) Assay mechanisms:
- The free antigens or antibodies can compete with the labeled antigen or antibody to bind the immobilized antigens or antibodies. Given that antibodies are generally more stable than other protein molecules in solution and are suitable for standardized production, printing antigen on a series of glass slides and using fluorescent-tagged antibodies for staining is preferred. If a clinical specimen in question contains a specific antibody for the target antigenic determinant or the antigen, the binding of the tagged antibody to the antigen will be competitively inhibited.
- (3) Application and staining procedure:
- One-step staining of the biochip allows detection of specific antibodies in body fluids of antigens in vivo and in vitro. The time required for biochip analysis, is therefore, reduced by 4 hours.
- (4) Specificity & sensitivity:
- Diagnostic Biochip B is a highly sensitive and specific biochip system. Its specificity is at the level of a single antigenic determinant.
- (C) Diagnostic Biochip C
- Diagnostic Biochip C is composed of a large repertoire of carbohydrate and protein antigens as well as antibodies. This is a largely extended Diagnostic Biochip A. This biochip makes it possible to diagnose and characterize a wide range of microbial infections using a few microliters of serum specimen. This microarray has the printing capacity to include most common pathogens. Practically, it is limited by the availability of specific antigen preparations and their antibodies. 1000-2000 distinct antigens and antibodies can be printed on the chip. This enables a simultaneous detection of about 300 microbes, which include about 50-100 human pathogens. General properties of the master microarray are summarized as follows:
- (1) Capacity:
- 15,000-20,000 microspots per micro-glass slide, with spot sizes approximately 150 micron in diameter and at 200-micron intervals, center-to-center.
- (2) Diversity:
- 1000-1500 distinct antigenic preparations, about 100 antibodies specific for microbial antigens and about 30-50 antibodies for detecting human cytokines and other inflammation factors.
- (3) Repeats and dilutions:
- Each antigen has four dilutions (0.5 mg/ml to begin with) and each dilution has three repeats.
- (4) Antibody standard curves:
- Human antibodies of IgG, IgA and IgM isotype of known concentrations are printed on the chip to produce standard curves for normalization across the experiments and for quantitative calculation of the titer of the specific antibodies of a given isotype captured by the carbohydrate antigen.
- (D) Diagnostic Biochip D
- This biochip is composed of about 4,000 microspots of antigen and antibody preparations. Each antigen or antibody preparation of a given dilution was printed with four repeats in a vertical line of microspots on the biochip. This allows us to visually observe and statistically analyze the reproducibility of microarray printing and staining. The significance and sensitivity of antibody detection for each antigen at a given antigen concentration can also be statistically calculated. Some preparations, for example the gp120 glycoprotein of HIV-1 as highlighted in a square in FIG. 11, were printed from left to right in a series dilution of one to five, beginning at 0.5-1.0 mg/ml and with four dilutions thereafter. These biochips were stained with the normal or HIV-1 infected human serum specimens with the methods described above. Pictures of the ScanArray visualization of the multi-color fluorescent staining of biochips are shown in FIG. 11.
- In this experiment, we have demonstrated that: (a) a procedure for microarray printing, antigen/antibody immobilization and antibody staining is precisely reproducible. On the same biochip, the correlation factors of data crossing different microspots of the same preparation is in the range of (0.98) to (1.00); (b) detection of human serum antibodies by this method is highly sensitive. A few microliters of serum specimen allows a full-panel scanning of the repertoires of human antibodies of different Ig-isotypes in a single assay. A large repertoire of antibody specificities were recognized in the normal and HIV infected individuals; (c) the specificity of this system is illustrated by recognizing the epitope-binding specificities of monoclonal anti-dextran antibodies and by specific detection of human serum antibodies for the gp120 glycoproteins and gag p24 of HIV-1 in AIDS patients; (d) a large repertoire of microbial antigens can be patterned on a single micro-glass slide, reaching the capacity to include most common and conditional pathogens; and (e) a biochip-based high throughput technology requires a strong bioinformatic presence to support it. While one may need a day to perform a biochip assay for a given clinical specimen, one may need many days to process the large amount of data produced by the biochip analysis. Developing advanced computer algorithms to facilitate this process is of equal importance with improving the hardware of the biochip technology.
- (E) Diagnostic Biochip E
- This is a proteomic microarray-based biochip produced with the microarray platform used to produce carbohydrate microarrays. Discovery of a large repertoire of genes in the genome of microorganisms has provided novel targets for vaccination, diagnosis, and drug development against microbial infection. To take advantage of this, HIV-1, whose genome is relatively small and has been completely sequenced, is used herein to establish the protein-based microarray technology. A large panel of purified HIV proteins, including gp120 proteins derived from different clades of HIV-1, Gag p55, p24, P6, P7, P17 and/or theirE. coli expressed GST-fusion proteins, Tat, Nef, Integrase, and reverse transcriptase (RT), were printed and immobilized on the chemically modified glass slides. These protein chips were then applied to probe antibodies in normal and AIDS patients. As shown in FIG. 12, most HIV proteins printed on the chip gave positive detection of antibodies in HIV-infected individuals but not in normal controls, showing the sensitivity and specificity of this protein chip.
- Therefore, we conclude that: (a) these positively stained HIV proteins were stably immobilized on the biochip and retained their immunological properties; (b) the protein microarray system has reached the sensitivity to probe the repertoires of antibodies in clinical specimens; and, most importantly, (c) it is feasible to introduce a large panel of protein products of genes, including both surface and non-surface proteins, and newly discovered genes, for our biochip production and diagnostic application. This finding is significantly important since it allows us to explore the application of genomic information and genetic material that has been accumulated by the genome projects.
- (F) Diagnostic Biochip F
- This is an antibody-based microarray and is designed to enable a full-panel scanning of human cytokine. Cytokine detection at the protein level is technically difficult. These proteins are potent biological agents that function at very low concentrations (7). Some cytokine molecules are unstable after secretion or activation (7). A highly sensitive specific assay is required to detect these molecules. A method currently used for cytokine detection, either ELISA-based assays or radioimmunoassays, takes advantage of the Sandwich-antibody assay. Specifically, the first cytokine-specific antibody is immobilized on a solid surface to capture cytokine in solution and then the second anti-cytokine antibody is applied to detect the surface-immobilized cytokine. The second anti-cytokine can be biotinylated, allowing signal amplification with a labeled Streptavidin. These methods are highly sensitive but limited in detecting a cytokine on a one-by-one base.
- We have extended our microarray platform to produce the antibody-based biochips. The arrayed antigens allow specific capture of antibodies from body fluids and the antibodies immobilized on the glass chip can be used to detect soluble antigens and host factors, such as cytokines and other inflammatory factors. We immobilized a panel of anti-dextran mAbs at a concentration of 0.5 mg/ml on a set of glass slides. These include nitrocellulose-coated glass slides, polylysine treated slides, silane-treated glass slides and untreated, precleaned glass slides. These slides were then reacted with the fluorescence-tagged dextran preparations of distinct structures. Only the nitrocellulose-slides showed spots of specific fluorescent signals. Thus, anti-dextran mAbs were immobilized on the nitrocellulose-glass slide and retained their antigen binding specificities.
- We further addressed whether the nitrocellulose-coated slide can be applied to immobilize antibodies on a chip for long-term storage. To investigate the condition for the preservation of antibody microarrays, we placed these microarrays under different conditions: (a) in an air-dried condition at room temperature; and (b) in a blocking solution, stored at 4° C. After six months, we stained these antibody microarrays with tagged antigens. We found that both group (a) and group (b) slides preserved antigen-capturing activities and specificities. Signals obtained by the two groups differ, however, significantly, with the latter much stronger than the former. These experiments have indicated the potential of the nitrocellulose-based non-chemical immobilization method for antibody microarray production.
- An antibody microarray for a full-panel scanning of human cytokines was prepared. Polyclonal and monoclonal antibodies specific for human cytokines are currently available through various resources, providing a strong base for developing an antibody microarray to enable a highly sensitive, high throughput, full-panel cytokine scan.
- We have found that the current microarray platform favors detection of IgG antibodies but not IgM antibodies in solution. The former is an immunoglobulin (Ig) monomer and the latter is an Ig pentamer. One theory for this result is that the pore size of FAST slides is too small to allow IgM antibody to enter and bind antigen immobilized in the deeper layer of the 3D nitrocellulose network structure (see ref. 40 for a 3D illustration of the nitrocellulose coating). This finding is of significance since it provides information for the development of an improved surface for producing a diagnostic biochip.
- IV. Methods to Search and Identify Novel Carbohydrate Targets for Diagnosis and Vaccination
- A large collection of carbohydrate containing macromolecules are printed on the nitrocellulose-coated slides and then the carbohydrate microarrays are stained with antibody preparations or lectins to probe the microspots that display the antigenic determinants in question. The monoclonal and polyclonal antibodies elicited by a microbial antigen or by a pathogen, as well as serum specimens of an infected individual are all useful reagents for these analyses. A positively stained microspot indicates the presence of a target molecule or antigenic determinant. Further characterization of this antigen preparation could lead to the identification of a suitable diagnostic molecule for a given infectious disease.
- We have employedB. anthracis as a model pathogen to illustrate our research approach, from the identification of a target molecule to the further characterization of the structure using our carbohydrate microarray technology.
- (A)B. anthracis Related Carbohydrate Antigens as Diagnostic Molecular Targets
- Carbohydrate structures present inB. anthracis are potential molecular targets for vaccine development and for diagnostic application. These carbohydrate structures include glycoproteins and polysaccharides. Glycoproteins are expressed by the dormant spore of B. anthracis and are recognizable by specific lectins, such as Glycine max (41). Since the spore surface interacts with the host initially in an anthrax infection, these structures are likely the targets for host recognition and antibody responses. They are therefore important for both vaccination and diagnosis. Polysaccharides are expressed by the germinating spores of B. anthracis, which are detected by monoclonal antibodies raised against the cell wall Gal-NAG polysaccharide of the pathogen (22). The exo- and/or cell wall Gal-NAG polysaccharide, which is present in the culture medium for growing B. anthracis (4), can be isolated from the cell wall of the microbe (22,42). Given that the Gal-NAG polysaccharide is universally present among and specific for strains of Bacillus anthracis (22), its presence in solution and its structural stability, makes this molecule a potential target for the identification of B. anthracis and for developing an anthrax vaccine.
- Early studies were conducted by the late Professors Michael Heidelberger (see ref. 43 page 451 for a description) and Elvin A. Kabat (44-46) to investigate the antigenic cross-reactivities among blood group substances (ABO), Pneumococcus type 14-polysaccharide and the cell wall polysaccharide ofB. anthracis. A preparation of the anthrax polysaccharide is available in the KABAT collection at Columbia University. The anthrax polysaccharide was tested on a carbohydrate microarray and confirmed that the preparation has preserved its cross-reactivity to an anti-Pneumococcus type 14-polysaccharide antibody (data not shown).
- Following are some important characteristics of the cell wall Gal-NAG polysaccharide: (a) it is 12,000 Da in molecular weight and contains galactose, N-acetylglucosamine, and N-acetylmannosamine in an approximate molar ratio of 3:2:1 (22) or 10:2:1. This slight difference in molar ratio is attributed to differences in the hydrolysis conditions applied (47); (b) it is pyruvylated although the sugar residue and position of pyruvylation are yet to be determined (47); (c) it is most likelyB. anthracis specific and expressed by both germinating spores and the vegetative bacillus (22); (d) it shows antigenic determinants which are cross-reactive to
Pneumococcus type 14 polysaccharide (43) ; (e) it has no human blood group substances A, B, or H activity (43); and (f) anti-serum elicited by the anthrax polysaccharide has, however, cross-reactivities with a preparation of hydrolyzed blood group substance A that contains the type IT Gal-GlcNAc sequences (Gal β1→4GlcNAc) (see ref. 43, page 452 for a description of the study by Ivanovicx (1940)). - These characteristics lead to the conclusion that: (i) The Gal-NAG polysaccharide expresses potent antigenic determinants to mice and humans since the pyruvylated Gal-NAG structure is not present in the host; (ii) the polysaccharide itself is, however, poorly antigenic in solution since it is a T-independent antigen with relatively low molecular weight (1.2 KDa). Given this consideration, early observations that the polysaccharide was not protective to animals challenged byB. anthracis can be attributed to the nature of poor immunogenicity in its native configuration; (iii) its Gal-NAG core structure is similar to a core structure of blood group type II chain, Gal β1→4GlcNAc. Pyruvylation of the backbone structure blocks, however, its blood group substance H reactivity; and (iv) given that the pyruvate group is not seen in
Pneumococcus type 14 polysaccharide, the anthrax polysaccharide may contain a non-pyruvylated antigenic determinant mimicking those of thePneumococcus type 14 polysaccharide. This leads us to conclude, therefore, that the cell wall polysaccharide of B. anthracis contains more than one antigenic determinant. - A carbohydrate microarray was designed to maximize the surface display of its potential antigenic structures using the following method: (a) print the polysaccharide on a microchip to display its antigenic determinants in the native configuration; (b) isolate the pyruvylated and non-pyruvylated fractions of the polysaccharide and apply them on the microarray as described by Mesnage et al. (47). This allows investigation of the potential dominant role of the pyruvylated sugar structure in its antigenicity; and (c) synthesize a panel of oligosaccharide-protein conjugates.
- In the chip design, we have also included structures of oligosaccharides that are identical to or derived from those of
Pneumococcus type 14 polysaccharide and those reactive to lectin Glycine max (specific for alpha-D-galactose or 2-acetamido-2-deoxy-alpha-D-galactose residues) that recognize a proposed spore glycoprotein of Bacillus anthracis (41). - V. Methods to Search and Identify Pairs of Antigens and Antibodies for Antigen/Antibody Microarrays
- Detecting microbial antigens in serum or other body fluids is useful in the diagnosis of an infectious disease but generally it is difficult. It is, therefore, necessary to establish a highly sensitive antibody-based microarray to detect microbial antigens. In addition, such an antibody-based microarray will allow us to monitor a microbial pathogen in the environment as well as in host body fluids. Identification of highly specific antigens and antibodies for each pathogen is critical for the development of a diagnostic biochip.
- We have established a simple and effective strategy to screen for these reagents for microarray production. We printed a panel of forty-eight carbohydrate-containing macromolecules of distinct structural characteristics on a slide with the method established above. In previous investigations, these antigens were successfully applied to screen human myeloma and lymphoma proteins for antibodies with anti-carbohydrate activities (48, 52, 53). The carbohydrate microarray was applied to detect human serum antibodies. A total number of twenty serum specimens were randomly collected from normal individuals. As little as one micro-liter of serum specimen from each individual was applied for microarray staining. As shown in FIG. 14, twelve distinct specificities of IgM antibodies (12/48) and thirty-five IgG anti-carbohydrate antibodies (35/48) were identified. Carbohydrate molecules that were positively stained include twenty polysaccharides (20/24), eleven complex carbohydrates of cellular origin (11/19) and four semi-synthetic glycoconjugates (4/5). For anti-carbohydrate antibodies of IgM isotype, twelve distinct specificities were identified. The majority (7/12) were bound to Klebsiella polysaccharides. This is similar to our previous observation that antibodies bound to Klebsiella polysaccharides were most frequently found in the repertoire of human myeloma anti-carbohydrate antibodies (48-52). The repertoire of human IgG anti-carbohydrate antibodies is, however, broader than those of IgM isotype. There are twenty specific for microbial polysaccharides (20/24), including polysaccharides of microbial pathogens,E. coli-K92 and -K100; Pneumococcus type-C, -VIII, -IX, -SIV, -XIV and -27; Group B Meningococcus, H. Influenza Type A, and different types of Klebsiella. Human IgG antibodies specific for glycomers of complex carbohydrate structures (11/19) and those for the carbohydrate moieties of semi-synthetic glycoconjugates (4/5) were also detected.
- This antigen microarray was then applied to characterize monoclonal antibodies (FIG. 14, panels III and IV) to critically evaluate their antigenic or epitope-binding specificities and cross-reactivities. Antigenic cross-reactivity between microbial polysaccharide α(1, 6)dextran and a preparation of Chondroitin sulfate B polysaccharide that was derived from the intestinal mucosa of porcine was demonstrated. This has led to the recognition of a novel cross-reactive molecular marker of microbes and host cell (11). In addition, these experiments demonstrated that semi-synthetic glycoproteins are applicable for the construction of a carbohydrate microarray. This is of critical importance since it enables the application of rationally designed synthetic oligosaccharides for microarray construction and allows a critical examination of the specificity and cross-reactivity of carbohydrate-mediated molecular recognition.
- The flexible 8-chamber biochip system, as described above, is sufficient for this type of initial screening of a panel of molecular targets. In this format, all the available antigen preparations of the eight Category-A pathogens can be printed at various dilutions in a single sub-array chamber. A specific antibody, for example, a mouse monoclonal antibody bound to the anthrax polysaccharide, can be applied on the sub-array biochip to react with all the antigens on the chip. It may also be applied in a series of dilutions on different sub-array chambers. This simple experiment allows us to critically evaluate (a) antibody binding specificity and cross-reactivity; (b) the affinity of antigen-antibody interaction; and (c) the quality of the printed antigen and method for immobilizing the antigen.
- If an antigen/antibody pair is qualified by the 8-chamber biochip analysis, a further evaluation is conducted using a large-scale biochip, which displays both microbial antigens and those from human and other mammalian species. The highly specific pairs of antigens and antibodies are candidates for the diagnosis of corresponding microbial infections. Those who have cross-reactivities with human tissue antigens may be also useful for printing microarrays. As summarized above, identification of such cross-reactivities may lead to a better understanding of the biological relationship of microbes and their hosts, as well as the pathogenesis mechanisms of an infectious disease.
- VI. Methods to Search and Identify Novel Protein Targets for Diagnosis and Vaccination
- As described above, we have already established that our microarray platform is useful for printing protein microarrays and have demonstrated the principle and method to apply a large panel of protein antigens to extend our scope of investigation of microbial infections. This investigation has provided insights into how one could incorporate the genomic information and genetic material that has been accumulated by the genome sequencing projects into the development of diagnostic protein biochips. We report here the establishment of a strategy to efficiently utilize the information from the various pathogen genome projects to assist in the identification of novel molecular targets for diagnosis and vaccination. The pX01 plasmid ofB. anthracis will serve as a model to illustrate our strategy.
- (A) Methods to Search and Identify Candidates for the Protein Microarray
- Different categories of proteins can be used to produce the diagnostic protein microarray. For example, (a) both membrane-bound and secretory proteins of a pathogen, which may trigger the initial immune response in an infection, making them ideal targets for early diagnosis and vaccination; (b) non-surface expressed proteins, which could be useful in identifying and characterizing the progressive stages of an infection; and (c) the candidate genes that are unique to a given pathogen, namely the species-specific or stain-specific molecular targets, thereby enabling highly specific detection on the final biochip.
- Two categories of bioinformatic software, predictive and comparative, are currently available on-line. A two-step analysis can be used to identify candidate gene products to be included on the microarray. First, the structure, cellular localization, and function of newly discovered genes of the genome sequencing projects is predicted. Then a comparative analysis to predict the specificity and potential cross-reactivity of the candidate genes selected by the above structure-function predictive analysis is performed. A list of “predictive” software tools that will help in extrapolating a protein's function are available on-line. These include (a) TMHMM (http://www.cbs.dtu.dk/services/TMHMM-2.0/) for the prediction of transmembrane helices in proteins; (b) NetOGlyc 2.0 (http://www.cbs.dtu.dk/services/NetOGlyc/) for the prediction of mucin type GalNAc O-glycosylation sites in mammalian proteins; (c) PredictProtein (http://www.embl-heidelberq.de/predict protein/predictprotein.html) for the prediction of secondary structure, solvent accessibility, and transmembrane segments; and (d) 3D-PSSM Web Server V 2.6.0 (http://www.bmm.icne t.uk/˜3dpssm/) for protein fold recognition.
- With the predicted location and structure of the protein now known, either through published gene annotation done upon completion of a genome sequence, or through predictive bioinformatic software, it is equally important to determine whether the gene of interest is unique to the species through a comparative proteomic analysis. This is crucial if we hope to design a biochip that can specifically identify if the patient is suffering fromB. anthracis. A gene that is similar in both B. anthracis and B. subtilis would be a poor choice for the biochip, because it would lead to inconclusive results when deployed in the field. Therefore, careful study should be done in order to identify if genes are highly unique to the species, which would in turn result in a biochip with few cross-reactive ambiguous results. One example of a potentially valuable bioinformatic tool to address this problem is called the COGnitor program. This program takes an amino acid sequence and extrapolates its function by comparing the unknown protein's sequence of amino acids to amino acid sequences from other genes of characterized function in a series of genomes (54). Genes that are highly conserved in evolution would be identifiable using the COGnitor program; those that are unique to a given organism could be non-recognizable by a COGnitor search. Proteins that are not recognized by the COGnitor program are probably high priority candidates for diagnostic application since the proteins they encode are most likely species-specific antigens. For the genes that are recognized and classified by the program, additional steps of investigation must be taken to define whether they are suitable targets for a diagnostic use.
- (B) A Model to Illustrate our Comparative Genomic Strategy to Identify Unique Genes
- The pX01 plasmid ofBacillus anthracis has been fully sequenced, and 46 of the 142 identified genes have been functionally characterized in the literature (16). This provides us with a prime example of how a complete DNA sequence, with some gene annotation, would be approached using our comprehensive bioinformatic strategy.
- First, we use predictive bioinformatic software to determine the location and structural characteristics of the proteins from their amino acid sequences. One example of this is in predicting if a protein has transmembrane regions, as can be determined by TMHMM version 2.0 (55). We have selected the protein Px01-54 as an example. Okinaka et al. have given a description of this protein as a “S-layer precursor/surface layer protein.” This protein was run through the transmembrane predicting software TMHMM version 2.0 (see FIG. 15).
- It would seem that this protein contains both a transmembrane region, as well as a large extracellular component. One could hypothesize that, based on this result, the protein is on the surface of the bacteria, and is an ideal candidate to be printed on a microarray because it may play a role in initiating a primary immune response. Therefore, even if Okinaka et al did not characterize the gene, we could use this software to identify it as an ideal surface target that could induce a primary immune response.
- With the completion of the predictive stage for function and location of a protein, the next stage of bioinformatic analysis is conducted, namely to determine if the gene of interest is unique to an organism. As described above, the COGnitor program (54) can be used to identify the species-specific genes/proteins for printing the diagnostic protein chips. To test this idea, we have run the amino acid sequences of all the 46 annotated genes of Px01 plasmid ofB. anthracis through the COGnitor program. We present the results from this test in Table 2.
- Of the 46 genes analyzed, 34 could be recognized and classified according to the COGnitor program. A large number of the COG-classified genes are of category L, namely DNA replication, recombination and repair. Indeed, it is likely that such proteins contain highly conserved domains across many species. At the other extreme, twelve genes were not recognized by the COGnitor program, and were thereby not able to be classified into the COG classifications. These unclassifiable proteins have been listed as “No Cog” in Table 2. This “No Cog” classification indicates that these proteins have no similarity to other proteins currently in the database. Since the COG database includes 74,059 classified protein sequences from the genomes of 43 species of both prokaryotic and eukaryotic organisms (but excludes the human genome), a “No Cog” result suggests that the protein in question is more likely to be species or strain-specific to the pathogen. At the very least, one can claim that it is highly unlikely for a “No Cog” protein to contain a known evolutionarily conserved ancient domain that exists across many species' genomes. Being able to select against genes that exhibit such conserved domains is a welcome tool, for this could help to lower the probability of selecting a protein that may yield ambiguous results on the final biochip due to cross reactivity. Interestingly, the genes of the most unique lethal nature, as well as a series of surface antigens, are not recognized by the COGnitor program because they match no other species' genes. One example of an ideal gene to select has been presented, namely the px01-54 protein ofB. anthracis. This protein is expressed on the surface of the organism according to Okinaka et al. (16), spans a membrane according to the TMHMM program, and is not recognized by the COGnitor program, making it more likely to be unique to the species.
- In conclusion, combining knowledge from the published literature and bioinformatic software on a gene product's function, location, and ‘species unique’ level will greatly enhance the use of the final biochip because it will allow clear and accurate clinical diagnosis of a patient's immune response to a wide panel of pathogenic agents.
- 1. Blaustein, R. O., Koehler, T. M., Collier, R. J. & Finkelstein, A. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc Natl Acad Sci U S A 86, 2209-2213. (1989).
- 2. Thorne, C. B.Bacilluse anthracis. In Bacillus subtilis and Other Gram-positive Bacteria, ed. AL Sonenshein, J A Hoch, R Losick., 113-124 (1993).
- 3. Escuyer, V. & Collier, R. J. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect Immun 59, 3381-3386. (1991).
- 4. Strange, R. E. & Belton, F. C. Studies on a protective antigen produced in vitro from bacillus anthracis: Purification and chemisty of the antigen. Bri. J. Exp. Pathol. 35, 153-165 (1953).
- 5. Mourez, M. et al. Designing a polyvalent inhibitor of anthrax toxin.
Nat Biotechnol 19, 958-961. (2001). - 6. Brown, P. O. & Botstein, D. Exploring the new world of the genome with DNA microarrays. Nature. Genetics. 21, 33-37 (1999).
- 7. DeRisi, J. L., Iyer, V. R. & Brown, P. O. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science. 278, 680-686 (1997).
- 8. Ramsay, G. DNA chips: state-of-the art. Nature. Biotechnology. 16, 40-44 (1998).
- 9. MacBeath, G. & Schreiber, S. L. Printing proteins as microarrays for high-throughput function determination. Science 299, 1760-1763 (2000).
- 10. Lueking, A. et al. Protein microarrays for gene expression and antibody screening. Analytical. Biochemistry. 270, 103-111 (1999).
- 11. Wang, D., Liu, S., Trummer, B. J., Deng, C. & Wang, A. Carbohydrate microarray leading to the recognition of cross-reactive molecular markers of microbes and host cells. Nature Biotechnology 20 (2002).
- 12. Ekins, R. P. Multi-analyte immunoassay. J Pharm Biomed Anal 7, 155-168 (1989).
- 13. Stoll, D. et al. Protein microarray technology.
Front Biosci 7, C13-32. (2002). - 14. Volchkov, V. E. Ebola virus, complete genome. Institute of Virology, Philipps-University (2000).
- 15. Shchelkunov, S. N., Totmenin, A. V. and Sandakhchiev, L. S. Analysis of the nucleotide sequence of 23.8 kbp from the left terminus of the genome of variola major virus strain India-1967. Virus Res. 40, 169-183 (1996).
- 16. Okinaka, R. T. et al. Sequence and organization of pXO1, the largeBacillus anthracis plasmid harboring the anthrax toxin genes. J Bacteriol 181, 6509-6515. (1999).
- 17. Wang, D. & Kabat, E. A. in Structure of Antigens., Vol. Three. (ed. M.H.V.V. Regenmortal) 247-276 (CRC Press, Boca Raton New York London Tokyo; 1996).
- 13. Wyatt, R. et al. The antigenic structure of the HIVgp120 envelope glycoprotein. Nature 393, 705-711 (1998).
- 19. Robbins, J. B. & Schneerson, R. Polysaccharide-protein conjugates: a new generation of vaccines. J. Infct. Dis. 161, 821-832 (1990).
- 20. Schneerson, R., Barrera, O., Sutton, A. & Robbins, J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 152, 361-376. (1980).
- 21. Gladstone, G. P. & Walton, E. Effect of iron on the bactericidal proteins from rabbit polymorphonuclear leukocytes. Nature 227, 849-851. (1970).
- 22. Ezzell, J. W., Jr., Abshire, T. G., Little, S. F., Lidgerding, B. C. & Brown, C. Identification ofBacillus anthracis by using monoclonal antibody to cell wall galactose-N-acetylglucosamine polysaccharide. J Clin Microbiol 28, 223-231. (1990).
- 23. Finne, J., Leinonen, M. & Makela, P. H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 2, 355-357 (1983).
- 24. Finne, J. & Makela, P. H. Cleavage of the polysialosyl units of brain glycoproteins by a bacteriophage endosialidase. Involvement of a long oligosaccharide segment in molecular interactions of polysialic acid. Journal. of. Biological. Chemistry. 260, 1265-1270 (1985).
- 25. Mandrell, R. E. et al. Lipooligosaccharides (LOS) of some Haemophilus species mimic human glycosphingolipids, and some LOS are sialylated. Infection. &. Immunity. 60, 1322-1328 (1992).
- 26. Mandrell, R. E. Further antigenic similarities of Neisseria gonorrhoeae lipooligosaccharides and human glycosphingolipids. Infection. &. Immunity. 60, 3017-3020 (1992).
- 27. Feizi, T. & Loveless, R. W. Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences. Am. J. Respir. Crit. Care. Med. 154, S133-136. (1996).
- 28. Burrel, C. J. Serological markers of hepatitis
B. Clin Gastroenterol 9, 47-63. (1980). - 29. Boxall, E. H., Peterson, S., Diment, J., Graha m, S. E. & Shirley, J. A. A novel assay for hepatitis B e markers. J Med Virol 52, 280-285. (1997).
- 30. Basten, A. & Howard, J. G. in Contemporary Topics in Immunobiology, Vol. 2. (ed. A. J. S. Davies) 265 (Plenum, New York; 1973).
- 31. Humphrey, J. H., Parrott, D. M. V. & East, J. Studies on globulin and antibody production in mice thymectomised at birth.
Immunology 7, 419-439 (1964). - 32. Weissman, I. L., Gutman, G. A., Friedberg, S. H. & Jerabek, L. Lymphoid tissue architecture. III. Germinal centers, T cells, and thymus-dependent vs thymus-independent antigens. Adv. Exp. Med. Biol. 66, 229-237 (1976).
- 33. Beagley, K. W., Black, C. A., Dunkley, M. L. & McGhee, J. R. in Cytokine Regulation of Humoral Immunity. (ed. C. M. Snapper) 391-408 (John Wiley & Sons Ltd, Chichester, New York, Brisbane, Toronto, Singapore; 1996).
- 34. McGhee, J. R., Mestecky, J., Elson, C. O. & Kiyono, H. Regulation of IgA synthesis and immune response by T cells and interleukins. [Review]. Journal of
Clinical Immunology 9, 175-199 (1989). - 35. Mestecky, J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. [Review]. Journal of
Clinical Immunology 7, 265-276 (1987). - 36. Mongini, P. K. A., Stein, K. E. & Paul, W. E. T-cell regulation of IgG subclass antibody production in response to T-independent antigens. J. Exp. Med. 153, 1-12 (1981).
- 37. Kagnoff, M. F. & Murray, P. D. T dependent induction of an IgA and IgM anti-polysaccharide response. Advances in Experimental Medicine & Biology, 155-167 (1987).
- 38. Ivars, F., Nyberg, G., Holmberg, D. & Coutinho, A. Immune response to bacterial dextrans. II. T cell control of antibody isotypes. Journal of Experimental Medicine 158, 1498-1510 (1983).
- 39. Ehrhardt, R. O. et al. Differential activation requirements of isotype-switched B cells. Eur. J. Immunol. 26, 1926-1934 (1996).
- 40. Tonkinson, J. L. & Stillman, B. A. Nitrocellulose: a tried and true polymer finds utility as a post-genomic substrate.
Front Biosci 7, C1-C12. (2002). - 41. Cole, H. B., Ezzell, J. W., Jr., Keller, K. F. & Doyle, R. J. Differentiation ofBacillus anthracis and other Bacillus species by lectins.
J Clin Microbiol 19, 48-53. (1984). - 42. Cohen, S. et al. Attenuated nontoxinogenic and nonencapsulated recombinantBacillus anthracis spore vaccines protect against anthrax. Infect Immun 68, 4549-4558. (2000).
- 43. Smith, H. & Zwartouw, H. T. The polysaccharide fromBacillus anthracis grown in vivo. Biochem J 63, 447-452 (1956).
- 44. Kabat, E. A., Bezer, A. E., Baer, H. & Knaub, V. Immunochemical studies on blood groups. VII. Chemical changes associated with destruction of blood group activity and enhancement of the type XIV cross-reactivity by partial hydrolysis of hog and human blood group A, B, and O, substances. J. Exp. Med. 88, 43-57 (1948).
- 45. Kabat, E. A., Howe, C. & Schiffman, G. Immunnochemical studies on blood groups. J. Am. Chem. Soc. 80, 6656 (1958).
- 46. Kabat, E. A. Immunochemical studies on blood groups. J. Immunol. 82, 358-372 (1958).
- 47. Mesnage, S. et al. Bacterial SLH domain proteins are non-covale ntly anchored to the cell surface via a conserved mechanism involving wall polysaccharide pyruvylation.
Embo J 19, 4473-4484. (2000). - 48. Kabat, E. A. et al. Human monoclonal macroglobulins with specificity for Klebsiella K polysaccharides that contain 3,4-pyruvylated-D-galactose and 4,6-pyruvylated-D-galactose. J. Exp. Med. 152, 979-995 (1980).
- 49. Kabat, E. A. et al. The epitope associated with the binding of the capsular polysaccharide of the group B meningococcus and ofEscherichia coli K1 to a human monoclonal macroglobulin, IgM NOV. J. Exp. Med. 168, 699-711 (1988).
- 50. Kabat, E. A., Liao, J., Sherman, W. H. & Osserman, E. F. Immunochemical characterization of the specificities of two human monoclonal IgM's reacting with chondroitin sulfates. Carbohydr. Res. 130, 289-297 (1984).
- 51. Kabat, E. A., Liao, J., Shyong, J. & Osserman, E. F. A monoclonal IgM lambda macroglobulin with specificity for lacto-N-tetraose in a patient with bronchogenic carcinoma. J. Immunol. 128, 540-544 (1982).
- 52. Kabat, E. A. et al. A human monoclonal macroglobulin with specificity for a(2-8)-linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci andEscherichia coli K1, which crossreacts with polynucleotides and with denatured DNA. J. Exp. Med. 164, 642-654 (1986).
- 53. Nickerson, K. G., Liao, J. & Kabat, E. A. A monoclonal IgM kappa from a blood group B individual with specificity for alpha-galactosyl epitopes on partially hydrolyzed blood group B substance. Carbohydr. Res. 243, 345-357 (1993).
- 54. Tatusov, R. L., Koonin, E. V. & Lipman, D. J. A genomic perspective on protein families. Science 278, 631-637. (1997).
- 55. Krogh, A., Larsson, B., von Heijne, G. & Sonnhammer, E. L. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 305, 567-580. (2001).
- Fourth Series of Experiments
- HydroGel™ slides are produced by Packard BioScience for printing protein microarrays. We investigated whether Hydrogel can serve as an alternative substrate for producing carbohydrate microarrays and for producing HIV diagnostic protein microarrays.
- I. Materials and Methods
- A. Procedures for Printing and Staining of the Hydrogel-Based Biochips
- (1) Method for Printing on Hydrogel-Coated Slides
- The method for printing carbohydrates and proteins on Hydrogel-coated slides is essentially identical to that for printing on nitrocellulose slides. The only difference is that the pre-treatment of Hydrogel follows the method described by the manufacture as follows: (a) place HydroGel slides in 40° C. incubator for 20 minutes; and (b) remove prior to printing and allow slides to cool to room temperature for 5 minutes.
- 2) Method for Post-Printing Treatment
- The procedures for post-printing treatment were modified from the manufacture's instruction as follows: (a) incubate arrays overnight in a humidified 30° C. chamber; (b) rinse briefly (for 20 seconds) in PBST (PBS+0.05% Tween 20), followed by 3, 30 minute washes with PBST. Rinse for 20 seconds in PBS (pH 7.4); and (c) dry slides by centrifugation at 1600 RPM for 5 minutes in a table-top centrifuge.
- (3) Method for Staining
- The methods for staining Hydrogel biochips are identical to those for staining nitrocellulose biochips.
- II. Results and Discussion
- Applicants have shown the following surprising results:
- 1) Printing proteins and carbohydrate-containing macromolecules on hydrogel can be performed using Cartesian's PIXSYS 5500A Microarryer (CHIPMAKER 4), using a contact arraying procedure.
- 2) Protein preparations, including antibodies, BSA, Avidin and HIV-1 gp120, RT and gag proteins, can be quantitatively immobilized on the hydrogel, providing fine spots of about 150 microns in diameter and thus making it possible to produce a high density protein microarray.
- 3) Carbohydrate preparations, including polysaccharides, glycosaminoglycans, glycoproteins, semi-synthetic glycoconjugates and glycolipids, can be quantitatively immobilized on the hydrogel, providing fine spots of about 200 microns in diameter and thus making it possible to produce a high density carbohydrate microarray.
- 4) The immobilized protein and carbohydrate antigens analyzed have their immunological properties well-preserved at the time the slides were stained using specific antibodies.
- 5) Use of the Hydrogel-based protein and carbohydrate microarrays is advantageous due to their low fluorescent background. A disadvantage of the Hydrogel substrate is its absorption of relative lower amounts of materials on the biochip. For the same antigen preparations, the fluorescent signals detected on Hydrogel-slides are much lower than those detected on the nitrocellulose slides.
- 6) When the ratios of fluorescent intensity over background of given microspots are calculated, the results of nitrocellulose-chips and those of Hydrogel-chips are closely correlated in most cases (see Table 4 for a comparison among antigens of distinct structural characteristics).
- 7) The nitrocellulose-based biochip favors detection of IgG antibodies but not IgM antibodies in solution. The former is an immunoglobulin (Ig) monomer; and the latter is an Ig pentamer. Such bias is not seen in the Hydrogel-based biochips. This finding is of significance since it provides information to improve the nitrocellulose surface for producing a diagnostic biochip.
- Fifth Series of Experiments
- I. Introduction
- An infectious agent may expose and release multiple antigenic substances to a host, eliciting specific antibody responses. Many antigen-antibody binding assays are currently in use for clinical diagnosis of infectious and non-infectious diseases. These include the classical direct immunoassays, such as, immunodiffusion, immunoelectrophoresis, agglutination and immunoprecipitation, and recently developed methods, including immunofluorescence, radioimmunoassay (RIA), enzyme-immunoassay (EIA) and western blot. These approaches take advantage of the specificity of antigen-antibody interaction but are designed to operate on a one-by-one basis. Their successful diagnostic application for infectious diseases is, therefore, largely dependent on whether a clinician makes the correct decision regarding which diagnostic test should be run.
- Establishment of technologies to enable the simultaneous detection and characterization of a wide range of microbial infections represents a current challenge to the worldwide effort of biodefense. High-priority infectious agents that pose current risks to our national security include multiple microbial pathogens, such asBacillus anthracis (anthrax), Clostridium botulinum (botulism), Yersinia pestis (plague), Variola viruse (smallpox), Francisella tularensis (tularemia) and viral hemorrhagic fevers (Lassa virus, Ebola virus, Marburg virus and LCM virus). An assay system that allows detection and characterization of these pathogens in a single assay is currently unavailable.
- Rapid progress of the genome sequencing projects has brought new hopes as well as challenges to biodefense efforts. For example, a great deal of genomic information is available for numerous pathogens1,2,3. This leads the way to developing a generation of high throughput technologies to combat emerging infectious diseases. These include the nucleic acid-based microarrays 4,5 or DNA chips 6, and the protein-based microarrays 7,8. Application of these technologies in the field of infectious diseases is still in its early stages 9,10. Novel ideas are badly needed for the establishment of high throughput technologies to monitor potential bioterrorism attacks as well as naturally occurring emerging infectious diseases.
- Our laboratory has been focusing on the development of a biochip platform that is suitable for the production of both carbohydrate and protein-based microarrays. Our carbohydrate microarray technology is described herein. Such a technology is designed to display a large repertoire of pathogen-specific antigens of distinct structures in order to monitor a broad range of microbial infections. Since it is applicable for human and many other animal species, this system is particularly useful for monitoring the emergence of infectious diseases. In many infectious diseases, an intermediate reservoir plays important roles in the life cycle of the pathogen. In other cases, both human and animal species are accessible to a given pathogen.
- A number of category A pathogens (Bacillus anthracis, Clostridium botulinum, Yersinia pestis, and viral hemorrhagic fevers) and other emerging infectious diseases (Lyme disease and West Nile Virus infection) have such characteristics. Thus, the antigen/antibody-based biochips will play a significant role in the surveillance of emerging infectious diseases (FIG. 17).
- Both carbohydrate antigens and protein antigens are important for the production of a diagnostic biochip. As shown in FIG. 17, the presence of a polysaccharide inBacillus anthracis has been recognized for some time11,12,13. It is specific for B. anthracis, a useful molecular target for the identification of the pathogen. This structure is, however, masked before spore germination, casting doubt on its potential for vaccination use. A protein antigen of B. anthracis, the protective antigen (PA) is a well-recognized vaccine target. PA is an integrated component of the lethal toxin of Bacillus anthracis. It binds to a specific cellular receptor and forms cell bound complexes with edema factor (EF) and lethal factor (LF) 14-16. Understanding of this process led to the development of polyvalent inhibitor-based therapeutic strategies to protect a host from lethal attack by the toxin 17.
- Given our current knowledge of protein chemistry, on-chip protein structural alterations, including denaturation or partial denaturation and various degrees of conformational modification, are unavoidable in the course of a long time period in storage (months to years). However, the such alterations are acceptable when a protein chip is made for an immunological application because a naturally occurring infection or vaccination elicits specific antibodies directed to both the native and the denatured/partially denatured antigenic determinants.
- In summary, detecting a microbial antigen and/or its specific antibodies in bodily fluids are important in diagnosis of infectious diseases and in surveillance of emerging infectious diseases. This goal is achieved by an antigen/antibody-based microarray of high sensitivity, large capacity, and extensive antigenic diversity.
- II. Procedures for Production of Long-Lasting Protein Microarrays
- This section is directed to a central technical difficulty in the technology of proteomic microarrays—the structural and conformational instability of protein on-chip. Our procedures include a) a high throughput technology to screen for the antigen preparations that are applicable for our proposed microarray platform; b) the technology for the production and long-lasting preservation of protein microarrays; and c) Green Chip Technology to facilitate protein chip development.
- (A) High throughput Screening to Identify Stable Antigens for the Production Protein Chips
- In our preliminary investigation, we found that the on-chip stability of protein antigens varies among molecules and/or preparations. Molecular mechanisms underlying these differences are quite complex. To meet the urgent need of biodefense, we take a straightforward but efficient approach to facilitate the development of diagnostic biochips. Specifically, we have established a microarray-based high throughput screening technology to identify suitable microbial antigens for biochip production.
- Our method of protein chip fabrication is a non-covalent protein immobilization on a nitrocellulose-coated micro-glass slide. It uses a nitrocellulose-surface to immobilize an antigen, similar to the Western Blot assay, but has no treatment to denature the protein before its application. A protein microspot is, therefore, printed on the chip without any chemical or physical treatment to interfere with its native structure.
- We have designed a single step assay in which protein antigens are printed on the nitrocellulose-coated slides and then stained by antibodies to “see” whether specific antigenic determinants are displayed on chip and whether they are accessible to antibodies in solution. The monoclonal and polyclonal antibodies elicited by a microbial antigen or by a pathogen, as well as serum specimens of an infected individual, are all useful reagents for these analyses. A positively stained microspot indicates the presence of a target molecule or antigenic determinant. We have established two methods, a) an eight-chamber sub-array system (FIG. 10) and b) a full-scale biochip scanning (FIG. 11), to facilitate the screening process.
- 1. An Eight-Chamber Sub-Array System
- Each microglass slide contains eight well-separated sub-arrays of identical contents. Its microarray capacity is 600 microspots per subarray. A single slide is, therefore, designed to enable eight microarray analyses. Antibodies can be applied on separate subarrays in a serial dilution as in an ELISA assay.
- a) 8-chamber sub-arrays (See FIG. 10):
- Each microglass slide contains eight-well separated sub-arrays of identical contents. There are 600 microspots per subarray, with spot sizes of approximately 200 microns and at 300-micron intervals, center-to-center. A single slide is, therefore, designed to enable eight detections.
- b) Contains:
- i) A 600-spot subarray is composed of pathogen-specific protein antigens in question as well as a few selected carbohydrate antigens to serve as control spots. These selected carbohydrate antigens have been characterized on the chip. Their specific antibodies are seen frequently in body fluids of normal individuals;
- ii) Repeats and dilutions: Each antigen will be printed at 0.5-1.0 mg/ml and also at a one to ten dilution of the initial concentration for the second concentration. Each preparation at a given concentration will be repeated three times; and
- iii) Antibody isotype standard curves: Human or murine antibodies of IgG, IgA and IgM isotype of known concentrations will serve as standard curves for antibody detection and normalization.
- For each antigen preparation, approximately twenty-five micrograms of purified protein are sufficient for producing this set of testing chips. We designed the following protocol in order to enable a rapid and economic screening: a) Negative elimination; b) Specificity and cross-reactivity; and c) Conventional immunoassay. Preparations of mixed antibodies are made in such a way that a) the total protein concentrations of the mixed antibodies for each subarray staining is identical across subarrays; b) for each antibody preparation, there are series dilutions (˜four points); c) antibodies of same species are grouped to avoid frequently occurring cross-neutralization of antibody reactivity among different species and to allow detection of multiple Ig isotypes on the same spots.
- a) Negative elimination: A preparation of mixed monoclonal or polyclonal antibodies is applied to stain a subarray. Antibodies derived from the same species can be mixed together to stain a sub-array and a tagged secondary antibody can reveal their specific binding on antigen spots. To take the advantage of the above 8-chamber design, these antibodies are applied in serial dilutions to permit an estimation of their detection sensitivity and specificities;
- b) Specificity and cross-antigenic reactivity: A subarray of the antigen chip is stained using distinctly tagged monoclonal or affinity purified antibodies to identify specific antigen spots. This staining allows one to detect specificity as well as potential cross-antigenic reactivity among printed antigens. Such analysis has been detailed previously; and
- c) Conventional immunoassays to verify microarray results: ELISA, Dot blot, and/or Western Blot is performed. If an antigen is positively detected by an antibody on ELISA but negative or poorly detectable by protein microarray, this may suggest a problem with its on-chip immobilization. The protein may be conjugated to a carrier molecule (such as BSA) to improve its immobilization. If it is ELISA negative but Western positive to a corresponding antibody, the protein may be solubilized in a denaturing solution before printing on the chip.
- 2. A Full-Scale Biochip Scanning
- We have produced a microarray biochip composed of about 4,000 microspots of antigens. In addition to carbohydrate antigens, we printed a large panel of protein antigens. In this design, each antigen or antibody preparation of a given dilution was printed with four repeats in a vertical line of micro-spots on the biochip. This allowed us to visually observe and statistically analyze the reproducibility of microarray printing and staining. The significance and sensitivity of antibody detection for each antigen at a given antigen concentration can also be statistically calculated. Some preparations, for example the gp120 glycoprotein of HIV-1 as highlighted in a square in FIG. 11, were printed from left to right in a series dilution of one to five, beginning at 0.5-1.0 mg/ml and with four dilutions thereafter. These biochips were stained with the uninfected or HIV-1-infected human serum specimens with the methods described above. Pictures of the ScanArray visualization of the multi-color fluorescent staining of biochips are shown in FIG. 11.
- (B) Technologies for the Production and Preservation of Long-Lasting Protein Microarrays
- Given our understanding of protein chemistry, on-chip protein structural alteration, including denaturing or partial denaturation and various degrees of conformational modification, is unavoidable over a long period of time (months to years). Such alteration is generally un-acceptable when a protein chip is made to study the biological function of a protein, such as protein-protein interactions, small molecule transportation, enzymatic reactivities, and cell signaling activity, etc. To maintain these functional properties of proteins, substantial preservation of the native protein structure or conformation is generally necessary. For an immunological application, this situation is, however, significantly different since an antibody may recognize either the native or the denatured/partially denatured antigenic determinants. Antibodies of distinct epitope-binding specificities are frequently elicited in the course of a microbial infection. Technically, the ELISA-based immunoassays are preferential to the detection of antibodies that recognize the native antigenic determinants; the Western blot assays generally directed to the protein structures that are denatured/partial denatured and immobilized on a nitrocellulose membrane or other surfaces with hydrophobic characteristics. The “Western type” of antigenic structures also has large potential in protein chip application since many antigens on Western blot/nitrocellulose strips are stable and suitable for long-term preservation.
- Differing from the DNA-based microarray assay, which requires DNA and/or RNA denaturation to allow the A/T or C/G hybridization-taking place, the protein microarray assay requires preservation of protein structures (a general belief in the field). Protein on-chip stability has been considered a critical issue for the development of long-lasting protein microarrays. To address this question of protein stability, we analyzed in a model system, the HIV-1 protein chip (see FIG. 18).
- FIG. 18 shows the results from protein microarrays that were printed, air-dried, and stored at room temperature. In one set, slides were stained at
day 2 and another set in 11 months after printing. Serum specimens applied for theday 2 staining are identical to those for the 11 month-old slides. This allows a comparative analysis of protein antigenic reactivities on the chips that were stored for different time range, either for two days or for eleven months. Each bar represents the mean of four detections (Ratio of intensity over background). Data were calculated and statistically analyzed as described 9. - This experiment showed that some protein preparations, such as SF2 gp120-glycosylated and GST-gag p24 of HIV-1 preserved their antigenic reactivities quite well after a prolonged storage in air-dried condition at room temperature. Other preparations, including SF2gp120 non-glycosylated, LAV gp120 glycosylated, GST-gag p55 and GST-gag p55/mutant P222A, lost a large proportion of their antigenic reactivities on chip after long-term storage. These observations indicate an existing possibility that production of a long-lasting protein chip using our microarray platform is most likely feasible.
- 1. Long-Lasting Preservation of Global Patterns of Antibody Reactivities On-Chips
- To test further this possibility, we characterized a large collection of antigen preparations. Specifically,we stained three sets of biochips that were made identically in the same printing experiment using same antibody preparations at three time points,
day 2, eight months, and eleven months after they were made and simply stored at room temperature in air. A clustering analysis-based software was developed by our lab to characterize the antigenic reactivities on-chip in a global manner. Results illustrated in FIG. 19 reveal that although some proteins showed reduced antigenic reactivities on-chip after a long-term storage in air at room temperature, the global patterns of antigenic reactivities remain the same or similar among three different experiments across the three time points:day - In three replicate experiments, biochips were stained at day 2 (Experiment A), 8 months (Experiment B), or 11 months (Experiment C), using the same specimens, either serum of an uninfected individual or an HIV-1 infected patient. Results were presented as the Log ratio of the intensity over background for each antigen microarray at a given concentration. A hierarchical clustering method is applied on the data under the platform of Matlab. The correlation between color bar and the log ratio of intensity over background is indicated in FIG. 19 (right corner).
- 2. Methods of Post-Printing Handling to Improve Protein Chip Stability
- We have established a few methods for the post-printing treatment of protein chips to improve the stability of our protein chip. Our methods are relatively simple and generally applicable to many protein antigens, including those that have distinct structural characteristics. This is, in fact, a challenge to the proteomic microarray technology. Most, if not all protein antigens, express two general types of antigenic determinants, being either labile or stable on chip. To improve the stability of diagnostic protein chips, two different types of approaches may be considered: methods to stabilize the native structures of protein on chip and methods to remove the labile epitopes and/or to enrich the stable epitopes. We established, therefore, the following approaches to establish a long-lasting antigenic protein microarray:
- a) Lyophilizing Protein On-Chip
- Many protein preparations can be lyophilized and stably stored at low temperature for a long period of time. We treat our printed protein chips by a step of lyophilizing. We then seal them in a plastic bag and store them at lower temperatures, including 4° C., −20° C., and −80° C. These chips are analyzed as described above after a period of storage (two days, six months and two years). Results are compared with those of
experiment 1 whereby the printed chips are placed at room temperature in the air-dried condition. A technical concern is whether the process of lyophilizing sucks off a proportion of printed proteins. If a significant signal reduction is seen, a period air-drying the freshly made chip can be employed to avoid the signal reduction. - b) Dessication of Protein Microarrays:
- Place a protein chip in a desiccator for a period of five to ten days in the presence of a desiccating reagent without a vacuum. Then stain the chip with antibodies to probe corresponding antigenic determinants. We predict that some but not all antigenic structures/protein epitopes are sensitive to dehydration. ELISA and Western blot assay are conducted to further characterize the two classes of antigenic structures, the dehydration sensitive and the dehydration resistant antigenic determinants.
- c) Hydration of Protein Microarrays:
- Prepare three sets of protein chips by covering them with a thin layer of “sticky” aqueous solution, i.e., 40% glycerol in 1× PBS. One set (six chips) is stored at 4° C., one set at −20° C. and the last set at −80° C. After a period of storage (two days, six months, and two years), two chips/sixteen sub-arrays are stained and the data analyzed as described above.
- In Western blot diagnosis of HIV-1 and many other infectious diseases, serum antibodies of infected individuals are found in many cases to be specific to denatured or partially denatured protein antigens. We, however, for the first time, take advantage of this host immunity to develop a novel protein chip assay. Differing from Western blot, the protein chips can substantially extend the spectrum of pathogens that can be detected in a single assay. In addition, a chip assay is rapid, high throughput, and economic. It requires only a few microliters of serum specimen. Theoretically, similar structural alteration may also occur in vivo in the cellular events of antigen processing/trafficking during a natural infection, generating antigenic structures that differ from those expressed by the native proteins. Such structures are still “foreign” to a host and capable of induction of specific antibody responses. The potential of this category of antigenic structures for diagnostic use, especially in association with the high throughput protein microarray technology, is yet to be explored.
- In summary, protein microarrays can be treated in three different ways, including lyophilizing, desiccation, and hydration, and stored for a various periods of time, ranging from two days to two years.
- (C) Green Chip Technology—the Second Generation of Protein Chips
- As described above, we have established technologies to explore the available antigens and antibodies to rapidly establish protein antigen-based microarrays to meet the urgent needs of biodefense. The potential of these approaches is, however, limited by the availability of pathogen-specific antigens and antibodies. Here, we apply the state-of-art technologies of protein engineering to facilitate the development of protein microarrays. Specifically, we a) introduce the technology of green fluorescent protein (GFP) in our next generation of protein microarrays, the Green Chip Technology; b) establish a molecular engineering-based strategy to produce recombinant proteins that fluoresce on the chip and are capable of displaying stable antigenic determinants on the surface of a microarray. This method can be applied to many molecular targets whose nucleotide sequences and/or structural information are available. This method is, therefore, designed to extend the repertoire of pathogen signatures for the production of diagnostic microarrays. We use the protective antigen (PA) ofB. anthracis as a model to demonstrate this technology.
- Efficacy of protein immobilization on a nitrocellulose-coated microslide depends on the physicochemical property of protein molecules. Since only noncovalent molecular interactions are involved, a common influencing factor is the molecular weight (MW) of a target molecule. In some circumstances, protein antigens or pathogen-specific antigenic determinants are too small to be immobilized on the chip without altering their antigenic reactivities. We, therefore, fuse a target molecule to a carrier protein molecule to improve its surface adhering property. In this case, we select a fluorescent carrier molecule, the green fluorescent protein (GFP). GFP was originally isolated from the biolyminescent jellyfish Aequorea Victoria44. The protein, as well as its variants, have been successfully expressed in various other organisms and have been used as a detection system. The two variants that are readily available as purified proteins are EGFP (enhanced green fluorescent protein) and GFPuv (UV-optimized GFP variant). Their excitation maxima are 488 and 395 nm, respectively, while their emission maxima are 507 and 509 nm, respectively.
- We tested purified GFPuv on our protein microarray chip. It generates bright fluorescent signal upon excitation at fluorescence channel (488 nm) but not at Cy3 (552 nm) and Cy5 (633 nm) chanels of a microarray scanner (GSI SA5000) (FIG. 20 and table 5). This makes it practical to use the FITC channel to monitor protein stability, printing quality, and data normalization and, while using Cy3, Cy5 and other GFP negative channels to detect antigen-antibody interaction on the same spots. In addition, the GFP signal is retained on the chip after it is air-dried and extensively washed (FIG. 20). Introduction of GFP to the protein chip “up-grades” our protein chip technology. It provides not only an effective and convenient means to monitor the quality of protein microarrays but also an internal control for each microspot. The latter is greatly important for data processing and data mining and therefore will generally improve the quality of protein chips.
- 1. The PA Antigen ofB. anthracis as a Model for the Green Chip Technology
- PA is the central component of the three-part lethal toxin ofBacillus anthracis. It binds to a specific cellular receptor and forms toxic, cell bound complexes with edema factor (EF) and lethal factor (LF) 14-16. It was named PA since it acted protective when an animal was injected with the protein and then challenged by the lethal pathogen B. anthracis. PA itself is a good antigen for eliciting antibody responses in a number of mammalian species, making it an important vaccine against anthrax 45. The crystal structure of monomeric PA at 2.1 Å resolution and the water-soluble heptamer at 4.5 Å resolution have been resolved (FIG. 21) 46. PA is, therefore, an ideal molecule model for studying the relationship between protein structure and its antigenic reactivity.
- Our investigation is directed at the recognition of the antigenic determinants of PA that are stable on a chip, useful for vaccine evaluation, and highly specific for pathogen recognition. We focus on the relationship between structure and the on-chip antigenic reactivity of the molecule. Specifically, we ask a) whether the structures that are buried in its native configuration are useful for protein chips, and b) whether the structures that are displayed on the surface in the native form are stable and long lasting on chip. The structures hidden in a native protein may become exposed in vivo by cellular or enzymatic processing or in vitro owing to its on-chip structural alteration. Our working hypothesis is that such hidden structures are previously unrecognized pathogen signatures and are suitable for the production of long-lasting diagnostic protein chips. In PA, an important “hidden structure” is the surface of PA63, which is masked by the N-
terminal 20K fragment of PA (PA20). Release of this fragment from PA leads to heptamer formation by PA63. - Our overall experimental design uses antibodies of distinct epitope binding specificities to recognize the antigenic determinants of PA, to monitor their possible alteration on chip during storage, and thereby identify the stable antigenic structures for long-lasting protein chips. Experimentally, we a) produce a panel of recombinant proteins of PA and its derivatives; b) produce the domain-specific PA protein microarrays using these recombinant PAs; c) immunize mice using PA and its conjugates to elicit antibody responses and monitor the time course of the response by PA protein chips; and d) generate monoclonal antibodies to ensure the availability of antibodies of various binding specificities, including those that bind PA specifically by Western Blot and those specific for the antigen on ELISA.
- 2. GFP-Fusion Proteins of PA, its Derivatives, and their Fluorescent Protein Microarrays
- a) Construction of expression vectors, protein induction and purification: Construct a panel of twelve GFP-PA fusion proteins as outlined in FIG. 22. Briefly, six sets of PCR primers have been designed according the published nucleotide sequences of PA (on the PX01 plasmid) and the domain structure of the protein. Use a cDNA clone containing the full-length PA as a template for PCR amplification to produce six PCR fragments, including a full-length PA, an N-terminal truncated PA (PA63), and
domain 1 to 4. These PCR fragments are subcloned into an E. coli expression vector, pGFPuv cDNA Vector (BD/Clontech), to express corresponding GFP fusion proteins. In vector design, the expressed fusion protein will be accumulated intracellularly as GFP alone. In addition, a His-tag can be cloned either at the N-terminal or the C-terminal of a recombinant protein, allowing protein purification using Ni-NTA column/resin under either denatured or native condition as described by the manufacture (QIAGEN Inc., USA). This will enable the binding of protein on Ni-NTA ELISA plate and Western blot using anti-His antibodies. Additional methods of purification include: i) the native condition of purification; ii) denaturing conditions; and iii) the GFPuv protein is resistant to the 8M Urea, which serves as one of the alternative methods for GFP-fusion protein purification. - b) Printing and validating the fluorescing PA microarrays: Methods for microarray printing, preservation, scanning, and data processing are the same as described above. Given our current knowledge, these GFP-fusion proteins are as bright as GFP alone. If some clone loses its fluorecent property, anti-GFP antibody can be used to detect them on the chip. Proteins may be solublized using a solution containing 8 M urea. We observed previously that proteins solubilized in this way can be immobilized on a nitrocellulose membrane or on an ELISA plate. Printing is on the 8-chanber subarray system as described above. Protein chips are stored under different conditions as described above and analyzed two days, six months, and one year after printing. Antibody staining is detailed below using a panel of monoclonal and polyclonal antibodies.
- c) Animal immunization and production of monoclonal antibodies: A panel of polyclonal and monoclonal anti-PA antibodies is currently available. These reagents are tested by ELISA and by Western blot to identify different categories of specificities: a) Recognize native epitope: ELISA strongly positive, but Western negative or weakly positive to PA; b) Recognize denatured/partially denatured epitope: Western strongly positive, but ELISA negative or weakly positive; and c) Recognize the stable epitopes: Both methods strongly positive. These are relative ways of classification but have been proven useful for predicting an antigenic structure.
- 3. “Green Chip Technology” to Reveal the Hidden Antigenic Determinants
- As described above, we believe that the on-chip protein structural alteration, including denaturation or partial denaturation and various degrees of conformational modification, is unavoidable in the course of a long period of time (months to years). Such alteration is, however, not necessarily a limiting factor to the diagnosis of infectious disease and other immunological disorders on a protein chip. We reason that antibodies elicited by an antigenic stimulation, either by a microbial infection or by a vaccination, have the potential to recognize multiple antigenic structures, including either the native/conformational sensitive antigenic determinants or the denatured or partially denatured/conformationally insensitive antigenic determinants. For instance, the ELISA-based immunoassays preferentially detect antibodies that recognize the native antigenic determinants; the Western blot assays are directed to the protein structures that are denatured/partially denatured and immobilized on a nitrocellulose membrane or other surfaces with hydrophobic characteristics. “Western-like” antigenic structures have high potential in protein chip application since they are generally stable and suitable for long-term preservation. Given the complexity of protein structure and the question regarding their antigenic reactivity, we use the protective antigen (PA) ofB. anthracis as a model and example for other important microbial antigens.
- Experimentally, we a) take advantage of our green chip technology to monitor the structural stability and quality of printed protein chips by capturing its GFP signal on the chip over periods of time; b) use a large panel of monoclonal and polyclonal antibodies specific for distinct antigenic determinants of PA, including specificities to the native structures as well as reactivities directed to the denatured/partially denatured structures. This type of on-chip epitope scanning is high throughput. We perform it at defined points in time as described above.
- 4. Use of Two GFP Variants, EGFP and GFPuv, on Microarrays
- We demonstrated that two molecular variants of GFP, EGFP (enhanced GFP) and GFPuv (UV-optimized GFP variant), are applicable for our platform of chip fabrication. These variants were specially included for this investigation since their fluorescing activities are protein conformation dependent. Detection of the signals that they generated over times provides a simple and efficient method to monitor their structural stability on-chip. Results summarized in FIG. 30 show that these GFP proteins were stably immobilized on the nitrocellulose slides and were fluorescing on-chip after air-drying, extensive washing and prolonged storage at room temperature. These properties are similar to those of FITC-labeled polysaccharides, as well as the Cy3- and Cy5-conjugates of streptavidin that were printed and tested in the same experiments.
- III. A Procedure for Production of Epitope-Specific Carbohydrate Microarrays
- This section is directed to the high throughput production of the oligosaccharide-based, epitope-specific carbohydrate microarrays. This invention makes it possible to produce a glycochip whereby a single type of glycoconjugate, the oligosaccharide-polyacrylomide conjugate, is utilized to display a large repertoire of oligosaccharides of distinct structures.
- (A) αGal Anti-αGal System as a Model
- We have chosen the αGal anti-αGal system as a model to establish the technology of the oligosaccharide-based, epitope-specific carbohydrate microarrays. Since αGal is a key antigenic determinant that is responsible for the hyperacute rejection in animal to human xenotransplantation, the microarrays produced by this investigation are valuable for monitoring such anti-xenoantigenic responses.
- We printed both αGal-protein conjugates (data not shown) and αGal-polyacrylamide conjugates on nitrocellulose coated glass slides and then stained the microarray with αGal-specific antibodies. Since we have already established that glycoproteins can be stably immobilized on the nitrocellulose slide, the use of αGal-protein conjugates in this study serves as a control for neoglycopolymers.
- 1. Microarray Experiment-1: Lectin Staining
- To validate whether the αGal-sugar epitopes are displayed by the PACE-conjugates, we spotted a panel of α-Gal-PAGE conjugates of defined structures on a nitrocellulose-coated glass slide.
- We spotted PAGE-based neoglycoconjugates at an initial concentration of 0.6 mg/ml and then diluted the conjugates in serial dilutions of 1:4. We stained the microarray chips using a lectin that is specific for the sugar chain. The Banderiraea Simplicifolla BS-1 lectin (Sigma) is used in FIG. 23A. The lectin was coupled with a biotin molecule. The microspots-captured lectin was thus revealed by a streptoavidin-Cy5 conjugate. Glycoconjugates utilized in this study include: (i) DW450 phenyl α-Galactopyranosyl-(1-3) b-D-galactopyranosyl-(1-4)-1-thio-b-D-glucopyranoside; (ii) DW451α-Galactosyl −2; (iii) DW452 α-Galactosyl −3; (iv) DW453 α-Galactosyl −4; (v) DW454 polylactose (1/2.5); (vi) DW455 α-Gal polymer A; (vii) DW456 α-Gal polymer B; (viii) DW457 α-Gal polymer C; (ix) DW458 α-Gal polymer D; (x) DW459 α-Gal polymer E; and (xi) DW460 α-Gal polymer F.
- Results shown in FIG. 23A demonstrate that the αGal-sugar epitopes are displayed by the PAGE-conjugates and are specifically detected by the lectin Banderiraea Simplicifolla BS-1.
- 2. Experiment-2: Human Antibody Characterization of the αGal-Glycochips
- To investigate further whether the PAGE-conjugates of oligosaccharides are applicable for our platform of microarray production, we stained the microarrays with a preparation of affinity purified human anti-α-Gal antibodies at a 1:5 dilution (FIG. 23B upper) and at 1:50 (FIG. 23B bottom). The captured human IgG antibodies were then stained with an anti-Hu-IgG-Biotin conjugate, and subsequently stained using Av-Cy5 at the 1:250 dilution. Data for three repeats of the experiment were statistically analyzed.
- Glycoconjugates utilized in this study include: (i) DW450 phenyl α-Galactopyranosyl-(1-3) b-D-galactopyranosyl-(1-4)-1-thio-b-D-glucopyranoside; (ii) DW451α-Galactosyl-2; (iii) DW452 α-Galactosyl-3; (iv) DW453 α-Galactosyl-4; (v) DW454 polylactose (1/2.5); (vi) DW455 α-Gal polymer A; (vii) DW456 α-Gal polymer B; (viii) DW457 α-Gal polymer C; (ix) DW458 α-Gal polymer D; (x) DW459 α-Gal polymer E; and (xi) DW460 α-Gal polymer F.
- Results shown in FIG. 23B illustrate that the αGal-sugar epitopes are displayed by the PAGE-conjugates and are specifically detected by a preparation of affinity purified human anti-αGal antibodies. This experiment provides direct information regarding the use of this sugar chip in detecting human anti-αGal antibodies. Therefore, this sugar chip itself is a means for monitoring the hyperacute rejection in animal-to-human xenotransplantation that is mainly mediated by human anti-αGal antibodies. The potential of this epitope-specific sugar chip is, however, far beyond this specific application.
- 3. Experiment-3: Interaction between Lectin BS-1 and the α-Gal Sugar Epitopes is Epitope-Density Dependent
- We spotted α-Gal-PAGE conjugates at an initial concentration of 0.6 mg/ml and then diluted the conjugates in serial dilutions of 1:3. We stained the microarray chips using a lectin that is specific for the sugar chain. The Banderiraea Simplicifolla BS-1 lectin (Sigma) is used in FIG. 29. The lectin was coupled with a biotin molecule. The microspots-captured lectin was thus revealed by a streptavidin-Cy5 conjugate.
- Results shown in FIG. 29 demonstrate that the α-Gal-sugar epitopes are displayed by the polyacrylamide-conjugates and are specifically detected by the lectin Banderiraea Simplicifolla BS-1. In addition, we demonstrated, for the first time, on biochips that the molecular interaction between Lectin BS-1 and the α-Gal-sugar epitopes is epitope-density dependent. Such sugar chain specific molecular recognition can only take place when the molar ratio of oligosaccharide:carrier is greater than 1:2.5. This finding demonstrated a great advantage of this platform of oligosaccharide microarrays since it allows us to produce an epitope-specific carbohydrate microarray with various sugar chain densities and thereby mimic the in vivo cell-cell recognitions that are mediated by sugar chains and their cellular receptors.
- 1. Volchkov, V. E. Ebola virus, complete genome.Institute of Virology, Philipps-University (2000).
- 2. Shchelkunov, S. N., Totmenin, A. V. and Sandakhchiev, L. S. Analysis of the nucleotide sequence of 23.8 kbp from the left terminus of the genome of variola major virus strain India-1967.Virus Res. 40, 169-183 (1996).
- 3. Okinaka, R. T. et al. Sequence and organization of pXO1, the largeBacillus anthracis plasmid harboring the anthrax toxin genes. J Bacteriol 181, 6509-6515. (1999).
- 4. Brown, P. O. & Botstein, D. Exploring the new world of the genome with DNA microarrays.Nature. Genetics. 21, 33-37 (1999).
- 5. DeRisi, J. L., Iyer, V. R. & Brown, P. O. Exploring the metabolic and genetic control of gene expression on a genomic scale.Science. 278, 680-686 (1997).
- 6. Ramsay, G. DNA chips: state-of-the art.Nature. Biotechnology. 16, 40-44 (1998).
- 7. MacBeath, G. & Schreiber, S. L. Printing proteins as microarrays for high-throughput function determination.Science 299, 1760-1763 (2000).
- 8. Lueking, A. et al. Protein microarrays for gene expression and antibody screening.Analytical. Biochemistry. 270, 103-111 (1999).
- 9. Wang, D., Liu, S., Trummer, B. J., Deng, C. & Wang, A. Carbohydrate microarray leading to the recognition of cross-reactive molecular markers of microbes and host cells.Nature Biotechnology 20 (2002).
- 10. Grifantini, R. et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays.
Nat Biotechnol 20, 914-921. (2002). - 11. Gladstone, G. P. & Walton, E. Effect of iron on the bactericidal proteins from rabbit polymorphonuclear leukocytes.Nature 227, 849-851. (1970).
- 12. Strange, R. E. & Belton, F. C. Studies on a protective antigen produced in vitro from bacillus anthracis: Purification and chemisty of the antigen.Bri. J. Exp. Pathol. 35, 153-165 (1953).
- 13. Ezzell, J. W., Jr., Abshire, T. G., Little, S. F., Lidgerding, B. C. & Brown, C. Identification ofBacillus anthracis by using monoclonal antibody to cell wall galactose-N-acetylglucosamine polysaccharide. J Clin Microbiol 28, 223-231. (1990).
- 14. Blaustein, R. O., Koehler, T. M., Collier, R. J. & Finkelstein, A. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers.Proc Natl Acad Sci U S A 86, 2209-2213. (1989).
- 15. Thorne, C. B.Bacilluse anthracis. In Bacillus subtilis and Other Gram-positive Bacteria, ed. AL Sonenshein, J A Hoch, R Losick., 113-124 (1993).
- 16. Escuyer, V. & Collier, R. J. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells.Infect Immun 59, 3381-3386. (1991).
- 17. Mourez, M. et al. Designing a polyvalent inhibitor of anthrax toxin.
Nat Biotechnol 19, 958-961. (2001). - 18. Deng, C., Wang, A., Wang, D. & Zhang, P. in Talks on DIMACS Workshop on Analysis of Gene Expression Data. DIMACS Piscataway, N.J.; 2001).
- 19. Deng, C., Zhang, P., Wang, A., Trummer, B. & Wang, D. in Proceedings of IEEE International Joint Conference on Neural Networks Hawaii, U.S.A; 2002).
- 20. Ramdas, L. et al. Sources of nonlinearity in cDNA microarray expression measurements.Genome Biol 2 (2001).
- 21. Kim, S. et al. General nonlinear framework for the analysis of gene interaction via multivariate expression arrays.
J Biomed Opt 5, 411-424. (2000). - 22. Tseng, G. C., Oh, M. K., Rohlin, L., Liao, J. C. & Wong, W. H. Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects.Nucleic Acids Res 29, 2549-2557. (2001).
- 23. Jain, A. K., Duin, R. P. W. & Mao, J. Statistical Pattern Recognition: A Review.IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHINE INTELLIGENCE 22, 4-37 (2000).
- 24. Nadler, M. & Smith, E. P. Pattern recognition engineering. (John wiley & Sons Inc., New York; 1993).
- 25. Bow, S. -T. Pattern recognition and image preprocessing. (Marcel Dekker, Inc, New York; 1992).
- 26. Alon, U. et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays.Proc Natl Acad Sci U S A 96, 6745-6750. (1999).
- 27. Ben-Dor, A. Clustering gene expression patterns.Journal of
Computational Biology 6, 281-297 (1999). - 28. Heyer, L. J., Kruglyak, S. & Yooseph, S. Exploring expression data: identification and analysis of coexpressed genes.
Genome Res 9, 1106-1115. (1999). - 29. Carr D B, Somogyi R & G S, M. Templates for Looking at Gene Expression Clustering.Statistical Computing and
Graphics Newsletter 8, 20-29 (1997). - 30. Michaels, G. S. et al. Cluster analysis and data visualization of large-scale gene expression data.Pac Symp Biocomput, 42-53. (1998).
- 31. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns.Proc Natl Acad Sci U S A 95, 14863-14868. (1998).
- 32. Butte, A. J. & Kohane, I. S. Mutual information relevance networks: functional genomic clustering using pairwise entropy measurements.Pac Symp Biocomput, 418-429. (2000).
- 33. DeRisi, J. et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer.
Nat Genet 14, 457-460. (1996). - 34. Schena, M. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. [see comments.]., (1995).
- 35. Schena, M. et al. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes.Proc Natl Acad Sci U S A 93, 10614-10619. (1996).
- 36. Vapnik, V. N. Statistical learning theory. (John Wiley & Sons, New York; 1998).
- 37. Vapnik, V. N. An overview of statistical learning theory.IEEE TRANSACTIONS ON
NEURAL NETWORKS 10, 988-999 (1999). - 38. Burges, C. J. C. A tutorial on support vector machines for pattern recognition.Data Mining and
Knowledge Discovery 2, 121-167 (1998). - 39. Su, A. et al. Molecular classification of human carcinomas by use of gene expression signatures.Cancer Res. 61, 7388-7393 (2001).
- 40. Brown, M. P. S. et al. Knowledge-based analysis of microarray gene expression data by using support vector machines.PNAS 97, 262-267 (2000).
- 41. Furey, T. S. et al. Support vector machine classification and validation of cancer tissue samples using microarray expression data.
Bioinformatics 16, 906-914. (2000). - 42. Ramaswamy, S. et al. Multiclass cancer diagnosis using tumor gene expression signatures.Proc Natl Acad Sci U S A 98, 15149-15154. (2001).
- 43. Fried, R., Gather, U. & Imhoff, M. Online pattern recognition in intensive care medicine.Proc AMIA Symp, 184-188. (2001).
- 44. Chalfie, M. Green fluorescent protein.Photochem Photobiol 62, 651-656. (1995).
- 45. Reuveny, S. et al. Search for correlates of protective immunity conferred by anthrax vaccine.Infect
Immun 69, 2888-2893. (2001). - 46. Petosa, C., Collier, R. J., Klimpel, K. R., Leppla, S. H. & Liddington, R. C. Crystal structure of the anthrax toxin protective antigen.Nature 385, 833-838. (1997).
- 47. Peterson, L. Factor analysis of cluster-specific gene expression levels from cDNA microarrays.Comput
Methods Programs Biomed 69, 179. (2002). - Sixth Series of Experiments
- I. Introduction
- Microorganisms express carbohydrate-containing macromolecules of different molecular configurations, including polysaccharides, glycolipids and glycoproteins. Carbohydrate structures play critical roles in the entry and colonization of microbes, their host recognition, and induction of immune responses1-5. They are, therefore, important molecular targets for vaccine development. A notable example is vaccination with the protein-conjugates of Haemophilus influenza type b polysaccharide that resulted in the decline in the incidence of H. influenza meningitis and other infections in infants and children 6,7. Presence of polysaccharides and glycoproteins in B. anthracis has been recognized for some time 8-10. Whether these carbohydrate structures are suitable targets for anthrax vaccination is, however, an open question. This issue will be discussed in association with their biological roles in the life cycle of the bacteria, chemical and immunological characteristics of these molecules, and recent experimental evidence that indicates the potential of a successful carbohydrate-based anthrax vaccination strategy.
- (A) Carbohydrate Structures are Expressed at Various Stages of the Life Cycle ofB. anthracis
- The life cycle ofBacillus anthracis (FIG. 8), at various stages of development, exposes a number of carbohydrate molecular targets that are accessible to antibodies or lectins in solution.
- (1) Dormant Spore
- At first, the spore surface interacts with the host. A loosely fitting exosporium composed of protein, lipid, and carbohydrate is observed outside the spore coat. Two exosporium-specific major glycoproteins have been described forB. cereus 11, 12. Staining of spores of B. cereus and B. anthracis by specific lectins suggested the presence of carbohydrate structures on the surface of their spores 10. Information regarding their carbohydrate structures is, however, currently unavailable.
- (2) Phagocytosis and Spore Germination
- After entry into the host, spores are taken up by macrophages and are transported to the regional lymph nodes that typically drain the site of inoculation13, 14. Germination of B. anthracis spores may occur intracellularly, such as in the phagolysosome of alveolar macrophages or extracellularly in the presence of serum and elevated CO2. Whether and how the intracellular germinating spores circumvent the antimicrobial environment of the phagolysosome is unknown. During germination, the antigenic determinant(s) of somatic polysaccharide, the cell wall Gal-NAG polysaccharide of B. anthracis is exposed 9.
- (3) Vegetative Growth of Bacillus
- As the phagocytic capacity of the lymph node is overwhelmed, the spores progress to successive growth of vegetative bacillus. Depending on the growth conditions, the bacillus can be either encapsulated or nonencapsulated. The capsule is a polymer of γ-D-glutamic acid with molecular weights between 20 and 55 kDa in vitro and estimated to be 215 kDa in vivo15. This structure is poorly immunogenic to the host 16. The capsule may inhibit host defense through inhibition of phagocytosis of the vegetative cells by macrophages. Most (if not all) of the bacilli isolated from infected host are encapsulated, thereby masking their S-layer proteins and the cell wall polysaccharide. The capsule is thus considered to be one of the two major contributing factors to the virulence of B. anthracis 17-20.
- (4) Toxins, Protein Factors and Polysaccharides
- Vegetative bacillus releases multiple factors, such as toxins, cellular protein factors, and soluble polysaccharides. The presence of proteins and polysaccharides in the culture media of growingB. anthracis has long been recognized. In the early 1950s, potential vaccine candidates of B. anthracis were evaluated in animal models 8. Different molecular fractions were injected into animals, and then these immunized animals were challenged with lethal dosages of B. anthracis spores. The protein fractions provided a strong protection for the immunized animals. It is now well understood that the protective antigen, abbreviated PA, is an integrated component of the lethal toxin of B. anthracis. It binds to a specific cellular receptor and forms toxic cell-bound complexes with edema factor (EF) and lethal factor (LF) 20-22. Neutralization antibodies to PA or a polyvalent factor that inhibits the formation of the complex may protect animals from lethal attack by the toxin 23. A considerable number of polysaccharides are also present in the culture media growing the bacteria.
- (B) Current Anthrax Vaccines
- Anthrax vaccination was the first effective bacterial vaccination in history24. Two types of anthrax vaccines are currently in use for humans: A) the spores of the toxigenic, nonencapsulated B. anthracis STI-1 strain 25-27and B) the cell-free PA-based vaccines consisting of aluminum hydroxide-adsorbed supernatant material from cultures of the toxigenic, nonencapsulated B. anthracis strain V770-NPI-R 28 or alum-precipitated culture filtrate from the Sterne strain.
- The use of live, attenuated STI-1 occasionally results in general and local adverse responses, observed both after primary application and revaccination, and the frequency of responses increases with the number of vaccinations29. Such residual virulence makes it unacceptable for human use in Western countries. The PA-based cell-free vaccines from culture supernatants of the Sterne strain30, 31 were later developed and are currently in use in Western countries. Recombinant PA can now be produced from different heterologous organisms, including B. subtilis 27, and the safety and consistency of the PA preparations have been improved. There are, however, concerns about its efficacy for vaccination. Multiple immunizations are required and there are cases of reactogenicity. For example, PA vaccines provide less protection than live spore vaccines against lethal challenges with several strains of B. anthracis 32. Therefore, other antigens in addition to PA and/or cellular immunity may be required for full protection.
- Recent efforts have been focused on genetically engineering highly attenuated spore-forming nontoxinogenic and nonencapsulated strains ofB. anthracis, which express recombinant protective antigen (rPA) at high levels 27, 32. Using a recombinant strain expressing high levels of rPA (>100 mg/ml), Cohen et al.32 demonstrated that a single immunization of guinea pigs with the spores was able to induce a long lasting immune response (at least 12 months) and provided protection against a lethal challenge of virulent (Vollum) anthrax spores. The recombinant B. anthracis spore vaccine appears to be more efficacious than the vegetative cell vaccine, suggesting that some B. anthracis spore-associated antigen(s) may contribute significantly to protective immunity.
- (C) Consideration of the Candidate Carbohydrate Molecules
- Hybridoma and monoclonal antibody technology has provided a powerful means to explore potential molecular targets for diagnosis and vaccine development. Using the guanidine cell wall extracts ofB. anthracis to immunize mice, Ezzell et al. were able to establish two IgM monoclonal antibodies that were directed at an epitope associated with the cell wall Gal-NAG polysaccharide 9. Electron microscopy showed that both mabs interacted with the cell wall of vegetative cells, as well as with the cortex of spores. Neither mAb reacted with encapsulated vegetative cells, such as those from infected guinea pigs, nor did they react with intact spores. These mabs stained intensely to all B. anthracis strains tested, and with two exceptions, none of 20 other Bacillus strains was stained 9. Thus, its expression is restricted to B. anthracis and a few B. cereus strains that are closely related to B. anthracis. This structure is, however, predominantly masked by the bacterial capsule.
- Expression of spore-associated glycoproteins by several Bacillus species has been recently documented12. Garcia-Patrone and Tandecarz reported that two glycoproteins (205 kDa and 72 kDa) were found in B. thuringiensis sporangia 12. These glycoproteins were predominantly localized in the exosporium and/or the spore coat, but a small proportion was also seen in membranes. Deglycosylation of these glycoproteins yielded a 54 kDa polypeptide in both cases, indicating that the 205 kDa preparation is the multimer of the 72 kDa glycoprotein. The oligosaccharides of this glycoprotein had N-acetyl-galactosamine at the reducing end, rhamnose and a component not yet identified. The rhamnose residue is seen in the microbial polysaccharide at relatively high frequency and is frequently recognized by a host as a part of a dominant antigenic structure 12, 33-38.
- Using lectins as probes, Cole et al. (1983)10 found that lectins of different sugar-binding specificities interact differentially with Bacillus species. B. anthracis was agglutinated by several lectins that are specific for α-galactose or 2-acetamido-2-deoxy-α-D-galactose residues, including lectins of Griffonia simplicifolia, Glycine max, abrus precatorious, and Ricinus communis. By contrast, B. mycoides and many other bacillus strains were strongly reactive with the lectin from Helix pomatia and weakly reactive with the Glycine max lectin. When purified spores of several Bacillus species were mixed with lectins, the patterns of lectin-spore agglutinations observed were essentially similar to those of lectin-vegetative cells. These results suggest that there are sugar chain structures present on the surfaces of both spore, non-encapsulated vegetative cells, as well as spore, encapsulated vegetative cells of B. anthracis. Identification and characterization of these carbohydrate structures are of critical importance for spore recognition and vaccine development directed to the spores of B. anthracis.
- II. Experimental Details and Results
- Our recent efforts have been focused on developing a carbohydrate-based microarray to extend the scope of biomedical research on carbohydrate-mediated molecular recognition and anti-infection responses. We have developed a simple and efficient procedure for producing a carbohydrate microarray. In our current platform, about 20,000 microspots of antigens can be printed on a single microarray slide, reaching the capacity to include most known human microbial pathogens, auto-antigens and tumor-associated antigens. The detection system is highly sensitive and efficient. A broad spectrum of antibody specificities can be monitored with as little as a few microliters of serum specimen. This carbohydrate microarray platform is thus readily applicable for biomedical research on carbohydrate-based molecular recognition and for clinical diagnosis of infectious diseases and other diseases39.
- Applying this technology, we have conducted experiments to examine whether antibodies elicited by anthrax spore antigens contain anti-carbohydrate reactivities. Two preparations of rabbit anti-anthrax spore antibodies, one from a U.S.-based company (Catalog No. B0003-05G, United States Biological, Swampscott, Mass.) and another from a U.K.-based company (Catalog No. ab8244, Abcam Limited, Cambridge, U.K.), were employed for this investigation. We reasoned that if such antibody reactivities were present in the polyclonal anti-anthrax spore antibodies and if relevant carbohydrate structures are included on a carbohydrate microarray, staining of a microarray using anti-anthrax spore antibodies should allow us to identify the antibody reactivities on the carbohydrate microarray. Results of this investigation are summarized in FIGS. 24 and 25.
- In order to facilitate the recognition of the antibody reactivities that are specifically associated with an immunization and/or an infection, we have developed a computer algorithm to extract significant biological microarray signals from a large amount of “background noise” that was generated by irrelevant antibody specificities. The latter represents the so called “pre-existing antibody sink” (FIG. 24, B-subject 1). This method is termed dimension reduction, a concept adopted from the field of communication. Results of our analysis using this method are shown in FIG. 25.
- The “fingerprint” illustration of serum antibodies in FIG. 24 clearly shows that the antibody profiles of the three rabbit anti-sera are different. The anti-Pn23-polysaccharide reactivities are, however, significantly elevated in both immunized rabbit serum specimens (rabbit subjects 2 and 3).
- To confirm the biochip finding that anti-anthrax spore antibodies cross-react with Pn23-polysaccharide, we performed a polysaccharide antigen-specific ELISA assay on the two anti-anthrax antibodies and six rabbit serum specimens, including four non-immunized and two dextran-conjugates immunized rabbit anti-sera. The anti-Pn23-polysaccharide activities were only seen in the rabbits that were challenged with anthrax spore extracts (FIG. 26).
- The chemical composition and structure of Pn23-polysaccharide has been extensively studied35, 36, 40, 41. It is composed of neutral sugar residues of D-gal., D-glu., and L-rham. These residues form the repeating unit of the capsular polysaccharide. A tetra-saccharide model of the repeating unit is shown below (FIG. 27).
- Earlier works conducted by the late professor Michael Heidelberger and his colleagues33 demonstrated that the side-chain L-rhamnose residue is immunodominant and is responsible for the strong antigenic cross-reactivities among polysaccharide antigens of Pn23, Streptococcal group B and G. Interestingly, Garcia-Patron and
Tandecarz 12 reported recently that this residue is also a component of the glycoprotein of B. thuringiensis sporangia. Structural information of the oligosaccharide chain of the glycoprotein(s) of B. anthracis sporangia is currently unavailable in the literature. - To facilitate our investigation, we established a non-anthrax model to investigate the immunological cross-reactivities of anti-anthrax spore antibodies to Pn23-polysaccharide. We have specifically selectedB. cereus strain 4342 from the American Type Culture Collection (ATCC) since this strain and B. anthracis are monomorphic at multiple allozyme loci, being part of the same highly related cluster of isolates within the B. cereus lineage 42, 43. In addition, Schurch et al. 43 found recently that B. cereus strain 4342 was sensitive to the γ phage, which is distinct from most other B. cereus strains so far studied but is identical to strains of B. anthracis. We hypothesize that the two B. cereus strains share common carbohydrate structures, either on their cell walls or on the spores, or on the surfaces of both cell walls and spores.
- We have tested whether the pre-incubation of antibodies with purified spores, either fromB. cereus strain 4342 (closely related to B. anthracis) or B. cereus strain 246 (genetically and phenotypically distal from B. anthracis), can remove or reduce their anti-Pn23-polysaccharide specificities. Specifically, preparations of rabbit anti-anthrax spore antibodies were incubated with spores of B. cereus 4342 (B anthracis-mimic strain) or control B. cereus strains at 4° C. overnight or at 37° C. for 60 minutes. Rabbit IgG antibodies purified by the Protein A column were applied at concentrations of 0.5 and 5 μg/ml. As determined in our preliminary investigation, their anti-Pn23 activities were detected at these antibody dilutions. The spores were removed from their antibody mixtures by centrifuge and the spore-free antibody solutions were applied for an ELISA assay to measure their anti-Pn23-polysaccharide activities.
- The anti-rabbit serum was added to the tubes of spore 246, 4342, and a PBS-control. They were mixed by vigorously shaking at 4° C. overnight. The mixed compounds were centrifuged for 30 minutes at 4000 rpm at 4° C. and the supernatants were collected and were saved at 4° C. ELISA plates were coated with
Pn23 5 μl/ml in 0.02M BBS, 100 μl/well at 37° C. for 2 hours. Next, the blocking reaction with 2% NBC-PBS was performed, 200 μl/well at 37° C. for 1 hour. The supernatants were added at 100 μl/well at 37° C. for 90 minutes. Anti-rabbit IgGAP was added at a dilution of 1:5000 in 2% NBC-PBS, 100 μl/well at 37° C. for 60 minutes. OD readings were taken at 405 nm, one hour after the substrates were added. The same experiment was repeated three times and results were expressed as the relative ELISA binding activities of each assay. The anti-Pn23 activities of the rabbit anti-anthrax spore serum that were incubated with PBS were listed as 100% activity for this comparison in FIG. 28. - As shown in FIG. 28, such treatment usingB. cereus strain 4342 but not B. cereus strain 246 was able to substantially reduce the anti-Pn23-polysaccharide activities of the anti-anthrax spore antibodies.
- Given this finding, we concluded that there is present a sugar chain structure on the spores ofB. cereus strain 4342 (closely related to B. anthracis) and of B. anthracis that shares antigenic similarity with Pn23-polysaccharide. Such sugar chain structure and its derivatives are potential molecular targets for the molecular recognition of B. anthracis and for vaccine development against anthrax and Pneumococcus type 23 (Pn23) infections. These include preparations of Pn23-polysaccharides, other polysaccharides with similar structures, glycoproteins and polysaccharides of B. cereus 4342 and B. anthracis, and especially the protein-conjugates of these sugar chain structures. In addition, such sugar chains can be coupled to the protective antigen (PA) of B. anthracis and other potent protein carriers. Thereby, a new generation of cell-free B. anthracis vaccines can be generated.
- In summary, our recent studies applying carbohydrate microarray technology have led to the discovery of strong antigenic cross-reactivities between the anthrax spore and a capsular polysaccharide of
Pn type 23. The experiments conducted supra confirm this immunological cross-reactivity. This investigation has, therefore, identified a carbohydrate structure that has great potential to serve as a new molecular target for spore recognition and for vaccination against anthrax infection. - 1. Karlsson, K. A., Angstrom, J., Bergstrom, J. & Lanne, B. Microbial interaction with animal cell surface carbohydrates.APMIS. Suppl. 27, 71-83 (1992).
- 2. Feizi, T. & Loveless, R. W. Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences.Am. J. Respir. Crit. Care. Med. 154, S133-136. (1996).
- 3. Wang, D. & Kabat, E. A. inStructure of Antigens., Vol. Three. (ed. M.H.V.V. Regenmortal) 247-276 (CRC Press, Boca Raton New York London Tokyo; 1996).
- 4. Finne, J., Leinonen, M. & Makela, P. H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.Lancet. 2, 355-357 (1983).
- 5. Mandrell, R. E. et al. Lipooligosaccharides (LOS) of some Haemophilus species mimic human glycosphingolipids, and some LOS are sialylated.Infection. &. Immunity. 60, 1322-1328 (1992).
- 6. Robbins, J. B. & Schneerson, R. Polysaccharide-protein conjugates: a new generation of vaccines.J. Infct. Dis. 161, 821-832 (1990).
- 7. Schneerson, R., Barrera, O., Sutton, A. & Robbins, J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.J Exp Med 152, 361-376. (1980).
- 8. Strange, R. E. & Belton, F. C. Studies on a protective antigen produced in vitro from bacillus anthracis: Purification and chemisty of the antigen.Bri. J. Exp. Pathol. 35, 153-165 (1953).
- 9. Ezzell, J. W., Jr., Abshire, T. G., Little, S. F., Lidgerding, B. C. & Brown, C. Identification ofBacillus anthracis by using monoclonal antibody to cell wall galactose-N-acetylglucosamine polysaccharide. J Clin Microbiol 28, 223-231. (1990).
- 10. Cole, H. B., Ezzell, J. W., Jr., Keller, K. F. & Doyle, R. J. Differentiation ofBacillus anthracis and other Bacillus species by lectins.
J Clin Microbiol 19, 48-53. (1984). - 11. Charlton, S., Moir, A. J., Baillie, L. & Moir, A. Characterization of the exosporium ofBacillus cereus. J Appl Microbiol 87, 241-245. (1999).
- 12. Garcia-Patrone, M. & Tandecarz, J. S. A glycoprotein multimer fromBacillus thuringiensis sporangia: dissociation into subunits and sugar composition. Mol Cell Biochem 145, 29-37. (1995).
- 13. Lincoln, R. E. et al. Role of the lymphatics in the pathogenesis of anthrax.J Infect Dis 115, 481-494. (1965).
- 14. Ross, J. M. The pathogenisis of anthrax following the administration of spores by the respiratory route.J. Pathol. Bact. 73, 485-494 (1957).
- 15. Record, B. R. Physicochemical examination of polyglutamic acid fromBacillus anthracis grown in vivo. Biochem. J. 63, 443-447 (1956).
- 16. Goodman, J. W. & Nitecki, D. E. Studies on the relation of a prior immune response to immunogenicity.Immunology 13, 577-583. (1967).
- 17. Zwartouw, H. T. Polyglutamic acid fromBacillus anthracis grown in vivo: structure and aggressin activity. Biochem. J. 63, 437-454 (1956).
- 18. Makino, S., Uchida, I., Terakado, N., Sasakawa, C. & Yoshikawa, M. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation inBacillus anthracis. J Bacteriol 171, 722-730. (1989).
- 19. Preisz, H. Experimentelle Studien Aber Virulenz, Empfanglichkeit und Immunitat beim Milzbrand.Zeitschr. Immunitat. -
Forsch 5, 341-452 (1909). - 20. Thorne, C. B.Bacilluse anthracis. In Bacillus subtilis and Other Gram-positive Bacteria, ed. AL Sonenshein, J A Hoch, R Losick., 113-124 (1993).
- 21. Blaustein, R. O., Koehler, T. M., Collier, R. J. & Finkelstein, A. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers.Proc Natl Acad Sci U S A 86, 2209-2213. (1989).
- 22. Escuyer, V. & Collier, R. J. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells.Infect Immun 59, 3381-3386. (1991).
- 23. Mourez, M. et al. Designing a polyvalent inhibitor of anthrax toxin.
Nat Biotechnol 19, 958-961. (2001). - 24. Mock, M. & Fouet, A. Anthrax.Annu. Rev. Microbiol. 55, 647-671 (2001).
- 25. Shlyakhov, E. N. & Rubinstein, E. Human live anthrax vaccines in the former USSR.
Vaccine 12, 727-730. (1994). - 26. Turnbull, P. C. Anthrax vaccines:past, present and future.
Vaccine 9, 533-539. (1991). - 27. Turnbull, P. C. B. Current status of immunization against anthrax: old vaccines may be here to stay for a while.Curr. Opin. Infect. Dis. 13, 113-120 (2000).
- 28. Puziss, M. et al. Large-scale production of protective antigen ofBacillus anthracis anaerobic cultures. Appl. Microbiol. 11, 330-334 (1963).
- 29. Stepanov, A. V., Marinin, L. I., Pomerantsev, A. P. & Staritsin, N. A. Development of novel vaccines against anthrax in man.J Biotechnol. 44, 155-160. (1996).
- 30. Ivins, B. et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosolBacillus anthracis spore challenge in guinea pigs. Vaccine 13, 1779-1784. (1995).
- 31. Friedlander, A. M., Pittman, P. R. & Parker, G. W. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax.Jama 282, 2104-2106. (1999).
- 32. Cohen, S. et al. Attenuated nontoxinogenic and nonencapsulated recombinantBacillus anthracis spore vaccines protect against anthrax. Infect Immun 68, 4549-4558. (2000).
- 33. Heidelberger, M., Davie, J. M. & Krause, R. M. Cross-reactions of the group-specific polysaccharides of streptococcal groups B and G in anti-pneumococcal sera with especial reference to type 23 and its determinants.J Immunol 99, 794-796. (1967).
- 34. Allen, P. Z. & Prescott, B. Immunochemical studies on a Mycoplasma pneumoniae polysaccharide fraction: cross-reactions with
type Immun 20, 421-429. (1978). - 35. Richards, J. C. & Perry, M. B. Structure of the specific capsular polysaccharide of Streptococcus pneumoniae type 23F (American type 23).Biochem Cell Biol 66, 758-771. (1988).
- 36. Roy, A. & Roy, N. Structure of the capsular polysaccharide from
Streptococcus pneumoniae type 23. Carbohydr Res 126, 271-277. (1984). - 37. White-Scharf, M. E. & Rosenberg, L. T. Evidence that L-rhamnose is the antigenic determinant of hyporesponsiveness of BALB/c mice to Klebsiella pneumoniae type 47.Infect Immun 22, 18-21. (1978).
- 38. Lim, S. & Salton, M. R. Isolation and characterization of a succinylated polysaccharide from the cell wall of Micrococcus agilis.Microbios 44, 95-105 (1985).
- 39. Wang, D., Liu, S., Trummer, B. J., Deng, C. & Wang, A. Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells.
Nat Biotechnol 20, 275-281. (2002). - 40. Ray, A. K., Maddali, U. B., Roy, A. & Roy, N. Synthesis of di- and tri-saccharides related to the polysaccharide from
Streptococcus pneumoniae type 23 and a study of their inhibition in the precipitin reaction. Carbohydr Res 197, 93-100. (1990). - 41. van Steijn, A. M., Kamerling, J. P. & Vliegenthart, J. F. Synthesis of a spacer-containing repeating unit of the capsular polysaccharide ofStreptococcus pneumoniae type 23F. Carbohydr Res 211, 261-277. (1991).
- 42. Helgason, E. et al.Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis—one species on the basis of genetic evidence. Appl Environ Microbiol 66, 2627-2630. (2000).
- 43. Schuch, R., Nelson, D. & Fischetti, V. A. A bacteriolytic agent that detects and killsBacillus anthracis. Nature 418, 884-889. (2002).
-
TABLE 1 Structural Properties of Dextrans and Inulin Preparations FITC conjugates Plain dextrans Dex- N279 LD7 N1299S Dex-20K Dex- 70K 2000K Inulin Structural characteristics Molecular ˜10,000 42 ˜20,000 19.6 71.2 2,000 3.2 Weight (kDa) Sugar Residue Glucose Glucose Glucose Glucose Glucose Glucose Glucose Conformational Linear Linear Heavily Linear Linear Linear Linear characteristics Chain Chain Branched Chain Chain Chain Chain Dominant Only Dominant Dominant Dominant Dominant (?) Molar Ratio 0 0 0 0.01 0.005 0.008 0.007 (FITC:sugar) Proportions of Linkages (%)1 α(1,6) 5 0 31 5 5 5 0 Terminal nonreducing end group α(1,6) 90 100 32 90 90 90 0 Backbone α(1,3)α(1,6) 0 0 1 0 0 0 0 Backbone α(1,2)α(1,6) 0 0 5 0 0 0 0 Backbone α(1,3) 5 0 1 5 5 5 0 Branches α(1,2) 0 0 30 0 0 0 0 Branches β(2.1) Linkage 0 0 0 0 0 0 100(?) -
TABLE 2 Microarray detection and charcaterization of human and murine anti-carbohydrate antibodiesa Antigen microspots I. Human IgM II. Human IgG III. Anti-Dex 4.3F1 IV. Anti-Dex 16.4.12E Antigen name Classb ID Location Mean s.d. Int./Bk.c Mean s.d. Int./Bk. Means.d. Int./Bk. Mean s.d. Int./Bk. Klebsiella type 71 1 A1 19,293 1,786 1.12 32,140 3,367 3.86 9,074 215 1.01 11,432 324 1.02 Klebsiella type K11 1 2 A2 19,560 3,349 1.13 15,262 7,630 1.52 9,584 837 1.06 11,432 262 1.03 Klebsiella type K11 1 2 A2 19,560 3,349 1.13 15,262 7,630 1.52 9,584 837 1.06 11,432 262 1.03 Klebsiella type K13 1 3 A3 39,103 4,354 2.17 25,997 719 3.20 23,003 3,573 2.56 12,256 648 1.10 Klebsiella type K21 1 4 A4 22,847 2,131 1.27 29,255 890 3.63 8,817 203 0.98 12,487 367 1.12 Dudmans Rhizoblum TA1 1 5 A5 31,625 2,768 1.77 16,198 693 2.06 8,438 448 0.93 10,901 226 0.98 Bhondroitin sulfate “B” 2 6 A6 17,009 633 0.96 10,830 411 1.40 59,264 822 6.38 18,063 935 1.62 Pneumococcus type C 1 7 C1 17,014 1,661 0.98 25,187 3,499 3.02 8,813 373 0.98 11,256 271 1.00 Pneumococcus type VIII 1 8 C2 17,194 1,407 0.98 12,075 3,754 1.47 8,862 362 0.99 11,450 512 1.02 Pneumococcus type XIV 1 9 C3 17,012 1.262 0.96 12,292 4,286 1.52 8,879 330 0.99 11,359 375 1.02 Cow 21 (blood group B) 3 10 C4 19,336 2,180 1.08 9,280 839 1.15 9,020 325 1.00 11,309 450 1.02 Bacto- agar 20°C. Ext 1 11 C5 19,792 2,512 1.09 9,682 1,276 1.20 9,106 251 1.02 11,269 527 1.02 Arabino galactan (Larch) 1 12 C6 16,216 453 0.90 8,599 474 1.08 8,564 433 0.97 10,909 357 0.99 IM3- BSA d4 13 E1 19,743 1,898 1.11 14,322 1750 1.70 10,490 258 1.17 65,535 0 5.34 IM3- KLH d4 14 E2 18,077 1,185 1.01 10,641 930 1.27 8,629 390 0.98 62,128 5069 5.42 Lea (N-110% 2x) 3 15 E3 17,046 728 0.95 8,960 605 1.08 8,742 287 1.00 11,026 501 0.98 Beach P1 (blood group B) 3 16 E4 17,419 525 0.97 10,022 423 1.21 8,638 307 0.96 10,928 561 0.97 Tij II (blood group B and Lea) 3 17 E5 17,946 464 0.99 9,400 503 1.14 8,556 202 0.95 11,006 457 0.98 OGd 3 18 E6 20,682 2,620 1.13 8,819 459 1.08 8,912 427 1.00 11,148 705 0.99 ASORd 3 19 G1 16,555 449 0.93 8,933 320 1.06 8,627 547 0.96 10,923 566 1.00 LNT-BSAd 4 20 G2 19,063 1,266 1.05 9,010 267 1.08 8,509 497 0.96 11,000 316 0.99 Phosphomannan 1 21 G3 17,571 785 0.97 16,124 923 1.93 8,585 483 0.96 11,224 394 1.01 Meningococcus group B 1 22 G4 16,747 620 0.93 8,839 403 1.06 8,633 285 0.96 11,115 623 0.99 Haemophilus influenzae type A 1 23 G5 17,804 656 0.98 11,007 208 1.33 8637 378 0.95 11,205 499 1.01 Esherichia coli K92 1 25 G5 17,353 770 0.95 8,785 328 1.07 8,714 396 0.97 11,248 190 1.01 Klebsiella type A3 1 25 I1 27,018 9910 1.40 13,001 6,947 1.94 10,278 1,120 1.12 11,496 136 1.01 Klebsiella type K12 1 26 I2 32,322 16450 1.69 11,539 5,029 1.72 9,303 293 1.01 11,504 226 1.01 Klebsiella type K14 1 27 I3 23,360 1283 1.22 54,557 2,045 7.80 9.687 343 1.04 11,752 405 1.03 Klebsiella type K33 1 28 I4 54,607 2574 2.60 22,890 1,259 3.37 16,135 3,620 1.70 11,286 424 1.00 Chondroitin sulfate “A” 2 29 I5 18,093 1252 0.99 7,646 730 1.16 9,443 451 1.01 11,322 215 1.00 Chondroitin sulfate “C” 2 30 I6 17,699 983 0.97 7,547 607 1.14 11,936 3,057 1.35 11,810 396 1.05 Pneumococcus type SIV 1 31 K1 19,002 662 1.00 11,485 819 1.68 9,305 351 1.03 11,388 94 1.00 Pneumococcus type IX 1 32 K2 18,932 1303 1.00 10,600 3,827 1.56 9,345 697 1.02 11,407 227 1.01 Pneumococcus type 27 1 33 K3 23,308 6222 1.24 13,455 7,158 1.97 9,104 914 1.00 11,394 252 1.00 Cow 26 (blood group B) 3 34 K4 19,184 1743 1.03 8,020 885 1.19 9,296 916 1.01 11,309 205 1.00 Helix pomatia galactan 1 35 K5 17,885 722 0.97 7,298 550 1.11 9,186 917 0.99 11,369 268 1.01 Helix nemoralis galactan 1 36 K6 18,135 715 0.98 7,412 416 1.10 9,179 773 0.98 11,234 185 1.00 IM6-BSAd 4 37 M1 18,897 184 1.01 9,991 784 1.41 10,610 423 1.13 62,509 2,863 5.43 IM6-KLHd 4 38 M2 17,761 289 0.96 7,857 544 1.13 9,303 250 1.00 13,534 460 1.19 Lea (N-1 IO4NaOH) 3 39 M3 18,430 926 1.00 7,857 626 1.11 9,223 216 0.98 11,293 240 1.00 Cyst 9 (blood group A) 3 40 M4 18,182 552 0.99 9,081 733 1.30 9,129 333 0.98 11,571 689 1.04 Dextran N-150-N (60K) 1 41 M5 17,527 717 0.96 7,908 671 1.17 57,385 1,630 6.02 12,653 197 1.13 Hog (bloof group H) 3 42 M6 17,791 1,015 0.98 7,706 506 1.13 9,604 288 1.01 11,526 145 1.04 AGORd 3 43 O1 18,218 305 0.98 7,698 485 1.09 9,228 384 0.99 11,327 360 1.00 Inulin 1 44 O2 17,655 361 0.95 7,636 326 1.08 9,274 391 0.99 11,264 511 1.00 Levan (B-512E) 1 45 O3 18,003 318 0.97 11,807 2.116 1.68 9,493 190 1.00 11,423 521 1.01 Meningococcus group Y 1 46 O4 17,278 841 0.95 7,749 433 1.09 91.58 80 0.97 11.454 687 1.01 E. coli K1 1 47 O5 17,518 1.219 0.97 7,442 508 1.11 9,193 222 0.97 11,236 364 1.00 E. coli K100 1 48 O6 17,852 807 0.99 15,823 2.152 2.33 9,157 163 0.96 11,178 270 1.00 Background (n = 200) 18,267 844 7,522 727 9,161 356 11,252 385 Total number of positives: 12 35 4 4 # background. -
TABLE 3 COGnitor Analysis of Annotated Genes on the PX01 Plasmid of B. anthraces. Cog Information Chart from Okinaka et al Journal of Bacteriology Oct 1999 p6509-6515. Calcined Independently and Added to the Chart ORF Start Stop Strand Size (aa) Description Cog Class Cog Category 137 173709 173894 1 61 Hypothetical protein similar ro host factor protein (68 aa), ymah; B. su R Uncharacterized ACR, host factor I protein 139 174581 174871 2 96 Hypothetical protein (138 aa), uvgU; B. subtilis (299121); 59/96 aa psiti O Disulfide bond formation protein DsbB 138 174200 174493 2 97 Small DNA binding, pagR-like; B. anthracis (AF031382); 63/98 aa positi K Predicted transcriptional regulators 109 131939 132238 2 99 Similar to small DNA binding proteins, pagR; plasmid pXO1, B. antraci K Predicted transcriptional regulators 121 153605 153937 2 110 Adenine phosphoribosyl trasferase, apt; plasmid pXO1; B. anthracis (A F Adenine/guanine phosphoribosyltransferases and related PRPF 129 163846 164238 1 130 Truncated transposase for IS1627; B. anthracis (U30712); 93/137 aa po L Putative tranposase 118 149232 149864 2 150 Unknown function; plasmid pXO1; B. anthracis (LI3841) No Cog No Cog 87 101962 102444 2 160 Unknown function, putative thioredoxin (137 aa), yoll; B. subtilis (Z9911 OC Thiol-disulfide isomerase thioredoxins 120 152064 152636 1 190 Putative transposase (401 aa); S. pyogenes (AF064540); 108/192 aa p L Transpose 115 142410 142991 2 193 Resolvase (191 aa), Tn1546-like; Enterococcus faecium (Q06237); 125 L Site-specific recombinases, DNA invertase Pin homologs 111 136229 136843 2 204 Hypothetical protein in the protective antigen domain, ypa; plasmid pXO No Cog No Cog 127 162232 162876 2 214 Putative transposase for IS1627; plasmid pXO1; B. antracis (U30712) L Putative transposase 141 175663 176307 2 214 Thermonuclease precursor (TNASE)/micrococcal nuclease (231 aa); S. L Micrococcal nuclease (thermonuclease) homologs 85 99636 100319 1 227 Hypothetical protein (244 aa), ydiL in bltr-spollC intergenic region; B. su R Predicted metal-dependent membrane protease 130 165317 166030 1 237 Hypothetical protein (251 aa); yrpE; B. subtilis (U93875); 213/251 aa po No Cog No Cog 96 116307 117131 1 274 Putative transposase for IS1627; plasmid pXO1; B. anthracis Sterne Le L Putative transposase 91 109000 109842 1 280 Hypothetical protein (193 aa), ywoA in ngrB-spollQ intergene region; B. I Membrane-associated phospholipid phosphatase 94 112516 113403 1 296 UDP-glucose-pyrophosphorylase (292 aa), glaB; B. subtilis (Q05852); 2 M UDP-gluose pyrophosphorylase 18 25124 26071 1 315 Intergrase/recombinase protein (311 aa); thermoautotrophicum (AE0 L Integrase 103 123018 123971 1 317 Probable integrase/recombinase (296 aa), ripX; B. subtilis (P46352); 93 L Integrase 39 48912 29889 2 325 Transposase (478 aa), IS231E; B. thringiensis (Q02403); 282/299 aa L Predicted transposase 112 138540 139523 2 327 Spore germination response gerXC; plasmid pXO1; B. anthracis (AF10 No Cog No Cog 114 141002 142081 2 359 Spore germination response, gerXB; plasmid pXO1; B. anthracis (AF10 No Cog No Cog 132 167948 169033 1 361 Putative integrase (356 aa); Streptococcus mutans (AF065141); 206/34 S Uncharacterized BCR 136 172285 17380 1 364 Response regulator aspartate phosphatase C (393 aa), rapC; B. subtilis (D50453); 126/238 aa positive (52%0 and 527117 aa positive (44%) 93 111374 112474 1 366 Hyaluronate synthase (419 aa), hasA; Streptococcus pyogenes (L2118: M Glycosyltransferases, probably involved in cell wall biogenesis 86 100777 101922 2 381 Hypothetical protein (402 aa), yrkO; B. subtilis (D84432); 199/376 aa po R Uncharacterized membrane protein 54 67634 68815 1 393 S-layer precursor/surface protein (814 aa); B. anthracis (P49051); No Cog No Cog 45 57659 58966 2 435 Cell division protein (372 aa), ftsZ; P. horikoshii (AP000001); 103/213 a D Cell division GTPase 95 113430 114761 1 443 Putative NDP-sugar-dehydrogenase (440 aa), ywqF; B. subtilis (Z99122 M Predicted UDP-glucose 6-dehydrogenase 23 31621 33006 2 461 Potential cooling region (609 aa); Clostridium difficile (X98606); 249/390 L Retron-type reverse transcriptase 81 95978 97363 1 461 Ras- and transposon-related protein (225 aa), yocA; B. subtilis (AF0278 M Membrane proteins related to metalloendopeptidases 119 150042 151469 1 475 trans-acting positive regulator, atxA; plasmid pXO1, B. anthracis (L1384 No Cog No Cog 59 74068 75501 1 477 Secretory protein kinase (474 aa)m kln; C. limicola (U77780); 186/310 aa N Type IV secretory pathway, VirB11 components, and related AT 35 42103 43539 1 478 Transposase (478 aa), IS231E; B. thuringiensis (Q02403); 455/478 aa L Predicted transposase 36 43808 45262 2 484 Transposase (478 aa), IS231E; B. thuringiensis (Q02403); 347/468 aa L Predicted tranposase 113 139480 140958 2 492 Spore germination response, gerXA; plasmid pXO1; B. anthracis (AF10 No Cog No Cog 7 6544 8190 2 548 Reverse transcriptase (574 aa), IS629; E. coli (AB11549); 306/543 aa p L Retron-type reverse transcriptase 90 106772 108730 1 652 Hypothetical protein (980 aa), PFB0765w; Plasmodium falciparum (AE L ATPase involved in DNA repair 110 133161 135455 2 754 Anthrax toxin protective antigen, pagA, formerly pag; plasmid pXO1; B. No Cog No Cog 122 154224 156626 2 800 Calmodulin-sensitive adenylate cyclase/edema factor, cya; plasmid pXO D Chromosome segregation ATPase 107 127442 129871 1 809 Anthrax toxin lethal factor, lef; plasmid pXO1; B. anthracis (M29081 and No Cog No Cog 142 176736 179399 2 887 Topoisomerase 1, top 1; plasmid pXO1; B. anthracis (M97227) L Topoisomerase IA 116 143195 146110 1 972 Transposase for TN21 (988 aa), tnpA; E. coli (P13694); 619/916 aa pos No Cog No Cog 79 91443 95111 1 1,222 Hypothetical hydrophobic protein (567 aa); Bacillus firmus (U64515); 12 N Methyl-accepting chemotaxis protein 13 15040 19002 2 1,320 Erythrocyte invasion/rhoptry protein (2,401 aa); P. yoelli (U36927); 520/ No Cog No Cog -
TABLE 4 (Expt12140HIV-ratio) Nitrocellulose and hydrogel as substrates for carbohydrate and protein microarrays Ratio of fluorescent intensity over background of microspots Human IgG specific FAST Slides Hydrogel for Mean SD Sum Mean SD Sum 1_Polysaccharides 5.35 8.28 6383.02 5.17 10.16 6163.61 (2-250) n = 149 2_Glycosylaminogly- 1.74 1.08 181.25 1.81 0.63 188.30 can (GAG) (152-164) n = 13 3_Glycoprotein 2.27 3.36 1836.22 2.79 4.88 2254.38 (166-266) n = 101 4_Semi-synthetic 1.57 1.02 313.67 2.01 1.63 402.20 glycoconjugates (248-292) n = 45 5_Glycolipides 1.45 0.34 139.52 1.68 0.19 161.18 (249-305) n = 58 6_HIV-1 proteins 4.32 8.40 6051.71 2.61 6.19 3659.95 (307-481) n = 175 7_Other Proteins 3.57 6.95 2428.71 3.44 6.47 2340.21 (483-567) n = 85 8_Ig 4.27 8.11 2186.80 6.94 38.21 3554.90 (569-632) n = 64 BK_Empty space 1.24 0.11 951.36 1.61 0.44 1237.51 selected (634-729) m = 96 BK_Saline spots 1.44 0.54 533.80 1.86 1.88 716.07 (test for cross- contamination) (731-778) n = 48 Total (n '2 834) 3.42 5.58 2633.25 3.37 9.89 2588.30 -
TABLE 5 GFPuv generates bright fluorescent signal upon excitation at 488 nm Channel Excitation (nm) Emission (nm) Positive Negative dexsy 335 526 Δ FAM 488 508 ⋆ Alexa488 488 522 ⋆ FluorX 488 522 ⋆ JOE 488 532 ⋆ FITC 488 522 ⋆ Alexa532 543 570 Δ TAMRA 543 570 Δ Cy3 543 570 Δ Alexa546 543 570 Δ TMR 543 570 Δ Alexa568 543 578 Δ ROX 594 614 Δ TexasRed 594 614 Δ Alexa594 594 614 Δ Cy5 633 670 Δ APC 650 660 Δ -
-
1 12 1 19 DNA Artificial Sequence Primer 1 atggttcttt agctttctg 19 2 22 DNA Artificial Sequence Primer 2 ctatcctatt ccattaagat cc 22 3 18 DNA Artificial Sequence Primer 3 gcgaagtaca agtgctgg 18 4 20 DNA Artificial Sequence Primer 4 ctcctgttaa cgtgtaagtt 20 5 20 DNA Artificial Sequence Primer 5 tcaggcagaa gttaaacagg 20 6 18 DNA Artificial Sequence Primer 6 gggaacaccg tcgaatag 18 7 18 DNA Artificial Sequence Primer 7 tggcagctta tccgattg 18 8 22 DNA Artificial Sequence Primer 8 gcgtttaagt tctttgttga cg 22 9 21 DNA Artificial Sequence Primer 9 caagaaacaa ctgcacgtat c 21 10 22 DNA Artificial Sequence Primer 10 caattcctcc gagtatctct tc 22 11 19 DNA Artificial Sequence Primer 11 tatcaagaat cagttagcg 19 12 21 DNA Artificial Sequence Primer 12 ccgatactct atcctattcc a 21
Claims (5)
1. A microarray comprising a nitrocellulose or Hydrogel support having affixed to its surface at discrete loci a plurality of compounds, wherein (a) at at least one discrete locus is affixed a compound associated with Bacillus anthracis and selected from the group consisting of a glycomer and a protein, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
2. A microarray comprising a plurality of nitrocellulose or Hydrogel or Hydrogel supports, each support having one or a plurality of compounds affixed to its surface at a single discrete locus or a plurality of compounds affixed to its surface at discrete loci, wherein (a) at at least one discrete locus is affixed a compound associated with Bacillus anthracis and selected from the group consisting of a glycomer and a protein, and (b) the composition of compounds at each discrete locus differs from the composition of compounds at at least one other discrete locus.
3. A method of detecting in a sample the presence of one or more agents associated with Bacillus anthracis which specifically bind to one or more glycomers, which method comprises:
(a) contacting the sample with the microarray of claim 1 or 2, wherein each glycomer is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding glycomer in the microarray; and
(b) determining whether any glycomer in the microarray has an agent specifically bound thereto,
thereby detecting the presence of the one or more agents in the sample.
4. A method of detecting in a sample the presence of one or more agents associated with Bacillus anthracis which specifically bind to one or more proteins, which method comprises:
(a) contacting the sample with the microarray of claim 1 or 2, wherein each protein is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding protein in the microarray; and
(b) determining whether any known protein in the microarray has an agent specifically bound thereto,
thereby detecting the presence of the one or more agents in the sample.
5. A method of detecting in a sample the presence of one or more glycomers or proteins which specifically bind to one or more antibodies or lectins associated with Bacillus anthracis, which method comprises:
(a) contacting the sample with the microarray of claim 1 or 2, wherein each antibody or lectin is affixed at at least one discrete locus and wherein the contacting is performed under conditions which would permit an agent, if present in the sample, to specifically bind to its corresponding antibody or lectin in the microarray; and
(b) determining whether any antibody or lectin in the microarray has an agent specifically bound thereto,
thereby detecting the presence of the one or more agents in the sample.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/367,204 US20040033546A1 (en) | 2002-04-10 | 2003-02-14 | Novel microarrays and methods of use thereof |
US11/472,731 US8133492B1 (en) | 2002-04-10 | 2006-06-21 | Pneumococcus polysaccharide-related vaccines |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2002/011612 WO2002083918A2 (en) | 2001-04-10 | 2002-04-10 | Novel microarrays and methods of use thereof |
US10/280,376 US20030228637A1 (en) | 2001-04-10 | 2002-10-24 | Novel microarrays and methods of use thereof |
US10/367,204 US20040033546A1 (en) | 2002-04-10 | 2003-02-14 | Novel microarrays and methods of use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/280,376 Continuation-In-Part US20030228637A1 (en) | 2001-04-10 | 2002-10-24 | Novel microarrays and methods of use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/472,731 Continuation US8133492B1 (en) | 2002-04-10 | 2006-06-21 | Pneumococcus polysaccharide-related vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040033546A1 true US20040033546A1 (en) | 2004-02-19 |
Family
ID=46298995
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/367,204 Abandoned US20040033546A1 (en) | 2002-04-10 | 2003-02-14 | Novel microarrays and methods of use thereof |
US11/472,731 Expired - Fee Related US8133492B1 (en) | 2002-04-10 | 2006-06-21 | Pneumococcus polysaccharide-related vaccines |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/472,731 Expired - Fee Related US8133492B1 (en) | 2002-04-10 | 2006-06-21 | Pneumococcus polysaccharide-related vaccines |
Country Status (1)
Country | Link |
---|---|
US (2) | US20040033546A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228637A1 (en) * | 2001-04-10 | 2003-12-11 | The Trustees Of Columbia University In The City Of New York | Novel microarrays and methods of use thereof |
DE102004061731B4 (en) * | 2004-12-17 | 2006-12-14 | Technische Universität Dresden | Programmable microstamp |
US20060292559A1 (en) * | 2005-06-23 | 2006-12-28 | Beckman Coulter, Inc. | Cell-based microarrays, and methods for their preparation and use |
WO2008039164A2 (en) * | 2005-07-19 | 2008-04-03 | The General Hospital Corporation | Immunogenic compositions comprising anthrax spore-associated proteins |
WO2008115198A3 (en) * | 2006-06-30 | 2008-11-13 | Univ Georgia Res Found | Anthrax carbohydrates,synthesis and uses thereof |
WO2009108652A1 (en) * | 2008-02-28 | 2009-09-03 | 3M Innovative Properties Company | Antibodies to clostridium difficile spores and uses thereof |
US20090246200A1 (en) * | 2006-06-30 | 2009-10-01 | Carlson Russell W | Anthrax carbohydrates, synthesis and uses thereof |
US20100099580A1 (en) * | 2005-11-09 | 2010-04-22 | The Trustees Of Columbia University In The City Of New York | Photochemical methods and photoactive compounds for modifying surfaces |
US20100255026A1 (en) * | 2005-10-06 | 2010-10-07 | Michael Jason Stump | Methods and compositions relating to anthrax spore glycoproteins as vaccines |
US20100331198A1 (en) * | 2006-09-11 | 2010-12-30 | Denong Wang | Photo-generated carbohydrate arrays and the rapid identification of pathogen-specific antigens and antibodies |
US7981625B2 (en) | 2008-04-15 | 2011-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Prostate cancer glycan markers and autoantibody signatures |
US8133492B1 (en) | 2002-04-10 | 2012-03-13 | The Trustees Of Columbia University In The City Of New York | Pneumococcus polysaccharide-related vaccines |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5098846A (en) * | 1987-05-27 | 1992-03-24 | Mclean Hospital | Solid phase protein assay by solid phase free site titration |
US6051380A (en) * | 1993-11-01 | 2000-04-18 | Nanogen, Inc. | Methods and procedures for molecular biological analysis and diagnostics |
US6329209B1 (en) * | 1998-07-14 | 2001-12-11 | Zyomyx, Incorporated | Arrays of protein-capture agents and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3826678A (en) | 1972-06-06 | 1974-07-30 | Atomic Energy Commission | Method for preparation of biocompatible and biofunctional materials and product thereof |
JP3455217B2 (en) | 1992-02-13 | 2003-10-14 | バイオ−メトリック システムズ インコーポレイテッド | Immobilization of chemical species in crosslinked matrix |
US6056964A (en) | 1995-03-29 | 2000-05-02 | Stanford Rook Limited | Immunotherapeutic agent and its use |
US5780606A (en) | 1995-06-07 | 1998-07-14 | Connaught Laboratories Limited | Neisseria meningitidis capsular polysaccharide conjugates |
WO1999012416A1 (en) | 1997-09-09 | 1999-03-18 | The Trustees Of Columbia University In The City Of New York | T-independent conjugate-vaccines |
CN1185492C (en) | 1999-03-15 | 2005-01-19 | 清华大学 | Single-point strobed micro electromagnetic units array chip or electromagnetic biologic chip and application thereof |
US6174683B1 (en) | 1999-04-26 | 2001-01-16 | Biocept, Inc. | Method of making biochips and the biochips resulting therefrom |
US6329206B1 (en) | 1999-06-22 | 2001-12-11 | Henkel Corporation | Method of determining inhibitor concentrations in inhibited acidic pickling solutions |
WO2002083918A2 (en) | 2001-04-10 | 2002-10-24 | The Trustees Of Columbia University In The City Of New York | Novel microarrays and methods of use thereof |
US20040033546A1 (en) | 2002-04-10 | 2004-02-19 | The Trustees Of Columbia University In The City Of New York | Novel microarrays and methods of use thereof |
-
2003
- 2003-02-14 US US10/367,204 patent/US20040033546A1/en not_active Abandoned
-
2006
- 2006-06-21 US US11/472,731 patent/US8133492B1/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5098846A (en) * | 1987-05-27 | 1992-03-24 | Mclean Hospital | Solid phase protein assay by solid phase free site titration |
US6051380A (en) * | 1993-11-01 | 2000-04-18 | Nanogen, Inc. | Methods and procedures for molecular biological analysis and diagnostics |
US6329209B1 (en) * | 1998-07-14 | 2001-12-11 | Zyomyx, Incorporated | Arrays of protein-capture agents and methods of use thereof |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040253634A1 (en) * | 2001-04-10 | 2004-12-16 | Denong Wang | Novel microarrays and methods of use thereof |
US20030228637A1 (en) * | 2001-04-10 | 2003-12-11 | The Trustees Of Columbia University In The City Of New York | Novel microarrays and methods of use thereof |
US8133492B1 (en) | 2002-04-10 | 2012-03-13 | The Trustees Of Columbia University In The City Of New York | Pneumococcus polysaccharide-related vaccines |
DE102004061731B4 (en) * | 2004-12-17 | 2006-12-14 | Technische Universität Dresden | Programmable microstamp |
US20060292559A1 (en) * | 2005-06-23 | 2006-12-28 | Beckman Coulter, Inc. | Cell-based microarrays, and methods for their preparation and use |
WO2008039164A2 (en) * | 2005-07-19 | 2008-04-03 | The General Hospital Corporation | Immunogenic compositions comprising anthrax spore-associated proteins |
WO2008039164A3 (en) * | 2005-07-19 | 2008-12-11 | Gen Hospital Corp | Immunogenic compositions comprising anthrax spore-associated proteins |
US20100255026A1 (en) * | 2005-10-06 | 2010-10-07 | Michael Jason Stump | Methods and compositions relating to anthrax spore glycoproteins as vaccines |
US9454077B2 (en) | 2005-11-09 | 2016-09-27 | The Trustees Of Columbia University In The City Of New York | Photochemical methods and photoactive compounds for modifying surfaces |
US8957225B2 (en) | 2005-11-09 | 2015-02-17 | The Trustees Of Columbia University In The City Of New York | Photochemical methods and photoactive compounds for modifying surfaces |
US20100099580A1 (en) * | 2005-11-09 | 2010-04-22 | The Trustees Of Columbia University In The City Of New York | Photochemical methods and photoactive compounds for modifying surfaces |
US8158832B2 (en) | 2005-11-09 | 2012-04-17 | The Trustees Of Columbia University In The City Of New York | Photochemical methods and photoactive compounds for modifying surfaces |
WO2008115198A3 (en) * | 2006-06-30 | 2008-11-13 | Univ Georgia Res Found | Anthrax carbohydrates,synthesis and uses thereof |
US20100233174A9 (en) * | 2006-06-30 | 2010-09-16 | Carlson Russell W | Anthrax carbohydrates, synthesis and uses thereof |
US8420607B2 (en) | 2006-06-30 | 2013-04-16 | University Of Georgia Research Foundation, Inc. | Anthrax carbohydrates, synthesis and uses thereof |
US20090246200A1 (en) * | 2006-06-30 | 2009-10-01 | Carlson Russell W | Anthrax carbohydrates, synthesis and uses thereof |
US9310366B2 (en) | 2006-06-30 | 2016-04-12 | University Of Georgia Research Foundation, Inc. | Anthrax carbohydrates, synthesis and uses thereof |
US20100331198A1 (en) * | 2006-09-11 | 2010-12-30 | Denong Wang | Photo-generated carbohydrate arrays and the rapid identification of pathogen-specific antigens and antibodies |
US8658573B2 (en) | 2006-09-11 | 2014-02-25 | The Trustees Of Columbia University In The City Of New York | Photo-generated carbohydrate arrays and the rapid identification of pathogen-specific antigens and antibodies |
CN101980723A (en) * | 2008-02-28 | 2011-02-23 | 3M创新有限公司 | Antibodies to clostridium difficile spores and uses thereof |
US8697374B2 (en) | 2008-02-28 | 2014-04-15 | 3M Innovative Properties Company | Antibodies to Clostridium difficile spores and uses thereof |
WO2009108652A1 (en) * | 2008-02-28 | 2009-09-03 | 3M Innovative Properties Company | Antibodies to clostridium difficile spores and uses thereof |
US7981625B2 (en) | 2008-04-15 | 2011-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Prostate cancer glycan markers and autoantibody signatures |
Also Published As
Publication number | Publication date |
---|---|
US8133492B1 (en) | 2012-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8133492B1 (en) | Pneumococcus polysaccharide-related vaccines | |
US20030228637A1 (en) | Novel microarrays and methods of use thereof | |
Wang | Carbohydrate microarrays | |
Wang et al. | Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells | |
Werz et al. | Carbohydrates as the next frontier in pharmaceutical research | |
Seeberger et al. | Synthesis and medical applications of oligosaccharides | |
Geissner et al. | Glycan arrays: from basic biochemical research to bioanalytical and biomedical applications | |
Zhang et al. | An array-based method to identify multivalent inhibitors | |
Dube et al. | Chemical tools to discover and target bacterial glycoproteins | |
Bernardes et al. | Combined approaches to the synthesis and study of glycoproteins | |
Ortiz Mellet et al. | Carbohydrate microarrays | |
Matsushita et al. | Artificial Golgi apparatus: globular protein-like dendrimer facilitates fully automated enzymatic glycan synthesis | |
DE60031957T2 (en) | COMBINATIVE, COMPLEX CARBOHYDRATE LIBRARIES AND METHOD FOR THE PREPARATION AND USE THEREOF | |
de Paz et al. | Recent advances in carbohydrate microarrays | |
Yan et al. | Next-generation glycan microarray enabled by DNA-coded glycan library and next-generation sequencing technology | |
de Paz et al. | Oligosaccharide microarrays to map interactions of carbohydrates in biological systems | |
Brzezicka et al. | Influence of Core β-1, 2-Xylosylation on glycoprotein recognition by murine C-type lectin receptors and its impact on dendritic cell targeting | |
Kalograiaki et al. | Direct evaluation of live uropathogenic Escherichia coli adhesion and efficiency of antiadhesive compounds using a simple microarray approach | |
Ganesh et al. | Molecular recognition of Brucella A and M antigens dissected by synthetic oligosaccharide glycoconjugates leads to a disaccharide diagnostic for brucellosis | |
Cunto-Amesty et al. | Directing the immune response to carbohydrate antigens | |
Lucas et al. | Carbohydrate moieties as vaccine candidates: Meeting summary | |
Shin et al. | Carbohydrate arrays for functional studies of carbohydrates | |
WO2001040796A2 (en) | Glycoarrays on the surface of biochips | |
Parthasarathy et al. | Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies | |
WO2009108170A9 (en) | Compositions and methods for determining immune status |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WANG, DENONG;REEL/FRAME:014229/0804 Effective date: 20030328 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:COLUMBIA UNIVERSITY NEW YORK MORNINGSIDE;REEL/FRAME:022000/0506 Effective date: 20060927 |